(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 3 July 2003 (03.07.2003)

PCT

(10) International Publication Number WO 03/054755 A2

(51) International Patent Classification⁷: G06F 17/60

(21) International Application Number: PCT/IB02/05539

(22) International Filing Date:

19 December 2002 (19.12.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/342,999

21 December 2001 (21.12.2001) US

(71) Applicant (for all designated States except US): PFIZER PRODUCTS INC. [US/US]; Eastern Point Road, Groton, CT 06340 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HARDHAM, John, Morgan [US/US]; Pfizer Global Research and Development,, Eastern Point Road, Groton, CT 06340 (US). KING, Kendall, Wayne [US/US]; Pfizer Global Research and Development,, Eastern Point Road, Groton, CT 06340 (US). KRISHNAN, Rajendra [US/US]; Pfizer Global Research and Development,, Eastern Point Road, Groton, CT 06340 (US). MCGAVIN, David, Ross [AU/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 (US). DREIER, Kimberly,

Jean [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 (US).

- (74) Agents: LUMB, Trevor, J. et al.; Pfizer Inc., 201 Tabor Road, Morris Plains, NJ 07950 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

O 03/054755 A2

(54) Title: VACCINE FOR PERIODONTAL DISEASE

(57) Abstract: The present invention relates to novel bacterial isolates identified by their 16S rRNA DNA, that cause periodontal disease in companion animals, polynucleotide sequences sontained therein, polypeptides encoded by such polynucleotide sequences and vaccines comprising such bycteria, polynucleotides, or polypeptides. Also provided are methods for trating and preventing periodontal disease and kits for detecting and treating periodontal disease kits for detecting and preventing periodontal disease.

-1-

VACCINE FOR PERIODONTAL DISEASE Cross-Reference to Related Application

This application claims the benefit of U.S. Provisional Patent Application No. 60/342,999 filed December 21, 2001, the contents of which are hereby incorporated by reference in its entirety.

5

10

15

20

25

30

35

Field of the Invention

The present invention relates to novel bacterial isolates identified by their 16S rRNA DNA, that cause periodontal disease in companion animals, polynucleotide sequences contained therein, polypeptides encoded by such polynucleotide sequences and vaccines comprising such bacterial isolates that have been inactivated or attenuated, polynucleotides or polypeptides. Also provided are methods for treating and preventing periodontal disease and kits for detecting, treating, and preventing periodontal disease.

Background Art

The vast majority of experimental data concerning periodontal diseases is based on studies of humans or bacteria isolated from humans. Relatively little is known with respect to periodontal disease in non-human animals, such as companion animals, and in particular, dogs and cats.

Periodontal disease comprises a group of infections involving supporting tissues of the teeth. These range in severity from mild and reversible inflammation of the gingiva (gum) to chronic destruction of periodontal tissues (gingiva, periodontal ligament, and alveolar bone) with eventual exfoliation of teeth.

From a microbiological standpoint, several features of this disease are of interest. The bacterial etiology is complex, with a variety of organisms responsible for the initiation and progression of disease in humans. Many, if not all, of these organisms may also be present in periodontally healthy individuals and can exist in commensal harmony with the host. Thus, disease episodes may ensue from a shift in the ecological balance between bacterial and host factors, as a result of, for example, alteration in the absolute or relative numbers of certain organisms, changes in pathogenic potential, or modulation of particular host factors. The local environment imposes a variety of unique constraints upon the constituent microbiota of the supragingival tooth surface and the subgingival crevice (the channel between the tooth root and the gingiva that deepens into a periodontal pocket as disease progresses).

Both the calcified hard tissues of the tooth and the epithelial cells of the gingival are available for colonization. These tissues are exposed to host salivary secretions and gingival crevicular fluid (a serum exudate), both of which contain molecules that interact directly with bacteria and alter prevailing environmental conditions. In addition, it is known that in humans, successful colonizers of the teeth and subgingival area must coexist with many (over 600) other species of bacteria that inhabit these regions. Study of the pathogenesis of periodontal diseases in humans is thus complicated by the ecological intricacy of the microenvironment.

-2-

The classification of the various manifestations of periodontal disease in humans is continually changing, and it will suffice to mention that diseases range in severity, rate of progression, and number of teeth affected and that different age groups can be susceptible following the eruption of primary teeth. The nature of the pathogenic agents varies among these disease entities, as well as among human patients and even between different disease sites within a patient. In general, however, severe forms of the disease are associated with a number of gram-negative anaerobic bacteria. Of this group, in humans, most evidence points to a pathogenic role for *Porphyromonas* (formerly *Bacteroides*) *gingivalis*. The presence of this organism, acting either alone or as a mixed infection with other bacteria, and possibly in concert with the absence of beneficial species and certain immunological responses in the host, appears to be essential for disease activity.

5

10

15

20

25

30

35

Colonization of the oral cavity requires that the bacteria first enter the mouth and then localize at and attach to the available surfaces. Host factors which function to prevent bacterial colonization include the mechanical shearing forces of tongue movement along with saliva and gingival crevicular fluid flow. Successful oral colonizers therefore possess a variety of attributes to overcome host protective mechanisms. The sessile plaque biofilm that subsequently accumulates on the hard and soft tissues of the mouth is a dynamic system composed of diverse microbial species. In humans, *P. gingivalis* is usually among the late or secondary colonizers of the oral cavity, requiring antecedent organisms to create the necessary environmental conditions.

Initial entry of *P. gingivalis* into the human oral cavity is thought to occur by transmission from infected individuals. Other vectors would therefore also appear to be operational. These studies indicate that individuals are colonized by a single (or at least a predominant) genotype, regardless of site of colonization or clinical status. Strains of many different clonal origins, in contrast, are present in different individuals. This supports the concept that *P. gingivalis* is essentially an opportunistic pathogen, with virulence not being restricted to a particular clonal type.

The human oral cavity provides a variety of surfaces to which *P. gingivalis* can adhere. There are the mineralized hard tissues of the teeth, along with mucosal surfaces including those of the gingiva, cheek, and tongue.

While a great deal is known about periodontal disease in humans, as described above, very little is known about the same disease in companion animals. Fournier, D. et al., "Porphorymonas gulae sp. nov., an Anaerobic, Gram-negative, Coccibacillus from the Gingival Sulcus of Various Animal Hosts", International Journal of a Systematic and Evolutionary Microbiology (2001), 51, 1179-1189 describe several strains isolated from various animal hosts, including a strain, P. gulae spp. nov., designated ATCC 57100. The authors hypothesize that strains for the animal biotype of P. gingivalis represent a Porphyromonas species that is distinct from P. gingivalis. There is no mention of a vaccine useful in treating periodontal disease in companion animals. Hirasawa and Takada, in

-3-

"Porphyromonas gingivicanis sp. nov. and Porphyromonas crevioricanis sp. nov., Isolated from Beagles", International Journal of Systemic Bacteriology, pp. 637-640, (1994), describe two bacterial species isolated from gingival crevicular fluids of beagles. These species are described in United States Patent Nos. 5,710,039 and US 5,563,063. Nowhere do the authors suggest the use of these species in a vaccine to treat periodontal disease. International Application PCT/AU98/01023, having publication number WO 99/29870, described various *P. gingivalis* polypeptides and nucleotides. However, no evidence of vaccines effective in preventing periodontal disease in companion animals is provided. Even though there is a great amount of information known about the human disease, little has been accomplished by way of preventing or treating the disease, even in humans.

5

10

15

20

25

30

35

There remains a need for a safe and effective vaccine for treating and preventing periodontal disease in companion animals.

Summary of the Invention

The present invention provides an isolated pigmented anaerobic bacteria having a 16S rRNA DNA sequence comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS: 86 to 94, provided that the bacteria is not a strain of *Porphyromonas gingivalis* designated as dog 20B.

In one embodiment, the bacteria is selected from the group consisting of Porphyromonas gulae B43, P. cansulci B46, P. circumdentaria B52, P. gulae B69, P. circumdentaria B97, P. cangingivalis B98, P. salivosa B104, P. denticanis B106 and P. endodontalis B114, , provided that the bacteria is not a strain of Porphyromonas gingivalis designated as dog 20B.

In another embodiment, the present invention provides an isolated pigmented anaerobic bacteria which causes, either directly or in combination with other pathogenic agents, periodontal disease in companion animals, wherein the bacteria can be used to prepare a vaccine for treating or preventing periodontal disease in companion animals, wherein the vaccine comprises an immunologically effective amount of at least one bacteria which has been inactivated or attenuated, provided that the bacteria is not a strain of *P. gulae* sp. nov. designated ATCC 51700. Preferably, the bacteria has a 16S rRNA DNA sequence at least about 95% homologous to any of the sequences depicted in SEQ ID NOS: 86 to 94. More preferably, the bacteria has a 16S rRNA DNA sequence comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS: 86 to 94.

In another embodiment, the present invention provides an isolated pigmented anaerobic bacteria which causes, either directly or in combination with other pathogenic agents, periodontal disease in companion animals, wherein the bacteria can be used to prepare a vaccine for treating or preventing periodontal disease in companion animals, wherein the vaccine comprises an isolated polypeptide immunologically effective as a vaccine for preventing or treating periodontal disease in companion animals, wherein the polypeptide is encoded by a polynucleotide molecule isolated from the bacteria provided that the bacteria

-4-

is not a strain of *P. gulae* sp. nov. designated ATCC 51700. Preferably, the bacteria has a 16S rRNA DNA sequence at least about 95% homologous to any of the sequences depicted in SEQ ID NOS: 86 to 94. More preferably, the bacteria has a 16S rRNA DNA sequence comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS: 86 to 94.

In a further embodiment, the present invention provides an isolated pigmented anaerobic bacteria which causes, either directly or in combination with other pathogenic agents, periodontal disease in companion animals, wherein the bacteria can be used to produce a vaccine for treating or preventing periodontal disease in companion animals, wherein the vaccine comprises an isolated polynucleotide molecule which encodes a polypeptide immunologically effective as a vaccine for preventing or treating periodontal disease in companion animals, wherein the polynucleotide molecule is isolated from the bacteria, provided that the bacteria is not a strain of *P. gulae* sp. nov. designated ATCC 51700. Preferably, the bacteria has a 16S rRNA DNA sequence at least about 95% homologous to any of the sequences depicted in SEQ ID NOS: 86 to 94. More preferably, the bacteria has a 16S rRNA DNA sequence comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS: 86 to 94.

The companion animal is preferably a dog or a cat.

5

10

15

20

25

30

35

In another aspect, the present invention provides isolated polynucleotide molecule comprising a nucleotide sequence isolated from a bacteria selected from the group consisting of a bacterium having the identifying characteristics of *Porphyromonas gulae* B43, *P. cansulci* B46, *P. circumdentaria* B52, *P. gulae* B69, *P. circumdentaria* B97, *P. cangingivalis* B98, *P. salivosa* B104, *P. denticanis* B106 and *P. endodontalis* B114 provided that the bacteria is not a strain of *P. gulae* sp. nov. designated ATCC 51700.

In one embodiment, the isolated polynucleotide molecule is isolated from a bacterium, wherein the bacterium is selected from the group consisting of *Porphyromonas gulae* B43, *P. cansulci* B46, *P. circumdentaria* B52, *P. gulae* B69, *P. circumdentaria* B97, *P. cangingivalis* B98, *P. salivosa* B104, *P. denticanis* B106 and *P. endodontalis* B114.

In another embodiment, the isolated polynucleotide according to claim 15 or 16 wherein the polynucleotide encodes for a polypeptide.

In yet another embodiment, the isolated polynucleotide according to claim 15 or 16 wherein, the polynucleotide encodes ribosomal RNA or transfer RNA.

In yet a further embodiment, the present invention provides an isolated polynucleotide molecule comprising any of the nucleotide sequences selected from the group consisting of SEQ ID NOS: 86 to 94 and homologues having at least 95% homology thereto, provided that the nucleotide sequence is not the 16S rRNA DNA from bacteria *P. gulae* sp. nov. designated ATCC 51700.

Preferably, the isolated polynucleotide molecule comprising any of the nucleotide sequences selected from the group consisting of SEQ ID NOS: 95 to 102 and 111-119, (fimA

-5-

or *oprF*, respectively), which sequence encodes a polypeptide immunologically effective as a vaccine for preventing or treating periodontal disease in companion animals, or complements thereto.

Also preferred is the isolated polynucleotide molecule comprises any of the nucleotide sequences depicted in SEQ ID NOS: 95 to 102 and 111-119, homologues having at least 95% homology thereto, which sequence encodes a polypeptide immunologically effective as a vaccine for preventing or treating periodontal disease in companion animals, or complements thereto.

5

10

15

20

25

30

35

In a further embodiment, the isolated polynucleotide molecule comprises any of the nucleotide sequences depicted in SEQ ID NOS: 95 to 102 and 111-119 or fragments or variants thereof, which sequence encodes a polypeptide immunologically effective as a vaccine for preventing or treating periodontal disease in companion animals, or complements thereto.

In yet a further embodiment, the isolated polynucleotide molecule comprises a nucleotide sequence which hybridizes under conditions of high stringency to any of the sequences depicted in SEQ ID NOS: 95 to 102 and 111-119, or complements thereto. Preferably, the isolated polynucleotide sequence, wherein said sequence comprises the sequence of *fimA*, selected from any of the sequences depicted in SEQ ID NOS: 95 to 102, a fragment or variant thereof, which fragment or variant has at least about 95%, 98% or 99% sequence identity thereto. Also preferred is the isolated polynucleotide molecule, wherein said sequence comprises the sequence of *oprF*, selected from, selected from any of the sequences depicted in SEQ ID NOS, 111 to 119, a fragment or variant thereof, which fragment or variant has at least about 95%, 98% or 99% sequence identity thereto.

Preferably, the fragment or variant of the polynucleotide molecule according to the present invention is at least about 98% homologous thereto.

In another embodiment, the present invention provides an isolated polynucleotide molecule, comprising a nucleotide sequence that hybridizes under conditions of high stringency to *fimA*, selected from any of the sequences depicted in SEQ ID NOS, 95 to 102, or the complement thereof.

In yet another embodiment, the present invention provides isolated polynucleotide molecule, comprising a nucleotide sequence that hybridizes under conditions of high stringency to *oprF*, selected from any of the sequences depicted in SEQ ID NOS, 111 to 119, or the complement thereof.

The present invention also provides an isolated polynucleotide molecule comprising a nucleotide sequence of about 30 nucleotides, which hybridizes under highly stringent conditions to a DNA molecule having a nucleotide sequence encoding a polypeptide having a sequence of at least about 10 contiguous amino acids of any of the polypeptides encoded by any of the nucleotide sequences of SEQ ID NOS: 95 to 102 and 109 to 119, or its complement. Preferably, the isolated polynucleotide molecule comprises at least about 90

5

10

15

20

25

30

35

-6-

PCT/IB02/05539

nucleotides, which hybridizes under conditions of high stringency to a DNA molecule having a nucleotide sequence encoding a polypeptide having a sequence of at least about 30 contiguous amino acids of any of the polypeptides encoded by any of the nucleotide sequences of SEQ ID NOS: 95 to 102 and 111 to 119, or its complement.

In another aspect, the present invention provides the isolated polynucleotide according to the present invention operably linked to a heterologous promoter. The isolated polynucleotide can further comprise an origin of replication active in a prokaryotic or eukaryotic cell.

In another aspect, the present invention provides a recombinant expression vector comprising a polynucleotide selected from the group consisting of any of the nucleotide sequences SEQ ID NOS: 95 to 102 and 111 to 119, fragments or variants thereof, operably linked to a promoter sequence.

In yet another aspect, the present invention provides a plasmid comprising a polynucleotide selected from the group consisting of any of the nucleotide sequences SEQ ID NOS: 95 to 102 and 111 to 119, fragments or variants thereof, operably linked to a promoter sequence.

In a further aspect, the present invention provides a host cell comprising the isolated polynucleotide sequence, vector or plasmid according to the present invention.

Preferably, the host cell is *E. coli* BL21 and said polynucleotide further comprises the expression vector pBAD/HisA or a λ expression plasmid.

In a further aspect, the present invention provides, a method for the production of recombinant FimA or, OprF, selected from any of the sequences depicted in SEQ ID NOS: 103 to 110 or 120 to 128, or fragments or variants thereof, said method comprising (1) growing the cells of claim 36 under conditions in which a polypeptide comprising FimA, OprF, or fragments or variants thereof is expressed, and (2) recovering said polypeptide. The polypeptide can be recovered in soluble or insoluble form.

In another aspect, the isolated polypeptide of the present invention is immunologically effective as a vaccine for preventing or treating periodontal disease in companion animals and comprises an amino acid sequence depicted in SEQ ID NOS: 103 to 110 and 120 to 128.

In one embodiment, the isolated polypeptide immunologically effective as a vaccine for preventing or treating periodontal disease in companion animals comprises an amino acid sequence depicted in SEQ ID NOS: 103 to 110 and 120 to 128 and homologues having at least 95%, 98%, or 99% sequence identity thereto.

In another embodiment, the isolated polypeptide immunologically effective as a vaccine for preventing or treating periodontal disease in companion animals comprises an amino acid sequence depicted in SEQ ID NOS: 103 to 110 and 120 to 128, or fragments or variants thereof.

In yet another embodiment, the isolated polypeptide immunologically effective as a vaccine for preventing or treating periodontal disease in companion animals having an amino

-7-

acid sequence encoded by a DNA molecule comprises a nucleotide sequence which hybridizes under conditions of high stringency to any of the sequences depicted in SEQ ID NOS: 95 to 102 and 111 to 119.

In yet a further embodiment, the isolated polypeptide immunologically effective as a vaccine for preventing or treating periodontal disease in companion animals, which polypeptide comprises at least about 10 contiguous amino acids comprises a fragment of any of the polypeptide sequences of SEQ ID NOS: 103 to 110 and 120 to 128, which polypeptide is immunologically effective, either alone or linked to a carrier, as a vaccine for preventing or treating periodontal disease in companion animals. Preferably, the isolated polypeptide comprises at least about 25 amino acids.

5

10

15

20

25

30

35

Preferably, the isolated polypeptide, for preventing or treating periodontal disease in companion animals, encoded by a DNA molecule comprising a nucleotide sequence which comprises the sequence of *fimA* (SEQ ID NOS: 95 to 102).

Also preferred, the isolated polypeptide, for preventing or treating periodontal disease in companion animals, encoded for by a DNA molecule comprising a nucleotide sequence which comprises the sequence of *oprF* (SEQ ID NOS: 111 to 119).

In a preferred embodiment, the isolated polypeptide is a recombinantly expressed polypeptide, which polypeptide is selected from the group consisting of FimA (SEQ ID NOS: 103 to 110) and OprF (SEQ ID NOS: 120 to 128).

In another embodiment, the recombinantly expressed polypeptide is fused to a carrier polypeptide. The fusion polypeptide is preferably essentially a poly-histidine or poly-threonine sequence.

In a further aspect, the present invention provides a vaccine for treating or preventing periodontal disease in companion animals comprising an immunologically effective amount of at least one inactivated pigmented anaerobic bacteria according to the present invention, and a pharmaceutically acceptable carrier.

In another aspect, the present invention provides a vaccine for treating or preventing periodontal disease in companion animals comprising an immunologically effective amount of at least one polynucleotide molecule according to the present invention, and a pharmaceutically acceptable carrier.

In yet another aspect, the present invention provides vaccine for treating or preventing periodontal disease in companion animals comprising an immunologically effective amount of at least one polypeptide according to the present invention, and a pharmaceutically acceptable carrier.

Preferably, the vaccine for treating or preventing periodontal disease in companion animals comprises an immunologically effective amount of FimA and a pharmaceutically acceptable carrier.

-8-

Also preferred is a vaccine for treating or preventing periodontal disease in companion animals comprising an immunologically effective amount of OprF and a pharmaceutically acceptable carrier.

The bacteria for use in the vaccines of the present invention may be selected from the group consisting of *Porphyromonas gulae* B43, *P. cansulci* B46, *P. circumdentaria* B52, *P. gulae* B69, *P. circumdentaria* B97, *P. cangingivalis* B98, *P. salivosa* B104, *P. denticanis* B106 and *P. endodontalis* B114.

5

10

15

20

25

30

35

In still another embodiment, the present invention provides a vaccine composition for treating or preventing periodontal disease in companion animals comprising an immunologically effective amount of at least one inactivated isolated pigmented anaerobic bacteria according to the present invention, a pharmaceutically acceptable carrier, and optionally an adjuvant.

In yet another embodiment, the present invention provides a vaccine composition for treating or preventing periodontal disease in companion animals comprising an immunologically effective amount of at least one polynucleotide molecule according to the present invention, a pharmaceutically acceptable carrier, and optionally, an adjuvant.

In still a further embodiment, the present invention provides a vaccine composition for treating or preventing periodontal disease in companion animals comprising an immunologically effective amount of at least one polypeptide according to the present invention, a pharmaceutically acceptable carrier, and optionally, an adjuvant.

In another aspect the present invention provides a method for treating or preventing periodontal disease in companion animals comprising administering to a companion animal in need thereof, a vaccine composition according to the present invention.

In another aspect the present invention provides a method for diagnosing periodontal disease in companion animals by analyzing a sample for bacteria, polypeptides or polynucleotides of the present invention, wherein the presence of the bacteria, polypeptides, or polynucleotides are indicative of disease. Preferably, the analyzing step includes analyzing the sample using a method selected from the group consisting of PCR, hybridization, and antibody detection.

In yet another aspect, the present invention provides a kit comprising, in at least one container, a composition for treating and preventing periodontal disease in companion animals comprising an effective amount of at least one inactivated isolated pigmented anaerobic bacteria, polypeptide, or polynucleotides of the present invention and a pharmaceutically acceptable carrier; wherein the kit further comprises a set of printed instructions indicating that the kit is useful for treating or preventing periodontal disease in companion animals. The kit may further comprises a means for dispensing said composition.

In still another aspect, the present invention provides a kit comprising in at least one container an isolated DNA molecule comprising a nucleotide sequence of at least about 15 contiguous nucleotides selected from any of SEQ ID NOS: 86 to 94, 95 to 102, and 111 to

5

10

15

20

25

30

35

119 which hybridizes under highly stringent conditions to the complement of any of the nucleotide sequences depicted in SEQ ID NOS: 86 to 94, 95 to 102, and 111 to 119, and a second isolated DNA molecule comprising in a second container an isolated DNA molecule comprising a nucleotide sequence of at least about 15 contiguous nucleotides selected from the complement of any of the nucleotide sequences depicted in SEQ ID NOS: 86 to 94, 95 to 102, and 111 to 119 which hybridizes under highly stringent conditions to any of the nucleotide sequences depicted in SEQ ID NOS: 86 to 94, 95 to 102, and 111 to 119, wherein the kit further comprises a set of instructions indicating that the kit is useful for the detection of *Porphyromonas* spp. Such a method may be used generally in all mammals, including humans.

In yet another aspect, the present invention provides a kit comprising in at least one container a protein having an amino acid sequence comprising at least 30 contiguous amino acids, which polypeptide is encoded by any of the nucleotide sequences of SEQ ID NOS: 95 to 102 and 111 to 119 and a statement indicating that the kit is useful for the detection of *Porphyromonas* spp. The kit may further comprise a second polypeptide, wherein the second polypeptide is an antibody which is conjugated to an enzyme that catalyzes a colorimetric or The enzyme is preferably selected from the group consisting of alkaline phosphatase and horseradish peroxidase. The kit may further comprise reagents for a colorimetric or chemiluminescent assay.

In a further aspect, the present invention provides a hybridization kit comprising in at least one container an isolated DNA molecule comprising a nucleotide sequence of at least about 15 contiguous nucleotides selected from any of SEQ ID NOS: 86 to 94, 95 to 102, and 111 to 119, or its complement, wherein the hybridization is specific to *Porphyromonas* spp. and wherein the kit further comprises a set of instructions indicating that the kit is useful for the detection of *Porphyromonas* spp. Preferably, the hybridization is performed under highly stringent conditions.

None of the bacteria, polynucleotides, polypeptides, vaccine, vaccine compositions or kits of the present invention comprise any of the bacteria, polynucleotides or peptides described in Fournier, D. et al., "Porphorymonas gulae sp. nov., an Anaerobic, Gramnegative, Coccibacillus from the Gingival Sulcus of Various Animal Hosts", International Journal of a Systematic and Evolutionary Microbiology (2001), 51, 1179-1189, including a strain, P. gulae spp. nov., designated ATCC 57100, Hirasawa and Takada, "Porphyromonas gingivicanis sp. nov. and Porphyromonas crevioricanis sp. nov., Isolated from Beagles", International Journal of Systemic Bacteriology, pp. 637-640, (1994), United States Patent Nos. 5,710,039 or US 5,563,063, or International Application PCT/AU98/01023, having publication number WO 99/29870.

Brief Description of the Figures

Figure 1 is a graph showing the results of a growth study identifying an "animal product-free" medium that supports the growth of *Porphyromonas gulae* B43. The following

-10-

medium were tested: ME-complete, ME-hemin, ME-vitamin K, ME-both hemin and vitamin K, PYG-complete, PYG-hemin, PYG-vitamin K, PYG-both hemin and vitamin K, and BHI.

Figure 2 is a graph showing mean bone loss in mice resulting from super infection with the indicated *Porphyromonas* sp.

Figure 3 is a graph showing percent bone loss in mice resulting from super infection with the indicated *Porphyromonas* sp.

5

10

15

20

25

30

35

Figures 4A and B are photographs showing in Figure 4A, an SDS PAGE, and in Figure 4B a Western blot analysis, using the anti-Xpress™ epitope serum (Invitrogen), of recombinant *P. gulae* B43 FimA expressed in *E. coli* BL21 from pBAD-HisA.

Figure 5 is a photograph showing SDS-PAGE analysis of recombinant *P. gulae* B43 OprF expressed in *E. coli* BL21 cells from a lambda expression plasmid.

Figure 6 is a graph showing the results of a homologous vaccine efficacy study based upon net bone loss;

Figure 7 is a graph showing a *P. gingivalis* 53977 homologous vaccine efficacy study based upon percent bone loss.

Figure 8 is a graph showing a *P. gulae* B43 homologous vaccine efficacy study based upon percent bone loss.

Figure 9 is a graph showing the results of a heterologous vaccine efficacy study based upon net bone loss.

Figure 10 is a graph showing the results for *P. gulae* B43 challenge groups of the heterologous vaccine efficacy study based upon percent bone loss.

Figure 11 is a graph showing the results for *P. gulae* B69 challenge groups of the heterologous vaccine efficacy study based upon percent bone loss.

Figure 12 is a graph showing the results for *P. salivosa* B104 challenge groups of the heterologous vaccine efficacy study based upon percent bone loss;

Figure 13 is a graph showing the results for *P. denticanis* B106 challenge groups of the heterologous vaccine efficacy study based upon percent bone loss.

Figure 14 is a graph showing the serological results of mice vaccinated with recombinant *P. gulae* B43 FimA or saline utilizing a FimA specific ELISA.

Figure 15 is a graph showing the serological results of mice vaccinated with recombinant *P. gulae* B43 OprF or saline utilizing an OprF specific ELISA.

Detailed Description of the Invention

Bacterial Isolates

The present invention provides isolated anaerobic bacteria, identified by their 16S rRNA DNA sequences, which cause periodontal disease and various other diseases and clinical manifestations in companion animals. More specifically, the bacteria are selected from the genus *Porphyromonas*.

-11-

Preferably, the isolated bacteria of the present invention include *P. gulae* B43, *P. cansulci* B46, *P. circumdentaria* B52, *P. gulae* B69, *P. circumdentaria* B97, *P. cangingivalis* B98, *P. salivosa* B104, *P. denticanis* B106, and *P. endodontalis* B114, although other species or strains are encompassed by the invention. In a preferred embodiment, the isolated bacteria of the present invention can be identified by their 16S rRNA DNA sequences shown in SEQ ID Nos. 86 to 94.

5

10

15

20

25

30

35

The diseases caused by infection with the bacteria of the present invention include, but are not limited to, companion animal periodontal disease, companion animal oral malodor (halitosis), bovine foot rot, canine coronary heart disease and canine systemic infections. Bacteria within the genus *Porphyromonas* have also been connected with various human diseases, including coronary heart disease, parotitis, oral malodor, gingivitis, periodontis, stroke, atherosclerosis, hyperlipidemia, bacterial vaginosis, intrauterine growth retardation (IUGR), and increased incidence of pre-term delivery of low birth weight infants.

The present invention provides isolated polynucleotide and isolated polypeptide molecules of *Porphyromonas* spp. More particularly, the invention provides isolated polynucleotide molecules having the nucleotide sequence of *Porphyromonas* spp. *fimA* and *oprF* genes or degenerate variants thereof and isolated polypeptide molecules having the amino acid sequences of the FimA and OprF proteins encoded by such genes, respectively.

The present invention also provides polynucleotide sequences having at least about 90% homology, preferably at least about 95%, and most preferably at least 99%, sequence identity to any of SEQ ID NOS: 95 to 102 and 111 to 119 as determined using any known standard identity algorithm. In addition, the present invention provides polynucleotide sequences that hybridize under stringent conditions to the complement of any of the polynucleotide sequences shown in SEQ ID NOS: 95 to 102 and 111 to 119.

In another specific embodiment, a nucleic acid which is hybridizable to any of the polynucleotide sequences depicted in SEQ ID No. 86 to 102 and 111 to 119, or their complements, under conditions of high stringency is provided. By way of example and not limitation, procedures using such conditions of high stringency for regions of hybridization of over 90 nucleotides are as follows. Prehybridization of filters containing DNA is carried out for 8 h to overnight at 65°C in buffer composed of 6X SSC, 50 mM Tris-HCI (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% FicoII, 0.02% BSA, and 500 µg/mL denatured salmon sperm DNA. Filters are hybridized for 48 h at 65°C in prehybridization mixture containing 100 µg/mL denatured salmon sperm DNA and 5-20 X 10⁶ cpm of ³²P-labeled probe. Washing of filters is done at 37°C for 1 h in a solution containing 2X SSC, 0.01% PVP, 0.01% FicoII, and 0.01% BSA. This is followed by a wash in 0.1X SSC at 50°C for 45 min before autoradiography.

Other conditions of high stringency which may be used depend on the nature of the nucleic acid (e.g. length, GC content, etc.) and the purpose of the hybridization (detection, amplification, etc.) and are well known in the art. For example, stringent hybridization of an oligonucleotide of approximately 15-40 bases to a complementary sequence in the

polymerase chain reaction (PCR) is done under the following conditions: a salt concentration of 50 mM KCl, a buffer concentration of 10 mM Tris-HCl, a Mg²⁺ concentration of 1.5 mM, a pH of 7-7.5 and an annealing temperature of 55-60°C.

In a preferred specific embodiment, after hybridization, wash conditions are as follows. Each membrane is washed two times each for 30 minutes each at 45°C in 40 mM sodium phosphate, pH 7.2, 5% SDS, 1 mM EDTA, 0.5% bovine serum albumin, followed by four washes each for 30 minutes in sodium phosphate, pH 7.2, 1% SDS, 1 mM EDTA. For high stringency hybridization, the membranes are additionally subjected to four washes each for 30 minutes in 40 mM sodium phosphate, pH 7.2, 1% SDS, 1 mM EDTA at 55°C, followed by four washes each for 30 minutes in sodium phosphate, pH 7.2, 1% SDS, 1 mM EDTA at 65°C.

5

10

15

20

25

30

35

The present invention further provides vaccines and vaccine formulations which, when administered to a companion animal in a therapeutically effective amount, are useful in treating or preventing (i.e., conferring resistance) to periodontal disease in a companion animal.

In one embodiment, the present invention provides a vaccine that comprises at least one attenuated (modified live) or inactivated whole cell *Porphyromonas* spp. preparation (bacterin). In another embodiment, the vaccine comprises a subunit fraction of a *Porphyromonas* spp. capable of inducing an immune response.

In a preferred embodiment the vaccine of the present invention comprises one or more subunit polypeptides or fragments or variants thereof, or one or more isolated polynucleotide sequences or fragments or variants thereof.

The attenuated (modified live) or inactivated vaccines (bacterins), or isolated subunit polypeptides, or isolated polynucleotides can be present in combination with other known vaccine formulation components such as with compatible adjuvants, diluents, or carriers.

Definitions and Abbreviations

The term "ORF" indicates "open reading frame", i.e. the coding region of a gene.

The term "Percentage of sequence identity" for nucleotide sequences and polypeptide sequences is determined by comparing two optimally aligned sequences over a comparison window, wherein optimal alignment provides the highest order match and can introduce nucleotide or amino acid additions or to the test or reference sequence. The percentage identity is determined by calculating the percentage of nucleotides- that are identical between the test and reference sequence at each position over the entire sequence. Optimal sequence alignment and percentage identity can be determined manually, or more preferably by a computer algorithm including but not limited to TBLASTN, BLASTP, FASTA, TFASTA, GAP, BESTFIT, and CLUSTALW (Altschul et al., 1990, J. Mol. Biol. 215(3):403-10; Pearson and Lipman, 1988, Proc. Natl. Acad. Sci. USA 85(8):2444-8; Thompson, et al., 1994, Nucleic Acids Res. 22(22):4673-80; Devereux et al., 1984, Nuc. Acids. Res. 12:387-395); Higgins, et al., 1996, Methods Enzymol. 266:383-402). Preferably, the NCBI Blast Server

-13-

(http://www.ncbi.nlm.nih.gov) set at the default parameters is used to search multiple databases for homologous sequences.

The term "heterologous", when used herein means derived from a different bacterial species or strain.

The term "homology", "homologous", and the like, when used herein means the degree of identity shared between polynucleotide or polypeptide sequences.

5

10

15

20

25

30

35

The term "homologous", when used in reference to a bacterial species means the same bacterial species or strain.

The term "host cell", when used herein means a bacteria or eukaryotic cell that harbors a plasmid, virus, or other vector.

The term "isolated" when used herein means removed from its naturally occurring environment, either alone or in a heterologous host cell, or chromosome or vector (e.g., plasmid, phage, etc.).

The terms "isolated anaerobic bacteria", "isolated bacteria", "isolated bacterial strain" and the like refer to a composition in which the bacteria are substantial free of other microorganisms, e.g., in a culture, such as when separated from it naturally occurring environment.

The term "isolated polynucleotide" indicates a composition in which the isolated nucleotide comprises at least 50% of the composition by weight. More preferably, the isolated polynucleotide comprises about 95%, and most preferably 99% by weight of the composition.

The term "isolated polypeptide" indicates a composition in which the isolated polypeptide comprises at least 50% of the composition by weight. More preferably, the isolated polypeptide comprises about 95%, and most preferably 99% by weight of the composition.

The term "functionally equivalent" as utilized herein, refers to a recombinant polypeptide capable of being recognized by an antibody specific to native polypeptide produced by the bacteria which causes periodontal disease in companion animals, or a recombinant polypeptide capable of eliciting or causing a substantially similar immunological response as that of the native protein from the endogenous bacteria. Thus, an antibody raised against a functionally equivalent polypeptide also recognizes the native polypeptide produced by the bacteria which causes periodontal disease in companion animals.

The term "immunogenicity" refers to the capability of a protein or polypeptide to elicit an immune response directed specifically against the bacteria that causes periodontal disease in companion animals.

The term "antigenicity" refers to the capability of a protein or polypeptide to be immunospecifically bound by an antibody raised against the protein or polypeptide.

The term "antibody", as used herein, refers to an immunoglobulin molecule able to bind to an antigen. Antibodies can be a polyclonal mixture or monoclonal. Antibodies can be

-14-

intact immunoglobulins derived from natural sources or from recombinant sources, or can be immunoreactive portions of intact immunoglobulins. Antibodies can exist in a variety of forms including, for example, as, Fv, Fab', F(ab')₂, as well as in single chains.

The term "companion animal", as used herein, refers to any non-human animal in captivity considered to be a pet. These may include, but are not restricted to, dogs, cats, horses, rabbits, monkeys, and rodents, including mice, rats, hamsters, gerbils, and ferrets.

5

10

15

20

25

30

35

The term "protection", "protecting", and the like, as used herein with respect to a vaccine, means that the vaccine prevents or reduces the symptoms of the disease caused by the organism from which the antigen(s) used in the vaccine is derived. The terms "protection" and "protecting" and the like, also mean that the vaccine can be used to "treat" the disease or one of more symptoms of the disease that already exists in a subject.

The term "therapeutically effective amount" refers to an amount of the bacteria, or a subunit, (e.g., polypeptides, polynucleotide sequences) and combinations thereof sufficient to elicit an immune response in the subject to which it is administered. The immune response can comprise, without limitation, induction of cellular and/or humoral immunity.

The term "preventing infection" means to prevent or inhibit the replication of the bacteria which cause periodontal disease in companion animals, to inhibit transmission of the bacteria, or to prevent the bacteria from establishing itself in its host, or to alleviate the symptoms of the disease caused by infection. The treatment is considered therapeutic if there is a reduction in bacterial load.

The term "pharmaceutically acceptable carrier" refers to a carrier medium that does not interfere with the effectiveness of the biological activity of the active ingredient and is not toxic to the subject to whom it is administered.

The term "therapeutic agent" refers to any molecule, compound or treatment, preferably an antibacterial, that assists in the treatment of a bacterial infection or a disease or condition caused thereby.

The term "fragment or variant thereof" refers to partial nucleotide or amino acid sequences according to the present invention. Preferably the fragments or variants of the polypeptides that are provided in the present invention are capable of eliciting a humoral and/or cellular immune response in a companion animal. Analogs are encompassed by the term "fragment or variant thereof". Mutant polynucleotides which may possess one or more mutations which are deletions, insertions or substitutions of nucleotide residues are encompassed by the term "fragment or variant thereof". Allelic variants are encompassed by the term "fragment or variant thereof".

Isolation and Characterization of Porphyromonas spp.

Bacteria provided by the present invention can be obtained using known sampling, culture and isolation techniques. For example, microbial samples can be obtained from a population of companion animals, such as from dogs and cats, exhibiting periodontal disease. Evidence of periodontal disease can be observed using known measures, such as dogs with

5

10

15

20

PCT/IB02/05539

periodontal pockets >3mm and cats with periodontal pockets >2mm. Known parameters for characterizing periodontal disease such as dental indices (gingival index and periodontal index) and periodontal pocket depths can determined for the sample population of companion animals. Individual samples can be obtained from the periodontal pocket of a particular animal, maintained under anaerobic conditions and cultured using various known culture media.

Clinical isolates can be characterized using known techniques such as a number of biochemical tests, and 16S rRNA DNA sequence analysis to determine their genus and species. Individual isolates can be transferred to plates and antibiotic disks (Anaerobe Systems) can be placed on the agar surface to determine the antibiotic resistance patterns of each isolate. Purified colonies can also be subjected to known indole and catalase tests (Anaerobe Systems). Lipase and lecithinase production patterns can be determined for individual isolates.

The isolates can be typed based on their 16S rRNA DNA sequence. Individual, well-isolated colonies can be utilized as a template for polymerase chain reactions (PCR) amplification of the 16S rRNA region using, for example, primers D0056 and D0057 (Seq. ID NO. 1 and Seq. ID NO. 2; Table 1). The resulting PCR products can be purified using available PCR preps kits (Promega Corp.; Madison, WI) and pooled by isolate. The purified PCR products can then be desalted and subjected to DNA sequence analysis. The resulting DNA sequences can be used to search available DNA databases. The bacterial isolates can then be typed based on the closest match identified by database searches.

Table 1. DNA sequence identification listing. All oligonucleotide primers were synthesized by either Gibco-BRL (USA) or Lark Technologies Inc. (USA).

SEQ ID NO.	Name	Target	DNA Sequence
1	D0056	16S rRNA	GGATTAGATACCCTGGTAGTC
2	D0057	16S rRNA	CCCGGGAACGTATTCACCG
3	PFZ175-AP1	16S rRNA	GGCTTAAGTGCCATAACGAG
4	PFZ175-AP2	16S rRNA	CTGGCGTCTTACGACGGCTG
5	PFZ175-AP3	16S rRNA	TGTCGTCAGCTCGTGCCGTG
6	D0067	fimA	GCGCAGCAAGGCCAGCCCGG
7	D0068	fimA	GAGCGAACCCCGCTCCCTGT
8	D0078	fimA	GCGACGCTATATGCAAGACAATC
9	D0097	fimA	ggcctcgagAACAAAGACAACGAAGCAGAAC
			cc
10	D0098	fimA	ggcaagcttACCAAATAACATTTTGTACAACA
			cc
11	PFZ185-AP1	fimA	TCATCCGACAATCCTGTGTG
12	PFZ185-AP2	fimA	AGCAGCTGCTAAATCGGCTC

SEQ ID NO.	Name	Target	DNA Sequence
13	PFZ185-AP3	fimA	TTGGCAAGACTCTTGCAGAG
14	PFZ185-AP4	fimA	CTGCAGTCAGTTCAGTTGTC
15	PFZ186-AP1	fimA	TACGTCAACAGGCTCTGCTG
16	PFZ186-AP2	fimA	GACAACTGAACTACTGCAG
17	PFZ186-AP3	fimA	AACATAGAAACCTTGTGGAG
18	PFZ186-AP4	fimA	TGTCGTCTGGTTGGGAAGAG
19	PFZ186-AP5	fimA	AATCTGATTGCCTCCCTGAG
20	PFZ187-AP1	fimA	GGGAACCGATTTAGCAGCAG
21	PFZ187-AP2	fimA	CCAATACAGGGTAATAGGTC
22	PFZ187-AP3	fimA	GTTGTCAATGCTTTTACCTC
23	PFZ187-AP4	fimA	GATTGAGAATATCAAATGTG
24	PFZ187-AP5	fimA	TTAGGCGTATAACCATTGTC
25	PFZ187-AP6	fimA	ATTTAACGGTGCTTACACAC
26	PFZ187-AP7	fimA	CCAATTGGCGGCCTGAGCTG
27	PFZ187-AP8	fimA	TGGCATAGTTGGTAGGTGTG
28	PFZ187-AP9	fimA	TGTAAGCACCGTTAAATGTG
29	PFZ187-AP11	fimA	CTGACAGGTTCTTTGACCAC
30	PFZ187-AP12	fimA	TGTTCCTTGGTTGAGCCGTG
31	PFZ187-AP13	fimA	GTGGTCAAAGAACCTGTCAG
32	PFZ187-AP14	fimA	CATAAACACACAGGATTGTC
33	PFZ187-AP15	fimA	TTGCTTCTTTGCAATGAGAC
34	PFZ187-AP16	fimA	AGCCATGCGAGCATGTACAC
35	PFZ187-AP17	fimA	CTGTCATGATCAAACCTGTG
36	PFZ187-AP18	fimA	ACCGTCTGCATTCACGAGTG
37	PFZ188-AP1	fimA	GCCTTCCAATGATGCTCCAC
38	PFZ188-AP2	fimA	GGACGTAGACCTGCATTCTG
39	PFZ188-AP3	fimA	CGCAATACGGGCATGAACAC
40	PFZ188-AP4	fimA	TTATGGTTATGATGGACCTC
41	PFZ188-AP5	fimA	TGGTACTCCTTTGAGTTCTG
42	PFZ188-AP6	fimA	CACACTTGCGCGGTAACCAC
43	D0086	oprF1	ATGAAGGTAAAGTACTTAATGC
44	D0087	oprF1	AGATGAATTACTTGGAGCGAACGAT
45	KWK-Pg-03	oprF1	TTACTTGGAGCGAACGATTACAACACG
46	PFZ209-AP1	oprF1	TTGGTGCAGCTCACTTCGAC
47	PFZ209-AP2	oprF1	ACCACATCAAACATAAAGTC
48	PFZ209-AP3	oprF1	ACATTCGGGGCATGATACAG

SEQ ID NO.	Name	Target	DNA Sequence
49	PFZ209-AP4	oprF1	ATGCCATTGAGCCAATGGAC
50	PFZ210-AP1	oprF1	TTGACTTCATGTTCGATGTG
51	PFZ210-AP2	oprF1	TGCCAATGAATTTTATGCTG
52	PFZ210-AP3	oprF1	CGCTTGGAGAGTTCTTCGAC
53	PFZ210-AP4	oprF1	TATCAACGATCTGAATGGTC
54	PFZ211-AP1	oprF1	AACTACTTCAAGCCCTACAG
55	PFZ211-AP2	oprF1	CGTAACCCAAACCTACCCAC
56	PFZ211-AP3	oprF1	ACGGGACGCTTGCTCAACTC
57	PFZ211-AP4	oprF1	ATTGGGGCTTGGTAAATGAC
58	PFZ211-AP5	oprF1	ATACGCTCTACACGAGGCTC
59	PFZ212-AP1	oprF1	CCGCCATGGCTGGAGCTCAC
60	PFZ212-AP2	oprF1	TTTGAAACCATATCCCACAC
61	PFZ212-AP3	oprF1	AGTAACTTCAGGACATTCTG
62	PFZ212-AP4	oprF1	ACGTCCAGTTTCTTGCCCAG
63	PFZ213-AP1	oprF1	TTGACTTCATGTTCGATGTG
64	PFZ213-AP2	oprF1	TTTGTGTTGGTAACCAACAC
65	PFZ213-AP3	oprF1	ACAGGACGCTTAGAGAGCTC
66	PFZ213-AP4	oprF1	ACGCGCTTATCAACGATCTG
67	PFZ213-AP5	oprF1	CTTCCCAAGGAACGTGTGTG
68	PFZ214-AP1	oprF1	ACTTTATGTTTGATGTTGTG
69	PFZ214-AP2	oprF1	CCAACACCGAACCAAGGCAC
70	PFZ214-AP3	oprF1	TCTCAACTCAGTATTCTCAG
71	PFZ214-AP4	oprF1	TAACCTTAATTTTGGTCGTG
72	PFZ215-AP1	oprF1	CACACCTACAACACTGCCAC
73	PFZ215-AP2	oprF1	TCAAACATGAAATCATAGTG
74	PFZ215-AP3	oprF1	CTCGGGGCAGAAAGCAGGAC
75	PFZ215-AP4	oprF1	GACTTGAACTCTCAGATCAG
76	KWK-Pg-06	oprF1	atgCAGGAAAATACTGTACCGGCAACG
77	KWK-Pgu-14	oprF1	gtgtgtcatatgCAGGAAAATACTGTACC
78	KWK-Pgu-15	oprF1	gtgtgttctagattaTTACTTGGAGCGAACG
79	KWK-Ps-02	oprF1	ACACCTGAGACTCAGACATTGC
80	KWK-Ps-03	oprF1	CATGCGCGAGCCTCAAAAAGC
81	KWK-Ps-04b	oprF1	CCTGCCACTCAACAGAAATCATATCAGAA
			GGAACTCC
82	KWK-Ps-05b	oprF1	CTGCTCATAAGACGGCTTTTGACCGTTCT
			GCAGG

TTGACTCTCC 84 D122 fimA TGGCTAARYTGACYGTAATGGTYTA 85 D123 fimA AGTTYACYAATACAGGRTAATAGGT 86 P. gulae B43 16S TTGCGATATACCGTCAAGCTTCCACAGAGAGAGAGATAACCGTGAAACCAAGAGAGATAACCGAGGAAACCAAGAGAGATAACCACCTGGGAAACCAAACCGAAACCGAAACCAAACCGAAACCAAACCGAAACCAAACCAAACCAAACCAAACCAAACCAAACCAAACCAACCGAAACCAACCGAAACCAAACCAACCAAACCAACCAAACCAAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAACCAAACCAAACAAAA	IO. Na	EQ ID NO.	Name	Target	DNA Sequence
84 D122 fimA TGGCTARYTGACYGTAATGGTYTA 85 D123 fimA AGTTYACYAATACAGGRTAATAGGT 86 P. gulae NA CACGCAGTAAACGATGATTACTAGG B43 16S TRNA GAAAGCGTTAAGTAACCGTCAAACTCACAAACGATGATTAATCCACCTGGG Polynucleotide Sequence ATTGACGGGGGCCCGCACAAGCGG AACATGTGGTTTAATTCGATGAATGCCGGGAACCTTAACTACCGGGAACCTTACCCGGGAACCTTACCCGGGAACCTTACCCGGGAACCTTACCCGGGAACCTTACCCGGGATGAAACTCAAACCGTGAACCTTACCCGGGATGAAACCCTTACCCGGGATGAAACCCTTACCCGGGATGAAACCCTTACCCGGATTGAAAGCCGTCTTCCCCGGGCTCAAACACGGTTAAGTGCCAACACGGTTAAGTGCCAACACGTTAAGTGCAACACGTTAAGAACCCTTACCAGAACCGTACAGCGCAACCCACACGTGTACAACACGGTTAACAAGGACTCACCGAGACTACCGGGAACCCACACGTGTTACAAACACCTTACCAGAACCCTTACCAGAACCCTTCCCAAACCACGGTTACAACACGACGAACCGGGTGCCTCTCCAAACCACCGGGTGAACACACCGAACACCGAACACGAACACACGAACACACACACACACACACACACACACACACACACACACA	KV	3	KWK-Ps-06b	oprF1	CTTTTGACCGTTCTGCAGGACATTGGTTC
85 D123 fimA AGTTYACYAATACAGGRTAATAGGT 86 P. guiae NA CACGCAGTAAACGATGATTACTAGG B43 16S TTGCGATATACCGTCAAGCTTCCACA FRNA Polynucleotide TACGCCGGCAACGGTGAAACTCAAACGATGATTAATCGATGATACCGGGAACCTTACCACAGGGGAACCTTACCACAGGGGAACCTTACCCGGGATTGAAATGTACCGGGAACCTTACCCGGGATTGAAATGTCCGACAGGGGAACCTTACCCGGGATTGAAATGTCCGACGGGAACCTTACCAGGGAACCTTACCAGGGAACCTTACCAGGGAACCTTACCAGGGAACCTTACCAGGGAACCTTACGAGGACGTCTTCCCGGGAGTTGAAATGTCGAGGAACCTTACCAGAGACGGAACCAACC					TTGACTCTCC
86 P. guilae B43 16S rRNA polynucleotide sequence ATTGACGGGGAAACGATGATTACTAGG AACATGTGGTTAAATCCACCTGGGG AACATGTGGTTAATTCGATGATACCGGGAACGGTGAAACTCAAA GGAAACCTTACCCGGGATTGAAATGT CGACGGGTAAAGCGGTAAACTGAAA GGAACCTTACCCGGGATTGAAATGT CGACGGATGGTGAAACCGTCAAA GGAACCTTACCCGGGATTGAAATGT CGACGGATGGTGAAACCGTCATCC CGGGGCGTCTATGTAGGTGCGTAACAGGT GCTTAAGTGCCATAACAGGTGTAACAG CATCGGTAGTTGCTAACAGGTTTAG AGGACTCTACCCGAGACTGCCGTCGG CACACGTGTTACAATCGGGG CACACGTGTTACAATCGGGGC CACACGTGTTACAATGGGAACAC GGCAGCTACCGAGACTCCCAGTTCGGA GGCAGCTACCGAGACTCCCAGTTCGGA GATTCGCAACCCTTCCCCAGTTCGGA GATTCGCAACCCTTCCCCAGTTCGGA GATTCGCAACTCCAGTAACG GGCGCGGTGAATAC 87 P. cansulci B46 16S rRNA polynucleotide CGTCGGCAACGATGAATCCACCTGGGAA CATCGGCAACGATGATTACTCCGG GAACCTTACCCGGGATTGAAACTCAAAGG CATGTGGTTTAATTCACCTGGGAA CATGTGGTTTAATTCACTCAGGAAC CATGTGGTTTAATTCACTCAGAGGAAC CATGTGGTTTAATTCACCTGAGGAACCATGAATACCCCTGAGGAACCATCACAAGGGAACCATCACAAGGGAACCATTAACTCACCTGAGGAACCATTAACTCACCTGAGGAACCATTAACTCACCTGAGGAACCATTAACTCACCAGAGGAACCATTAACTCACCAGAGAACCATCAAAGGAACCTTAACCACCTGAGGAACCATTAACTCACCAGAGAACCATCAAAGGAACCTTAACCACCAGAGGAACCATTAACTCACCAGAGAACCATCAAAGGAACCTTAACTCACCAGAGAACCATCAAAGGAACCTTAACTCACCAGAGAACCATCAAAGGAACCTTAACCACCAGAGAACCATCAAAGGAACCTTAACCACCAGAGAACCATCAAAGGAAACCTTAACTCACCAGAGAACCATCAAAGGAAACCTTAACCACCAGAACCAAGACGAAGACCAAACCAAACCAAGACGAAACCATCAAAACCATCAAAACCATCAAAACGATCAAAACCATCAAAACACCATCAAACCATCAAAACCATCAAAACACCATCAAAACCATCAAAACACCATCAAAACACCATCAAAACACCATCAAACCATCAAAACATCAAAACACCATCAAACACCATCAAACACCATCAAAACACATCAAAAAA	D1	4	D122	fimA	TGGCTAARYTGACYGTAATGGTYTA
B43 16S rRNA polynucleotide sequence ATTGACGGGGAACGGTGAAGCTTCCACA GGAAACCTTACCCGGGAACGGGGAACGCGG AACATGTGGTTTAATTCGATGATACG GGAACCTTACCCGGGATTGAAATGT CGACGGATGTAAATGTAACGGGGGCCCGCACAAGCGGG AACATGTGGTTTAATTCGATGATACG GGAACCTTACCCGGGATTGAAATGT CGACGGATGGTGAAAGCCGTCTTCC CGGGGCGTCTATGTAGGTGCTGAAG TGTCGTCAGCTCGTGCCGTGAGGT GCTTAAGTGCCATAACGAGGCGCAAC CATCGGTAGTTGCTAACAGGTTTAGG AGGACTCTACCGAGACTGCCGTCGT GCGCGAGGAAGGTGTGAACAGCGGAAC CATCGGTAGTTACAATGGGAGGACAC GGCAGCGAACGCCCTTACATCCGGGC CACACGTGTTACAATGGGAGGGACA GGCAGCTACCGGGCGACCGGGTGC TCTCGAAACCCTTCCCCAGTTCGGA GAGTCTGCAACTCGACTCCGTGAAG GATTCGCTAGTAATCGCGCATCAGC GGCGCGGTGAATAC 87 P. cansulci B46 16S rRNA polynucleotide Sequence TGACGGGGGCCCGCACAAGCGGAG CATGTGGTTTAATTCGATGATACCCC GAACCTTACCCGGGATTGAAATATACC GACAGGCAGCGAGAGTTGTTATCCC GGGGCATCTATGTAGGTGCTGCATC GGGGCATCTATGTAGGTGCTGCATCC GGGCATCTATGTAGGTGCTGCATCC GGGCATCTATGTAGGTGCTGCATCC GGGCATCTATGTAGGTGCTGCATCC GGGCATCTATCTATCTATCACCTCACACC GAACCTTACTATCACCTCACACACACACACCATCACACCAC	D1	5	D123	fimA	AGTTYACYAATACAGGRTAATAGGT
rRNA polynucleotide sequence ATTGACGGGGACCCGCACAAGCGG AACATGTGGTTTAATTCGATGATACC GGAACCTTACCCGGGATTGAAATGT CGACGGGGGCCCGCACAAGCGG AACATGTGGTTTAATTCGATGATACC GGAACCTTACCCGGGATTGAAATGT CGACGGATGGTGAAACCGTCTTCC CGGGGCGTCTATGTAGGTGCTGCAT TGTCGTCAGCTCGTGCGTGAGGTC GCTTAAGTGCCATAACGAGCGCAAAC CATCGGTAGTTGCTAACAGGTTTAGG AGGACTCTACCGAGACTGCCGTCGT GCGCGAGGAAGGTGTGAATACCGGCC CACACGTGTTACAATGGGAGGGACAAC GGCAGCTACCGGGCGACCGGGTGC TCTCGAAACCCTTCCCCAGTTCGGAAG GATTCGCTAGTAATCGCGCATCAGC GGCGCGGTGAATAC 87 P. cansulci B46 168 ATGCGATATGAGTGTATCCTCGG AACCGTTAAGTAATCCACCTGGGGA CGTCGGCAACGATGATACCCCTGGGGA CGTCGGCAACGATGATACCCCTGGGGA CGTCGGCAACGATGAAACCCTTCCCAAAGCG GCCGCGTAAACCATTACTCCGG GACCTTACACCCGGGAAC CATGTGGTTTAATTCCACTGGGAAC CATGTGGTTTAATTCGATGATACCCC GAACCTTACCCGGGATTGAAATATACC GACAGGCAGCGAGAGTTGTTATCCCC GGGGCATCTATGTAGGTGCTCCATGC GACACGTCATTAGGTGCTCCATGCC GAACCTTACCCGGGATTGAAATATACC GGGGCATCTATGTAGGTGCTCCATGCC GACACGTCATTAGGTGCTCCATGCC GACACGTCATTAGGTGCTCCATGCC GACACGTCATTAGGTGCTCCATGCC GACACGTCATTAGGTGCTCCATGCC GACACGTCATTAGGTGCTCCATGCC GGGGCATCTATGTAGGTGCTCCATGC	P.	6	P. gulae	NA	CACGCAGTAAACGATGATTACTAGGAGT
polynucleotide sequence TACGCCGGCAACGGTGAAACTCAAA ATTGACGGGGGCCCGCACAAGCGG AACATGTGTTTAATTCGATGATACCGGAACCTTTACCCGGGATTGAAATGTCGACGGGATGTAAACGTGCAAACCTTACCCGGGATTGAAAGCGTCTTCCCGGGGTCTATGTAGGTGCTGCATGTCACTGTCACTGTCACTGTCACTGTCACTGTCACTGTCACTGTCACTGTCACTGTCACTGTCACTGTCACTGTAGGTGCCATAACGACGCAACCCATCAGTAGTTACACAGGTTAACAACGTTAACAACAGGTTAACAACAGGTTAACAACAGGTTAACAACAGGTTAACAACAGGTAAACAACAGGTAACAACAGGAACAACAACAGGAACAACAACAGGAACAACA	В4		B43 16S		TTGCGATATACCGTCAAGCTTCCACAGC
sequence ATTGACGGGGGCCCGCACAAGCGG AACATGTGTTTAATTCGATGATACG GGAACCTTACCCGGGATTGAAATGT CGACGGATGGTGAAAGCCGTCTTCC CGGGGCGTCTATGTAGGTGCTGAAGT TGTCGTCAGCTCGTGCCGTGAGGTG GCTTAAGTGCCATAACGAGCGCAAC CATCGGTAGTTGCTAACACGGTTTAGG AGGACTCTACCGAGACTGCGTCGT GCGCGAGGAAGGTGTGAATACCGGGC CACACGTGTTACATCCGGGC CACACGTGTTACAATGGGAGGACAAG GGCAGCTACCAGGCCCTTACATCCGGGC CACACGTGTTACAATGGGAGGACAAGGCACACGGTTGCAAACCCTTCCCCAGTTCGGAAGAGTCGCAACCCTTCCCCAGTTCGGAAGAGATCGAACCCTTCCCAGTTCGGAAGAGATCGAACCCTTCCCAGTTCGGAAGAGATCGAACCACTCCAGTTCAGCAACCCTTCCCAGTTCAGCAACCCTTAACAACCACTAGCAGAACCACTAAACCAACACAAACCAAAACCAACACAAACCAAAACCAACAC	rRi		rRNA		GAAAGCGTTAAGTAATCCACCTGGGGAG
AACATGTGGTTTAATTCGATGATACG GGAACCTTACCCGGGATTGAAATGT CGACGGATGGTGAAAGCCGTCTTCC CGGGGCGTCTATGTAGGTGCTGCAT TGTCGTCAGCTCGTGCCGTGAGGTC GCTTAAGTGCCATAACGAGCGCAAC CATCGGTAGTTGCTAACAGGTTTAGG AGGACTCTACCCGAGACTGCCGTCGT GCGCGAGGAAGGTGTGGATGACGT ATCAGCACGGCCCTTACATCCGGGC CACACGTGTTACAATGGGAGGGACA GGCAGCTACCGGGCGACCGGGTGC TCTCGAAACCCTTCCCCAGTTCGGA GAGTCTGCAACTCGACTCCGTGAAG GATTCGCTAGTAATCGCGCATCAGC GGCGCGTGAAACGATGATTACTCGG AACCGTTAAGTAATCCACCTGGGGA Polynucleotide Sequence TGACGGGGCAACGATGAAACTCAAAGG CATGTGGTTTAATTCGATGATACCCC GAACCTTTACTTCGGAAGCCATCAAAGGGAACCATTCACACTGGGGAACCATTCACACCTGGGGAACGATGATATCCACCTGGGGAACCATGATAATCCACCTGGGGAACCATGATTAATCAAAAGGAACCATTAATTCAAAAGGAACCATTAATTCAAAAGGAACCATTAATTCAAAAGGAACCATTAACCCCGGGAATTAATT	ро		polynucleotide		TACGCCGGCAACGGTGAAACTCAAAGGA
GGAACCTTACCCGGGATTGAAATGT CGACGGATGGTGAAAGCCGTCTTCC CGGGGCGTCTATGTAGGTGCTGCAT TGTCGTCAGCTCGTGCCGTGAGGTC GCTTAAGTGCCATAACGAGCGCAAC CATCGGTAGTTGCTAACAGGTTTAGG AGGACTCTACCGAGACTGCCGTCGT GCGCGAGGAAGGTGTGGATGACGT ATCAGCACGGCCCTTACATCCGGGC CACACGTGTTACAATGGGAGGGACA GGCAGCTACCGGGCGACCGGGTGC TCTCGAAACCCTTCCCCAGTTCGGA GAGTCTGCAACTCGACTCCGTGAAG GATTCGCTAGTAATCGCGCATCAGC GGCGCGGTGAATAC 87 P. cansulci NA CACGCCGTAAACGATGATTACTCGG ATGCGAACGATGATACCTCGGGGA CGTCGGCAACGATGAAACCATCAAAGG TRNA polynucleotide Sequence TGACGGGGCCCGCACAAGCGGAG CATGTGGTTTAATTCGATGATACCCC GAACCTTACCCGGGATTGAAATACCC GACAGGCAGCGAGAGTTGTATCCCC GGGGCATCTATGTAGGTGTTTATCCCC GGGGCATCTATGTAGGTGTTTATCCCC GGGGCCATCTATGTAGGTGTTTATCCCC GGGGCCATCTATGTAGGTGTTTATCCCC GGGGCCATCTATGTAGGTGCTTCATCCC GGGGCATCTATGTAGGTGCTTCATCCC GGGGCATCTATGTAGGTGCTTCATCCC GGGGCCATCTATGTAGGTGCTTCATCCC GGGGCATCTATGTAGGTGCTGCATCC GGGGCATCTATGTAGGTGCTTCATCCC GGGGCATCTATGTAGGTGCTGCATCC GGGGCATCTATGTAGGTGCTGCATCC GCGCACCTTACCCGGGATTCATCTATCCCC GGGGCATCTATGTAGGTGCTTCATCCC GGGGCATCTATGTAGGTGCTGCATCC GCGCACCATCATCTATGTAGGTGCTGCATCC GCGCACCATCATCCTATCTATCATCATCATCATCATCATCCC GGGGCATCTATGTAGGTGCTTCATCCC GGGCATCTATGTAGGTGCTGCATCC GCGCACCATCATCCTATCTATCATCATCATCATCATCATCATC	se		sequence		ATTGACGGGGGCCCGCACAAGCGGAGG
CGACGGATGGTGAAAGCCGTCTTCC CGGGGCGTCTATGTAGGTGCTGCAT TGTCGTCAGCTCGTGCCGTGAGGTC GCTTAAGTGCCATAACAGGCGCAAC CATCGGTAGTTGCTAACAGGTTTAGG AGGACTCTACCGAGACTGCCGTCGT GCGCAGGAAGGTGTGGATGACGTGAACGAGCGCACCGGTGTACACGCGCGCCTCACATCCGGGC CACACGTGTTACAATGGGAAGGACACAGGGCCCTTACATCCGGGACCACCGGGTGCC TCTCGAAACCCTTCCCCAGTTCGGAAGGATTCGCAACTCGACTCCGTGAAAGGATTCGCTAGAACCGTTGCAACTCGACTCCGTGAAAGGATTCGCTAGAACCGTGAATACC 87					AACATGTGGTTTAATTCGATGATACGCGA
CGGGGCGTCTATGTAGGTGCTGCAT TGTCGTCAGCTCGTGCCGTGAGGTC GCTTAAGTGCCATAACGAGCGCAAC CATCGGTAGTTGCTAACAGGTTTAGG AGGACTCTACCGAGACTGCCGTCGT GCGCGAGGAAGGTGTGGATGACGT ATCAGCACGGCCCTTACATCCGGGC CACACGTGTTACAATGGGAGGGACA GGCAGCTACCGGGCGACCGGGTGC TCTCGAAACCCTTCCCCAGTTCGGAC GAGTCTGCAACTCGACTCCGTGAAG GATTCGCTAGTAATCGCGCATCAGC GGCGCGGTGAATAC 87					GGAACCTTACCCGGGATTGAAATGTAGA
TGTCGTCAGCTCGTGCCGTGAGGTC GCTTAAGTGCCATAACGAGCGCAAC CATCGGTAGTTGCTAACAGGTTTAGA AGGACTCTACCGAGACTGCCGTCGT GCGCGAGGAAGGTGTGGATGACGT ATCAGCACGGCCCTTACATCCGGGC CACACGTGTTACAATGGGAGGGACA GGCAGCTACCGGGCGCCCTTACATCCGGGC CACACGTGTTACAATGGGAGGGACA GGCAGCTACCGGGCACCAGTTCGGAAG GATTCGCTAGTAATCGCGCATCAGC GGCGCGGTGAATAC 87 P. cansulci NA CACGCCGTAAACGATGATTACTCGG GACGTTAAGTAATCACCTGGGGAA polynucleotide sequence TGACGGGGGCCCGCACAAGCGGAG CATGTGGTTTAATTCGATGATACCCC GAACCTTACCCGGGATTGAAATTACCCC GAACCTTACCCGGGATTGAAATTACCCC GAACCTTACCCGGGATTGAAATTACCCC GGACCGCACGAGGAGGTGTTATCCCC GGGCCACCAGGCGAGAGTTGAAATTACCCC GGACCTTACCCGGGATTGAAATTACCCC GGGCCACCAGGCGAGAGTTGTTATCCCC GGGGCATCTATGTAGGTGCTGCATCC					CGACGGATGGTGAAAGCCGTCTTCCCTT
GCTTAAGTGCCATAACGAGCGCAACC CATCGGTAGTTGCTAACAGGTTTAGA AGGACTCTACCGAGACTGCCGTCGT GCGCGAGGAAGGTGTGGATGACGT ATCAGCACGGCCCTTACATCCGGGC CACACGTGTTACAATGGGAGGGACA GGCAGCTACCGGGCGACCGGGTGC TCTCGAAACCCTTCCCCAGTTCGGAA GATTCGCTAGTAATCGCGCATCAGC GGCGCGGTGAATAC 87 P. cansulci B46 168 ATGCGATATGAGTGTATGCTTCTTACA FRNA AAGCGTTAAGTAATCCACCTGGGGA CATCGCCAACGATGAATCCACCTGGGGA CATCGGCAACGATGAAACTCAAAGG Sequence TGACGGGGGCCCGCACAAGCGGAG CATGTGGTTTAATTCGATGATACCCC GAACCTTACCCGGGATTGAAATATACC GACAGGCAGCGAGAGTTGTTATCCCC GGGCCATCATGTAGCTCTCTTACCCC GGGCCATCTATCTCGCGGATTGAAATATACCCC GAACCTTACCCGGGATTGAAATATACCCC GGGGCATCTATGTAGGTGCTGCATCCCC GGGGCATCTATGTAGGTGCTGCATCCCC GGGGCATCTATGTAGGTGCTGCATCCCC GGGGCATCTATGTAGGTGCTGCATCCCC					CGGGGCGTCTATGTAGGTGCTGCATGGT
CATCGGTAGTTGCTAACAGGTTTAGG AGGACTCTACCGAGACTGCCGTCGT GCGCGAGGAAGGTGTGGATGACGT ATCAGCACGGCCCTTACATCCGGGC CACACGTGTTACAATGGGAGGGACA GGCAGCTACCGGGCGACCGGGTGC TCTCGAAACCCTTCCCCAGTTCGGAA GAGTCTGCAACTCGACTCCGTGAAG GATTCGCTAGTAATCGCGCATCAGC GGCGCGGTGAATAC 87					TGTCGTCAGCTCGTGCCGTGAGGTGTCG
AGGACTCTACCGAGACTGCCGTCGT GCGCGAGGAAGGTGTGATGACGT ATCAGCACGGCCCTTACATCCGGGC CACACGTGTTACAATGGGAGGGACA GGCAGCTACCGGGCGACCGGGTGC TCTCGAAACCCTTCCCCAGTTCGGA GAGTCTGCAACTCGACTCCGTGAAG GATTCGCTAGTAATCGCGCATCAGC GGCGCGGTGAATAC 87					GCTTAAGTGCCATAACGAGCGCAACCCA
GCGCGAGGAAGGTGTGGATGACGT ATCAGCACGGCCCTTACATCCGGGC CACACGTGTTACAATGGGAGGGACA GGCAGCTACCGGGCGACCGGGTGC TCTCGAAACCCTTCCCCAGTTCGGAC GAGTCTGCAACTCGACTCCGTGAAG GATTCGCTAGTAATCGCGCATCAGC GGCGCGGTGAATAC 87 P. cansulci B46 168 ATGCGATATGAGTGTATGCTTCTTAG rRNA AAGCGTTAAGTAATCCACCTGGGGA polynucleotide Sequence TGACGGGGGCCCGCACAAGCGAGG CATGTGGTTTAATTCGATGATACCCC GAACCTTACCCGGGATTGAAATATAC GACAGGCAGCGAGAGTTGTTATCCCC GGGGCATCTATGTAGGTGTTTATCCCC GGGGCATCTATGTAGGTGTTATCCCC GGGGCATCTATGTAGGTGTTATCCCC GGGGCATCTATGTAGGTGCTTCTTACCCC GGGGCATCTATGTAGGTGCTTCTTACCCC GGGGCATCTATGTAGGTGCTGCATCCCC					CATCGGTAGTTGCTAACAGGTTTAGCTG
ATCAGCACGGCCCTTACATCCGGGCCCACACGGCCCCTTACATCCGGGCCCACACGTGTTACAATGGGAGGACACGGCACACGGTTACAATGGGAGGACACGGCACCCGGGTGCACCGGCACCCGGTTCGGAACGCACCCTTCCCCAGTTCGGAACGCACCCTTCCCCAGTTCGGAACGCACCCTTCCCCAGTTCGGAACGCACCCTTCCCCAGTTCGGAACGCACCCTCGCCAACCCACCACCCGCACAACGATGATTACTCGGAACCCTTCACCCCTCGAACGAA					AGGACTCTACCGAGACTGCCGTCGTAAG
CACACGTGTTACAATGGGAGGGACA GGCAGCTACCGGGCGACCGGGTGC TCTCGAAACCCTTCCCCAGTTCGGA GAGTCTGCAACTCGACTCCGTGAAG GATTCGCTAGTAATCGCGCATCAGC GGCGCGGTGAATAC 87					GCGCGAGGAAGGTGTGGATGACGTCAA
GGCAGCTACCGGGCGACCGGGTGC TCTCGAAACCCTTCCCCAGTTCGGAC GAGTCTGCAACTCGACTCCGTGAAG GATTCGCTAGTAATCGCGCATCAGC GGCGCGGTGAATAC 87 P. cansulci B46 168 rRNA polynucleotide sequence TGACGGGGGCCCGCACAAGCGGAG CATGTGGTTAATTCGATGATACTCAAGG GAACCTTACCCGGGATTCATTACTCACCTGGGGACCATCAAGCGAACCAAGCGAAGCGAAGCGAAGCGAAGCGAAGCGAAGCGAAGCGAAGCGGAGCAACCTTACCCGGGATTCAATACGCACTTACCCGGGATTCAAATACGCACCTTACCCGGGATTCAAATATACGAACCTTACCCGGGATTCAAATATACGAACCTTACCCGGGATTCAAATATACCGAACCTTACCCGGGATTCAAATATACCGAACCTTACCCGGGATTCAAATATACGAACCTTACCCGGGATTCAAATATACCGAACCTTACCCGGGATTCAAATATACCGAACCTTACCCGGGATTCAAATATACCGAACCTTACCCGGGATTCAAATATACCGAACCTTACCCGGGATTCAAATATACCGAACCTTACCCGGGATTCAAATATACCGAACCTTACCCGGGATTCAAATATACCGAACCTTACCCGGGATTCAAATATACCGAACCTTACCCGGGATTCAAATATACCGAACCTTACCCGGGATTCAAAATATACCGAACCTTACCCGGGATTCAAAATATACCGAACCTTACCCGGGATTCAAAATATACCGAACCTTACCCGGGATTCAAAATATACCGAACCTTACCCGGGATTCAAAATATACCGAACCTTACCCGGGATTCAAAATATACCGAACCTTACCCGGGATTCAAAATATACCGAACCTTACCCGGGATTCAAAATATACCGAACCTTACCCGGGATTCAAAATATACCGAACCTTACCCAACCGAACCTTACCCAACCGAACCTTACCCCGGGATTCAAAATATACCAACCGAACCTTACCCAACCGAACCTTACCCAACCGAACCTTACCCCGGGATTCAAAATATACCAACCA		:			ATCAGCACGGCCCTTACATCCGGGGCGA
TCTCGAAACCCTTCCCCAGTTCGGAAGGAGTCTGCAACTCGACTCCGTGAAGGAGTCTGCAACTCGACTCCGTGAAGGATTCGCTAGATACCCGGCGCGCGC					CACACGTGTTACAATGGGAGGGACAAAG
GAGTCTGCAACTCGACTCCGTGAAG GATTCGCTAGTAATCGCGCATCAGC GGCGCGGTGAATAC 87 P. cansulci B46 168 rRNA polynucleotide sequence TGACGGGGGCCCGCACAAGCGAG CATGTGGTTAATTCGATGATACGC GAACCTTACCCGGGATTAATCCACCTGGGAGCACGATGATACTCAAAGCGATGATAACTCAAAGCGAGGAACCCGAAGCGAAGCGAAGCGAAGCGAAGCGAAGCGAAGCGAAGCGAAGCGAAGCGAAGCGAAGCGAAGCGAAGCGAAGCGGAGCAACCTTACCCGGGATTGAAATATAACGACGAAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAACCTTACCCGGGATTGAAATATACGACGAGCAAGCA					GGCAGCTACCGGGCGACCGGGTGCGAA
GATTCGCTAGTAATCGCGCATCAGC GGCGCGGTGAATAC 87 P. cansulci B46 168 rRNA polynucleotide sequence TGACGGGGGGCCCGCACAAGCGATG CATGTGGTTTAATTCGATGAACTCAAAGG GAACCTTACCCGGGATTTAATTCGATGATACCCCGGGATTTAATTCGATGATACCCCGGGATTTAATTCGATGATACCCCGGGATTTAATTCGATGATACCCCGGGATTTAATTCGATGATACCCCGGGATTTAATTCCCCGGGATTTAATTCCCCGGGATTTAATTCCCCGGGATTTAATTCCCCGGGATTTAATTCCCCGGGATTTAATTCCCCGGGATTTAATTCCCCGGGATTTAATTCCCCGGGATTTAATTCCCCGGGATTTAATTCCCCGGGATTTAATTCCCCGGGATTTAATTCCCCGGGATTTAATTCCCCGGGATTTAATTCCCCGGGATTTAATTCCCCGGGATTCATCCCCGGGATTCATCCCCGGGATTCATCCCCGGGATTCATCCCCGGGATTCATCCCCGGGATTCATCCCCGGGATTCATCCCCGGGATTCATCCCCGGGATTCATCCCCGGGATTCATCCCCGGGATTCATCCCCGGGATTCATCCCCCGGGATTCATCCCCCGGGATTCATCCCCCGGGATTCATCCCCATCCCATCCCATCCAT					TCTCGAAACCCTTCCCCAGTTCGGATCG
GGCGCGGTGAATAC 87 P. cansulci B46 168 rRNA polynucleotide sequence TGACGGGGGCCCGCACAAGCGATGATTCCAAAGG CATGTGGTTTAATTCGATGAACTCAAAGC GAACCTTACCCGGGATTAAATCCACCTGGGAACACTCAAAGC GAACCTTACCCGGGATTGAAATATACCCCGGGAACCCTTATGTAGGTGCTGCATGAAACTATACCCCGGGATTGAAATATACCCCGGGATTGAAATATACCCCGGGAACCCTTATGTAGGTGCTGCATGAAACCTCAAAGCCGAAGCCAAAGCCGAAGCCAAAGCCCAAAGCCGAAGCCCAAAACCCCAAAACCCCAAAACCCCAAAACCCCAAAACCCC					GAGTCTGCAACTCGACTCCGTGAAGCTG
87 P. cansulci B46 16S rRNA polynucleotide sequence CACGCCGTAAACGATGATTACTCGG ATGCGATATGAGTGATTACTCTGG AAGCGTTAAGTAATCCACCTGGGGA CGTCGGCAACGATGAAACTCAAAGG CATGTGGTTTAATTCGATGATACGCG GAACCTTACCCGGGATTGAAATATACG GACAGGCAGCGAGAGTTGTTATCCC GGGGCATCTATGTAGGTGCTGCATG					GATTCGCTAGTAATCGCGCATCAGCCAT
B46 16S rRNA polynucleotide sequence GAACCTTACCGGGATTTACTCACCTGGGGATTGACCTCACAGGGGGGGG	ŧ				GGCGCGGTGAATAC
rRNA polynucleotide sequence CGTCGGCAACGATGAAACTCAAAGG TGACGGGGGCCCGCACAAGCGGAG CATGTGGTTTAATTCGATGATACGCG GAACCTTACCCGGGATTGAAATATAC GACAGGCAGCGAGAGTTGTTATCCC GGGGCATCTATGTAGGTGCTGCATG	P.	7	P. cansulci	NA	CACGCCGTAAACGATGATTACTCGGAGT
polynucleotide CGTCGGCAACGATGAAACTCAAAGG sequence TGACGGGGGCCCGCACAAGCGGAG CATGTGGTTTAATTCGATGATACGCC GAACCTTACCCGGGATTGAAATATAC GACAGGCAGCGAGAGTTGTTATCCC GGGGCATCTATGTAGGTGCTGCATG	В4		B46 16S		ATGCGATATGAGTGTATGCTTCTTAGCGA
sequence TGACGGGGCCCGCACAAGCGGAG CATGTGGTTTAATTCGATGATACGCC GAACCTTACCCGGGATTGAAATATAC GACAGGCAGCGAGAGTTGTTATCCC GGGGCATCTATGTAGGTGCTGCATG	rRI		rRNA		AAGCGTTAAGTAATCCACCTGGGGAGTA
CATGTGGTTTAATTCGATGATACGCC GAACCTTACCCGGGATTGAAATATAC GACAGGCAGCGAGAGTTGTTATCCC GGGGCATCTATGTAGGTGCTGCATG	pol		polynucleotide		CGTCGGCAACGATGAAACTCAAAGGAAT
GAACCTTACCCGGGATTGAAATATAG GACAGGCAGCGAGAGTTGTTATCCC GGGGCATCTATGTAGGTGCTGCATG	sec		sequence		TGACGGGGCCCGCACAAGCGGAGGAA
GACAGGCAGCGAGAGTTGTTATCCC GGGGCATCTATGTAGGTGCTGCATG	ļ				CATGTGGTTTAATTCGATGATACGCGAG
GGGGCATCTATGTAGGTGCTGCATG					GAACCTTACCCGGGATTGAAATATAGAT
				/	GACAGGCAGCGAGAGTTGTTATCCCTTC
GTCGTCAGCTCGTGCCGTGAGGTGT					GGGGCATCTATGTAGGTGCTGCATGGTT
					GTCGTCAGCTCGTGCCGTGAGGTGTCG
GCTTAAGTGCCCTAACGAGCGCAAC					GCTTAAGTGCCCTAACGAGCGCAACCCA
CATTATTAGTTACTAACAGGTTAAGC					CATTATTAGTTACTAACAGGTTAAGCTGA
GGACTCTAATAAGACTGCCGGCGTA					GGACTCTAATAAGACTGCCGGCGTAAGC

-19-

SEQ ID NO.	Name	Target	DNA Sequence
			CGTGAGGAAGGTGTGGATGACGTCAAAT
			CAGCACGGCCCTTACATCCGGGGCGAC
			ACACGTGTTACAATGGTAGGGACAAAGG
			GCAGCTACCGGGCGACCGGATGCGAAT
			CTCCAAACCCTATCCCAGTTCGGATCGG
			AGTCTGCAACTCGACTCTGTGAAGCTGG
			ATTCGCTAGTAATCGCGCATCAGCCATG
			GCGCGGTGAATAC
88	P.	NA	CACGCTGTAAACGATGAATACTAGATTTT
	circumdentari		TGCGATATACAGTAAGAGTCTAAGCGAA
	а		AGCGATAAGTATTCCACCTGGGGAGTAC
	B52 16S		GCCGGCAACGGTGAAACTCAAAGGAATT
	rRNA		GACGGGGCCCGCACAAGCGGAGGAAC
	polynucleotide		ATGTGGTTTAATTCGATGATACGCGAGG
	sequence		AACCTTACCTGGGATTGAAATTTAGGAGA
			ACGATTTATGAAAGTAGATTTTCCCTTCG
			GGGCTCCTAAGTAGGTGCTGCATGGTTG
			TCGTCAGCTCGTGCCGTGAGGTGTCGGC
			TTAAGTGCCATAACGAGCGCAACCCGCG
			TTGATAGTTACTAACAGATAAAGCTGAGG
			ACTCTATCGAGACAGCCGTCGTAAGACG
			CGAGGAAGGGCGGATGACGTCAAATC
			AGCACGGCCCTTACATCCAGGGCGACAC
			ACGTGTTACAATGGCAAGGACAAAGGGA
			AGCCACATAGCGATATGGAGCAGATCCT
			CAAACCTTGTCCCAGTTCGGATCGGAGT
			CTGCAACTCGACTCCGTGAAGCTGGATT
			CGCTAGTAATCGCGCATCAGCCATGGCG
			CGGTGAATACC
89	P. gulae	NA	CACGCAGTAAACGATGATTACTAGGAGT
	B69 16S		TTGCGATATACCGATAAGCTTCCACAGC
	rRNA		GAAAGCGTTAAGTAATCCACCTGGGGAG
	polynucleotide		TACGCCGGCAACGGTGAAACTCAAAGGA
	sequence		ATTGACGGGGGCCCGCACAAGCGGAGG
			AACATGTGGTTTAATTCGATGATACGCGA
			GGAACCTTACCCGGGATTGAAATGTAGA
ļ			TGACAGATGGTGAAAGCCGTCTTCCCTT
1			CGGGGCGTCTATGTAGGTGCTGCATGGT

-20-

GCTTAAGTGCCATAACGAGCGCAACCCC TATCGGTAGTTGCTAACAGGTCAAGCTC AGGACTCTACCGAGACTGCCGTCGTAA GCGAGAGGAAGGTGTGGATGACGTCAA TCAGCACGGCCCTTACATCCGGGGCGA ACACGTGTTACAATGGGAGGACAACG ACACGTGTTACAATGGGAGGACAAAG GCAGCACCGGCGCGACCGGATCGGAAC CTCGAAACCCTTCCCCAGTTCGGATCG AGTCTGCAACTCGGACCATC GCGCGGTGAATCC 90 P. NA CACGCTGTAACGATGAATACTAGATTT TGCGATATACAGTAGAGTCTAAGCGAA B97 16S GCCGCAACACGGTGAAACCACCAGCGAGGAGAA ACCGATAACAGAAACCAAAGCGAAGAAACCAAAGCGAAGAAACCAAAGAATACCAAAGAATACCAAAGAATACCAAAGAATACCAAAGAATACCAAAGAATACCAAAGAATACCAAAGAATACCAAAGAATACCAAAGAAACCAAAGAATACCAAAGAAACCAAAGAATACCAAGAAACCAAAGAAACCAAAGAAACCAAAGAAAACCAAAGAAAACCAAAGAAAACCAAAGAAAACCAAAGAAAACCAAAGAAAACCAAAGAAAACCAAAGAAAACCAAAGAAACCAAAGAAACCAAACAAGAACCAAACCAACCAGCAACCCGCACAAACGAACCAACCAGACCAACCAGACCAACCAGACCAACCAGAACCAAACGAACCAGACCAAACAAC	SEQ ID NO.	Name	Target	DNA Sequence
TATCGGTAGTTGCTAACAGGTCAAGCTC AGGACTCTACCGAGACTGCCGTCGTAAA GCGAGAGGAAGGTGTGGATGACGTCAA TCAGCACGGCCCTTACATCCGGGGCGAA TCAGCACGGCCCTTACATCCGGGGCGAAACG GCAGCTTACAATGGGAGGACAAAAG GCAGCTTTACAATGGGAGGACAAAAG GCAGCTACCGGGCGACCGGATCGGAAAC CTCGAAACCCTTCCCCAGTTCGGATCG AGTCTGCAACTCGACTCCGTGAAGCTG ATTCGCTAGTAATCGCGCATCAGCCATC GCGCGGTGAATACC 90 P. NA CACGCTGTAAACGATGAATACTAGATTT TGCGATATACAGTAAGAGTCTAAAGCGAA B97 16S GCCGGCAACGGTGAAACCAAAGCGAAAAGAAT GACGGGGGCCCGCACAAACCGAAGCAGAAAAAAAAAA				TGTCGTCAGCTCGTGCCGTGAGGTGTCG
AGGACTCTACCGAGACTGCCGTCGTAAA GCGAGAGGAAGGTGTGGATGACGTCAAA TCAGCACGGCCCTTACATCCGGGGCGAA ACACGTGTTACAATGGGAGGGACAAAAG GCAGCTACCGGGCGACCGGATGCGAAA CTCGAAACCCTTCCCCAGTTCGGATCG AGTCTGCAACTCGACTCCGTGAAGCTG ATTCGCTAGTAATCGCGCATCAGCCATC GCGCGGTGAATACC 90 P. NA CACGCTGTAAACGATGAATACTAGATTT GCGATATACAGTAAGAGTCTAAAGCAATACAAGAATACTAGAATA BB97 16S GCCGGCAACGGTGAAACTCAAAAGGAAT GACGGACCCGCACAAAGCGGAGGAAA Polynucleotide Sequence AACCTTACCTGGGATTGAAATTTCCCCTTC GGGCTCCTAAGTAGATTTACCCTTC GGGCTCCTAAGTAGGTGCCGTGAAGATGCTCAAA CACGATTTACTAACAGGTAATTCCCTTC GGGCTCCTAAGTAGGTGCCGTGAAGATGCTGAAC CACGTGTTACATCAAGGAACCGCACAACGCGAACCGCACAACGCGAACCCGCACAACGCGAACCCGCACAACGCGAACCCGCACAACGCGAACCCGCACAACGCGAACCCGCACAACGCGAACCCGCACAACGCGAACCCGCACAACGCGAACCCGCACAACGCGAACCCGCACACCCGCACAACCCGCACACCCGCACAACCCGCACCCACCCGCACACCCGCACACCCGCACACCCGCACACCCGCACCCACCCGCACACCCGCACCCACCCGCACACCCGCACCCACCCGCACACCCGCACCCACCCGCCACACCCGCCACACCCGCACACCCGCCACACCCGCCACACCCGCACACCCGCCACACCCGCACACCCGCCACACCCGCCACACCCGCCACACCCGCCACACCCGCCACACCCGCACACCCACCA				GCTTAAGTGCCATAACGAGCGCAACCCA
GCGAGAGGAAGGTGTGGATGACGTCAA TCAGCACGGCCCTTACATCCGGGGCGAA ACACGTGTTACAATGGGAGGACAAAAG GCAGCTACCGGGCGACCGGATGCGAAA CTCGAAACCCTTCCCCAGTTCGGATCG AGTCTGCAACTCGACTCCGTGAAGCTG ATTCGCTAGTAATCGCGCATCAGCCATG GCGCGGTGAATACC 90 P. NA CACGCTGTAAACGATGAATACTAGATTT GCGATATACAGTAGAGGTCTAAGCGAA AGCGATAACAGTAAACGATGAATACTAGATTT AGCGATATACAGTAAACGATGAAATACTAGAGTAA B97 16S IRNA GACGGGGGCCCGCACAAGCGGAGGAAA Polynucleotide ATGTGGTTTAATTCGATGATACGCGAGGAGAAACGTTAACGGAGGAGAAACTCAAAGGAAT GGGCTCCTAAGTAGGTGCTGCATGGTT TCGTCAGCTCGTGCCGTGAGGTGTCGC TTAAGTGCCATAACAGGCAAACCCGC TCGATAGTTACTAACAGGTAATGCTGAAG GACTCTATCGAGACAGCCGCAACACGGCGAACCCGC TCGATAGTTACAACAGGTAATGCTGAAG GACTCTATCGAGACAGCCGCTCGTAAGA CAGCACGGCCCTTACATCCAGGGCGAA CAGCACGGCCCTTACATCCAGGGCGAAC CACGTGTTACAATGGCAAGGACAAAGG AAGCCACATAGCGATTCGGATCGGA				TATCGGTAGTTGCTAACAGGTCAAGCTG
TCAGCACGGCCTTTACATCCGGGGCGAAACGACACGGCTACAATGGGAGGAACAAAAGGAACCCTTCCCCAGTTCGGATCGAACCCTTCGCAAACCCTTCCCCAGTTCGGATCGAACCCTTCGCAACTCGACTCGGATCGAACCCTTCGCAACTCGACTCGGATCGAAGCTGATTCGCAACTCGACTCGGATCGAAGCTGATTCGCAACTCGACTCGGATCAGCCATCGCGGGGAATACCC 90				AGGACTCTACCGAGACTGCCGTCGTAAG
ACACGTGTTACAATGGGAGGGACAAAAG GCAGCTACCGGGCGACCGGATGCGAA CTCGAAACCCTTCCCCAGTTCGGATCG AGTCTGCAACTCGACTCCGTGAAGCTG ATTCGCTAGTAATCGCGCATCAGCCATC GCGCGGTGAATACC P. NA CACGCTGTAAACGATGAATACTAGATTT CCCTAGAAACCATCAACGAATACAAGGAATACAAGGAATACAAGGAATACAAGGAATACAAGGAATACAAAGGAATACAAAGGAATACAAAGGAATACAAAGGAATACAAAGGAATACAAAGGAATACAAAGGAATACAAAGGAATACAAAGGAATACAAAGGAATACAAAGGAATACACAAAGGAATACACCAAAAGGAATACACAAAGGAATACACAAAGGAATACACAAAGGAATACACCAAAGAAGAAACCCAAAAGAAGAAAACCAAAAACAAAAACAAAAACAAAAACAAAAACAAAA				GCGAGAGGAAGGTGTGGATGACGTCAAA
GCAGCTACCGGGCGACCGGATGCGAACCTCGAAACCCTTCCCCAGTTCGGATCGAAGCTGATCGAAACCCTTCCCCAGTTCGGATCGATC				TCAGCACGGCCCTTACATCCGGGGCGAC
CTCGAAACCCTTCCCCAGTTCGGATCG AGTCTGCAACTCGACTCCGTGAAGCTG ATTCGCTAGTAATCGCGCATCAGCCATC GCGCGGTGAATACC 90 P. NA CACGCTGTAAACGATGAATACTAGATTT TGCGATATACAGTAAGAGTCTAAGCGAA B97 16S GCCGGCAACGGTGAAACTCAAAGGAAT Polynucleotide sequence ACCTTACCTGGGATTGAAATTTCCACTGGAGGAGAA ACCTTACCTGGGATTGAAATTTCCCTTC GGGCTCCTAAGTAGGTGAAATTTCCCTTC GGGCTCCTAAGTAGGTGAAACTCAAAGAGTGTTAAGTGCGAGG TTAAGTGCCATAACGAGGCGAACCCGG TCGATAGTTACTAACAGGTAATGCTGAAA CAGCACTTACCTGAGACAGCGGAGGAAACCCGGC TCGATAGTTACTAACAGGTAATGCTGAAA CAGCACGGCCCTTACATCCAGGGCGAACCCGG CACGTGTTACAATCGCAAGAGAACCCGCACAAGCGGACCAAACCAAACCAAACCAAACAAC				ACACGTGTTACAATGGGAGGGACAAAGG
AGTCTGCAACTCGACTCCGTGAAGCTG ATTCGCTAGTAATCGCGCATCAGCCATC GCGCGGTGAATACC 90 P. circumdentari a B97 16S IRNA polynucleotide sequence ACCTTACCTAGGATTGAACTTCACCGAGGAGGAGGAGGAGGATTTTCGACCTAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG				GCAGCTACCGGGCGACCGGATGCGAAT
ATTCGCTAGTAATCGCGCATCAGCCATC GCGCGGTGAATACC P. NA CACGCTGTAAACGATGAATACTAGATTT GCGATATACAGTAAGAGTCTAAGCGAA B97 16S IRNA polynucleotide sequence ACGTTACTGGGATTGAAACTCAAAGGAAT GGGCTCCTAAGTGAATTCCACCTGGGGAGGAA ACCTTACCTGGGATTGAAACTCAAAGGAAT TCGTCAGCTCGTGCCGTGAGGTGAAACTTACGCGAGG ACGATTTATGAAAGTAGATTTCCCTTC GGGCTCCTAAGTAGGTGCCGTGAAGTTTCCCTTC GGGCTCCTAAGTACGCGAGCGAACCCGG TCGATAGTTACTAACAGGTAATGCTGAA GACTCTATCGAGACAGCCGTCGTAAGA GAGAGGAAGGGCGGATGACGTCAAA CAGCACGGCCCTTACATCCAGGGCGA CACGTGTTACAATGGCAAAGAG AAGCCACATAGCGATTGGACAGATC TCAAACCTTGTCCCAGTTCGGATCGGA				CTCGAAACCCTTCCCCAGTTCGGATCGG
GCGCGGTGAATACC P. NA CACGCTGTAAACGATGAATACTAGATTT Circumdentari a H897 16S GCGGCAACGGTGAAACTCAAAGGAAT Polynucleotide ACCGTTAATCCGCCACAAGCGGAGGAAACTTAATCCGCGAAGCGGAGGAAACTTAATTCCGTTGAAATTTAGGACACTTAACTTAATTCGATGAATTTAATTCCTTCC				AGTCTGCAACTCGACTCCGTGAAGCTGG
P. CACGCTGTAAACGATGAATACTAGATTT Circumdentari a				ATTCGCTAGTAATCGCGCATCAGCCATG
circumdentari a B97 16S B97 16S GCCGCAACGGTGAAACTCAAAGGAAT polynucleotide sequence AACCTTACCTGGGATTTCCACCTGGGAGAA ACCTTACCTGGGATTAATTCGATGATACGCGAG ACGATTTATGAAAGTATTCCATTCC				GCGCGGTGAATACC
AGCGATAAGTATTCCACCTGGGGAGTA B97 16S GCCGGCAACGGTGAAACTCAAAGGAAT GRNA polynucleotide sequence AACCTTACCTGGGATTGAAATTTAGGAC ACGATTTATGAAAGTAGTATTCCCTTC GGGCTCCTAAGTAGGTGCTGCATGGTT TCGTCAGCTCGTGCCGTGAGGTGTCGC TTAAGTGCCATAACGAGCGCAACCCGC TCGATAGTTACTAACAGGTAATGCTGAC GACTCTATCGAGACAGCCGTCGTAAGA GACGACGGCCCTTACATCCAGGGCGAAC CAGCACGGCCCTTACATCCAGGGCGAAC CACGTGTTACAATGGCAAGGACAAAGG AAGCCACATAGCGATTCGAGACAGCCGTC TCAAACCTTGTCCCAGTTCGGATCGGA	90	P.	NA	CACGCTGTAAACGATGAATACTAGATTTT
B97 16S rRNA polynucleotide sequence ACCTTACCTGGGATTGAAATTTAGGAC ACGATTTATGAAAGTAGATTTCCTTC GGGCTCCTAAGTAGGTGCCATGGTT TCGTCAGCTCGTGCCGTGAGGTGAACCCGC TTAAGTGCCATAACAGGTGAACCCGC TCGATAGTTACTAACAGGTAATGCTGAC GACTCTATCGAGACAGCCGTCGAAGACCCGC TCGATAGTTACTAACAGGTAATGCTGAC GACTCTATCGAGACAGCCGTCGTAAGAC GACTCTATCGAGACAGCCGTCAAACCAGGCCCTTACATCCAGGGCGAC CAGCACGGCCCTTACATCCAGGGCGAC CACGTGTTACAATGGCAAGGACAAAGG AAGCCACATAGCGATTCGGATCGGA		circumdentari		TGCGATATACAGTAAGAGTCTAAGCGAA
rRNA polynucleotide sequence ACCTTACCTGGGATTGAAATTTAGGAG ACGATTTATTGATGAGATTTAGGAG ACGATTTATGAAAGTTGAAATTTAGGAG ACGATTTATGAAAGTAGATTTTCCCTTC GGGCTCCTAAGTAGGTGCTGCATGGTT TCGTCAGCTCGTGCCGTGAGGTGTCGG TTAAGTGCCATAACGAGCGCAACCCGG TCGATAGTTACTAACAGGTAATGCTGAG GACTCTATCGAGACAGCCGTCGTAAGA CAGCACGGCCCTTACATCCAGGGCGAG CACGTGTTACAATGGCAAGGGACAAAGG AAGCCACATAGCGATATGGAGACAGAGG TCAAACCTTGTCCCAGTTCGGATCGGA		а		AGCGATAAGTATTCCACCTGGGGAGTAC
polynucleotide sequence AACCTTACCTGGGATTGAAATTTAGGACACGATTTATTAGGACACGATTTATGAAAGTAGATTTTCCCTTCAGGCTCCTAAGTAGGTGCTGCATGGTTTCGTCAGCTCGTGCCGTGAGGTGTCGCCTAAGTAGCCATAACGAGCGCAACCCGCATAAGTAGCTAAACGAGCGCAACCCGCATAAGTAGCAGACACGCGTCGTAAGAAGAGAGAAGGGAAAGGGGAAGGGAAAAAAAA		B97 16S		GCCGGCAACGGTGAAACTCAAAGGAATT
AACCTTACCTGGGATTGAAATTTAGGACACGATTTATGAAAGTAGATTTTCCCTTCGGGCTCCTAAGTAGGTGCTGCATGGTTTCGTCAGCTCGTGCAGGTGCCGTGAGGTGCCGCAACCCGCGTAAGTAA		rRNA		GACGGGGCCCGCACAAGCGGAGGAAC
ACGATTTATGAAAGTAGATTTTCCCTTC GGGCTCCTAAGTAGGTGCTGCATGGTT TCGTCAGCTCGTGCCGTGAGGTGTCGC TTAAGTGCCATAACGAGCGCAACCCGC TCGATAGTTACTAACAGGTAATGCTGAC GACTCTATCGAGACAGCCGTCGTAAGA GAGAGGAAGGGGCGGATGACGTCAAA CAGCACGGCCCTTACATCCAGGGCGAC CACGTGTTACAATGGCAAGGACAAAGG AAGCCACATAGCGATATGGAGCAGATC TCAAACCTTGTCCCAGTTCGGATCGGA		polynucleotide		ATGTGGTTTAATTCGATGATACGCGAGG
GGGCTCCTAAGTAGGTGCTGCATGGTT TCGTCAGCTCGTGCCGTGAGGTGTCGC TTAAGTGCCATAACGAGCGCAACCCGC TCGATAGTTACTAACAGGTAATGCTGAC GACTCTATCGAGACAGCCGTCGTAAGA GAGAGGAAGGGCGGATGACGTCAAA CAGCACGGCCCTTACATCCAGGGCGAC CACGTGTTACAATGGCAAGGACAAAGG AAGCCACATAGCGATATGGAGCAGATC TCAAACCTTGTCCCAGTTCGGATCGGA		sequence		AACCTTACCTGGGATTGAAATTTAGGAGA
TCGTCAGCTCGTGCCGTGAGGTGTCGC TTAAGTGCCATAACGAGCGCAACCCGC TCGATAGTTACTAACAGGTAATGCTGAC GACTCTATCGAGACAGCCGTCGTAAGA GAGAGGAAGGGGCGGATGACGTCAAA CAGCACGGCCCTTACATCCAGGGCGAC CACGTGTTACAATGGCAAGGACAAAGG AAGCCACATAGCGATATGGAGCAGATC TCAAACCTTGTCCCAGTTCGGATCGGA				ACGATTTATGAAAGTAGATTTTCCCTTCG
TTAAGTGCCATAACGAGCGCAACCCGC TCGATAGTTACTAACAGGTAATGCTGAC GACTCTATCGAGACAGCCGTCGTAAGA GAGAGGAAGGGGCGGATGACGTCAAA CAGCACGGCCCTTACATCCAGGGCGAC CACGTGTTACAATGGCAAGGACAAAGG AAGCCACATAGCGATATGGAGCAGATC TCAAACCTTGTCCCAGTTCGGATCGGA				GGGCTCCTAAGTAGGTGCTGCATGGTTG
TCGATAGTTACTAACAGGTAATGCTGACGACTCTATCGAGACAGCCGTCGTAAGAAGAGGAGGGGGGGG				TCGTCAGCTCGTGCCGTGAGGTGTCGGC
GACTCTATCGAGACAGCCGTCGTAAGA GAGAGGAAGGGGCGGATGACGTCAAA CAGCACGGCCCTTACATCCAGGGCGAC CACGTGTTACAATGGCAAGGACAAAGG AAGCCACATAGCGATATGGAGCAGATC TCAAACCTTGTCCCAGTTCGGATCGGA				TTAAGTGCCATAACGAGCGCAACCCGCG
GAGAGGAAGGGCGGATGACGTCAAA CAGCACGGCCCTTACATCCAGGGCGAC CACGTGTTACAATGGCAAGGACAAAGG AAGCCACATAGCGATATGGAGCAGATC TCAAACCTTGTCCCAGTTCGGATCGGA				TCGATAGTTACTAACAGGTAATGCTGAG
CAGCACGGCCCTTACATCCAGGGCGACCCACGGCCCACCCCACATGGCAAGGACAAAGGCAAGCCACATAGCGATATGGAGCAGATCCCAGTTCGGATCGGAACCTTGCCAACTCCGTGAAGCTGGATCGGATCGGAACCTAGCCATCAGCCATGGCCATCAGCCATGAGCCATGGCCATGAGCCATGAGCCATGGCCATGAGCCATGAGCCATGAGCCATGAGCCATGAGCCATGAGCCATGAGCCATGAGCCATGAGCCATGAGCCATGAGCCATGAAACCCATGAGCCATGAGCCATGAGCCATGAGCCATGAGCCATGAGCCATGAGCCATGAGCCATGAGCCATGAGCCATGAGCCATGAGCCATGAGCCATGAGCCATGAGCCATGAGCCATGAGCCATGAAACCCATGAGCCATGAGCCATGAGCCATGAGCCATGAGCCATGAGCCATGAGCCATGAGCCATGAGCCATGAGCCATGAGCCATGAGCCATGAGCCATGAGCCATGAGCCATGAGCCATGAGCCATGAAACCCATGAGAGCCATGAGAGCCATGAGAGCAAAGCCATGAGAGCCATGAGAGCCATGAGAGCCATGAGAGAAGAGAAAAAAAA				GACTCTATCGAGACAGCCGTCGTAAGAC
CACGTGTTACAATGGCAAGGACAAAGG AAGCCACATAGCGATATGGAGCAGATC TCAAACCTTGTCCCAGTTCGGATCGGA				GAGAGGAAGGGCGGATGACGTCAAAT
AAGCCACATAGCGATATGGAGCAGATC TCAAACCTTGTCCCAGTTCGGATCGGA				CAGCACGGCCCTTACATCCAGGGCGACA
TCAAACCTTGTCCCAGTTCGGATCGGA TCTGCAACTCGACTCCGTGAAGCTGGA TCGCTAGTAATCGCGCATCAGCCATGG				CACGTGTTACAATGGCAAGGACAAAGGG
TCTGCAACTCGACTCCGTGAAGCTGGA TCGCTAGTAATCGCGCATCAGCCATGG				AAGCCACATAGCGATATGGAGCAGATCC
TCGCTAGTAATCGCGCATCAGCCATGG				TCAAACCTTGTCCCAGTTCGGATCGGAG
				TCTGCAACTCGACTCCGTGAAGCTGGAT
GCGGTGAATAC				TCGCTAGTAATCGCGCATCAGCCATGGC
				GCGGTGAATAC

-21-

SEQ ID NO.	Name	Target	DNA Sequence
91	P.	NA	CAGTAAACGATGATTACTCGGAGTATGC
	cangingivalis		GATATATGGTATGCTCCCAAGGGAAACC
	B98 16S		GATAAGTAATCCACCTGGGGAGTACGCC
	rRNA		GGCAACGGTGAAACTCAAAGGAATTGAC
	polynucleotide		GGGGGCCCGCACAAGCGGAGGAACATG
	sequence		TGGTTTAATTCGATGATACGCGAGGAAC
ŧ			CTTACCCGGGATTGAAATGTACATGACG
!			GTTGGGCGAGAGCCTGACTTCCCTTCGG
			GGCATGTATGTAGGTGCTGCATGGTTGT
			CGTCAGCTCGTGCCGTGAGGTGTCGGCT
			TAAGTGCCATAACGAGCGCAACCCACAT
			CGTCAGTTACTAACAGGTAGAGCTGAGG
			ACTCTGACGAGACTGCCGTCGTAAGGCG
			CGAGGAAGGTGTGGATGACGTCAAATCA
			GCACGGCCCTTACATCCGGGGCGACAC
			ACGTGTTACAATGGTAGGGACAAAGGGC
			AGCTACCTGGCGACAGGATGCGAATCTC
			CAAACCCTATCTCAGTTCGGATCGGAGT
			CTGCAACTCGACTCCGTGAAGCTGGATT
			CGCTAGTAATCGCGCATCAGCCATGGCG
			CGGTGAATACGTT
92	P. salivosa	NA	CAGTAAACGATGATAACTGGGCGTATGC
	B104 16S	3	GATATACAGTATGCTCCTGAGCGAAAGC
	rRNA		GTTAAGTTATCCACCTGGGGAGTACGCC
1	polynucleotide		GGCAACGGTGAAACTCAAAGGAATTGAC
	sequence		GGGGGCCCGCACAAGCGGAGGAACATG
			TGGTTTAATTCGATGATACGCGAGGAAC
			CTTACCCGGGATTGAAATTTAGCGGACT
			ATGTATGAAAGTACATATCCTGTCACAAG
			GCCGCTAAGTAGGTGCTGCATGGTTGTC
			GTCAGCTCGTGCCGTGAGGTGTCGGCTT
			AAGTGCCATAACGAGCGCAACCCACGTT
			GTCAGTTACTATCGGGTAAAGCCGAGGA
			CTCTGACAAGACTGCCGTCGTAAGGCGC
			GAGGAAGGTGTGGATGACGT

SEQ ID NO.	Name	Target	DNA Sequence
93	P. denticanis	NA	CACGCCGTAAACGATGCTCACCGGCTCT
	B106 16S		ATGCGATAAGACAGTATGGGGCTAATAG
	rRNA		AAATAATTAAGTGAGCCACCTGGGGAGT
	polynucleotide		ACGTCGGCAACGATGAAACTCAAAGGAA
	sequence		TTGACGGGGCCCGCACAAGCGGAGGA
			ACATGTGGTTTAATTCGATGATACGCGAG
			GAACCTTACCCGGGTTTAAATGTATGTTG
			CATTATGTAGAAATACGTATTTTCTTCGG
			AACTGCATACAAGGTGCTGCATGGTTGT
			CGTCAGCTCGTGCCGTGAGGTGTCGGG
			TTAAGTCCCATAACGAGCGCAACCCTTAT
			GATTAGTTGCTAACGGTTCAAGCCGAGC
			ACTCTATTCACACTGCCACCGTAAGGTG
			CGAGGAAGGAGGGGATGATGTCAAATCA
			GCACGGCCCTTATATCCGGGGCTACACA
			CGTGTTACAATGGTCGGTACAGCGGGTT
			GCATTTACGTGAGTAACAGCTAATCCCAA
			AAATCGGTCTCAGTTCGGATTGGAGTCT
			GCAACTCGACTCCATGAAGTTGGATTCG
			CTAGTAATCGCACATCAGCCATGGTGCG
			GTGAATAC
94	P.	NA	CACCGCAGTAAACGATGAATACTAGATCT
	endodontalis		TTGCGATATACGGTAAGGGTCTAAGCGA
	B114 16S		AAGCGATAAGTATTCCACCTGGGGAGTA
	rRNA		CGTCGGCAACGATGAAACTCAAAGGAAT
	polynucleotide		TGACGGGGCCCGCACAAGCGGAGGAA
	sequence		CATGTGGTTTAATTCGATGATACGCGAG
			GAACCTTACCCGGGATTGAAATTTAGCG
			GGCGGGCTATGAGAGTAGCCTTTCCTAC
			GGGACTGCTAAGTAGGTGCTGCATGGTT
			GTCGTCAGCTCGTGCCGTGAGGTGTTGG
			CTTAAGTGCCATAACGAGCGCAACCCAC
			GTTGATAGTTACTAACAGTTAAAGCTGAG
			GACTCTATCGAGACAGCCGGCGTAAGCC
			GTGAGGAAGGTGTGGATGACGTCAAATC
			AGCACGGCCCTTACATCCGGGGCGACA
			CACGTGTTACAATGGTGAGGACAGCGGG
			AAGCGGCCTGGTGACAGGTAGCAGATCC
		<u> </u>	

-23-

SEQ ID NO.	Name	Target	DNA Sequence
			CCAAACCTCATCCCAGTTCGGATTGGAG
			TCTGCAACTCGACTCTATGAAGCTGGATT
			CGCTAGTAATCGCGCATCAGCCATGGCG
			CGGTGAATAC
95	P. gulae	NA	TCTAAATCGAAAAAGATCCTAATAAAACA
	B43 fimA		ATATTCACTTTTAAAACAAAAACGAGATG
	polynucleotide		AAAAAGACTAAGTTTTTCTTGTTGGGACT
	sequence		TGCTGCCCTTGCTATGACAGCTTGTAACA
			AAGACAACGAAGCAGAACCCGTTGTAGA
			AGGTAACGCTACCATTAGCGTAGTATTGA
			AGACCAGCAATCCGAATCGTGCTTTCGG
			GGTTGCAGATGACGAAGCAAAAGTGGCT
			AAACTGACTGTAATGGTCTACAAGGGTG
			AGCAGCAGGAAGCCATCAAATCAGCCGA
			AAATGCAATTAAGGTTGAGAACATCAAAT
			GTGGTGCAGGCTCACGTACGCTGGTCGT
			AATGGCCAATACGGGTGGAATGGAATTG
			GCTGGCAAGACTCTTGCAGAGGTAAAAG
			CATTGACAACTGAACTAACTGCAGAAAAC
			CAAGAGGCTACAGGTTTGATCATGACAG
			CAGAGCCTGTTGACGTAACACTTGTCGC
			CGGCAATAACTATTATGGTTATGATGGAA
			CTCAGGGAGGCAATCAGATTTCGCAAGG
			TACTCCTCTTGAAATCAAACGTGTTCATG
			CCCGTATTGCGTTCACCAAGATTGAAGT
			GAAGATGAGCGAGTCTTATGTGAACAAA
			TACAACTTTACCCCCGAAAACATCTATGC
			ACTTGTGGCTAAGAAGAAGTCTAATCTAT
			TCGGTACTTCATTGGCAAATAGTGATGAT
			GCTTATTTGACCGGTTCTTTGACGACTTT
			CAACGGTGCTTATACCCCTGCAAACTATA
	1		CTCATGTCGTCTGGTTGGGAAGAGGCTA
			CACAGCGCCTTCCAATGATGCTCCACAA
			GGTTTCTATGTTTTGGAGAGTGCATACGC
			TCAGAATGCAGGTCTACGTCCTACCATTC

-24-

SEQ ID NO.	Name	Target	DNA Sequence
	-	11	TATGTGTAAAGGGTAAGCTGACAAAGCA
			TGATGGTACTCCTTTGAGTTCTGAGGAAA
			TGACAGCTGCATTCAATGCCGGCTGGAT
			TGTTGCAAACAATGATCCTACGACCTATT
			ATCCTGTATTAGTGAACTTTGAGAGC
96	P.	NA	TAATGGAGAACAGCAGGAAGCCATCGAA
	circumdentari		TCAGCCGAAAATGCGACTAAGATTGAGA
	a		ATATCAAATGTGGTGCAGGCCAACGTAC
	B52 fimA		GCTGGTCGTAATGGCCAATACGGGTGGA
:	polynucleotide		ATGGAATTGGCTGGCAAGACTCTTGCAG
	sequence		AGGTAAAAGCATTGACAACTGTACTGACT
			GAAGAAAACCAAGAGGCCACAGGTTTGA
			TCATGACAGCAGAGCCAAAAGCAATCGT
			TTTGAAGGCAGGCAAGAACTATATTGGAT
			ACGATGGAGCCGGAGAGGGCAACCACA
			TTGAGAATGCTCCTCTTGAAATCAAACGT
			GTACATGCTCGCATGGCTTTCACCGAAA
			TTAAAGTACAGATGAGCGCAGCCTACGA
			TAACATTTACACATTTACCCCTGAAAAGA
			TTTATGGTCTCATTGCAAAGAAGCAATCT
			AATTTGTTCGGGGCAACACTCGTGAATG
		1	CAGACGCTAATTATCTGACAGGTTCTTTG
			ACCACATTTAACGGTGCTTACACACCTAC
			CAACTATGCCAATGTTCCTTGGTTGAGCC
			GTGATTACGTTGCACCTACCGCTGGTGC
			TCCTCAGGGCTTCTACGTATTAGAAAATG
			ACTACTCAGCTAACAGTGGAACTATTCAT
			CCGACAATCCTGTGTGTTTATGGCAAACT
			TCAGAAAAACGGAGCCGACCTGACGGGA
			ACCGATTTAGCAGCAGCTCAGGCCGCCA
			ATTGGGTGGATGCAGAAGGCAAG

-25-

OLG ID NO.	Name	Target	DNA Sequence
97	P. gulae	NA	GGCGCAGCATAACCTCGACGAACTGCGA
	B69 fimA		CACTATATGCAGGACAATCTCTAAATCGA
	polynucleotide		ATAAAGATTCTAATAAAACAATATTCACTT
	sequence		TTAAAACAAAACAAGATGAAAAAGACTA
!			AGTTTTCTTGTTGGGACTTGCTGCCCTT
			GCTATGACAGCTTGTAACAAAGACAACG
	:		AAGCAGAACCCGTTGTAGAAGGTAACGC
			TACCATTAGCGTAGTATTGAAGACCAGCA
			ATCCGAATCGTGTTTTCGGGGTTGCAGA
			TGACGAAGCAAAAGTGGCTAAGTTGACC
!			GTAATGGTTTATAATGGAGAACAGCAGG
			AAGCCATCGAATCAGCCGAAAATGCGAC
			TAAGATTGAGAATATCAAATGTGGTGCAG
			GCCAACGTACGCTGGTCGTAATGGCCAA
			TACGGGTGGAATGGAATTGGCTGGCAAG
		*	ACTCTTGCAGAGGTAAAAGCATTGACAA
			CTGTACTGACTGAAGAAAACCAAGGGGC
			CACAGGTTTGATCATGACAGCAGAGCCA
			AAAGCAATCGTTTTGAAGGCAGGCAAGA
			ACTATATTGGATACGATGGAGCCGGAGA
			GGGCAACCACATTGAGAATGCTCCTCTT
			GAAATCAAACGTGTACATGCTCGCATGG
			CTTTCACCGAAATTAAAGTACAGATGAGC
			GCAGCCTACGATAACATTTACACATTTAC
			CCCTGAAAAGATTTATGGTCTCATTGCAA
			AGAAGCAATCTAATTTGTTCGGGGCAAC
			ACTCGTGAATGCAGACGCTAATTATCTGA
			CAGGTTCTTTGACCACATTTAACGGTGCT
			TACACACCTACCAACTATGCCAATGTTCC
			TTGGTTGAGCCGTGATTACGTTGCACCT
			ACCGCTGGTGCTCCTCAGGGCTTCTACG
			TATTAGAAAATGACTACTCAGCTAACAGT
			GGAACTATTCATCCGACAATCCTGTGTGT
			TTATGGCAAACTTCAGAAAAACGGAGCC
			GACCTGACGGGAACCGATTTAGCAGCAG
			CTCAGGCCGCCAATTGGGTGGATGCAGA
			A

SEQ ID NO.	Name	Target	DNA Sequence
98	P.	NA	TAATGGAGAACAGCAGGAAGCCATCGAA
	circumdentari		TCAGCCGAAAATGCGACTAAGATTGAGA
	а		ATATCAAATGTGGTGCAGGCCAACGTAC
	B97 fimA		GCTGGTCGTAATGGCCAATACGGGTGGA
	polynucleotide		ATGGAATTGGCTGGCAAGACTCTTGCAG
	sequence		AGGTAAAAGCATTGACAACTGTACTGACT
			GAAGAAAACCAAGAGGCCACAGGTTTGA
			TCATGACAGCAGAGCCAAAAGCAATCGT
			TTTGAAGGCAGGCAAGAACTATATTGGAT
			ACGATGGAGCCGGAGAGGGCAACCACA
			TTGAGAATGCTCCTCTTGAAATCAAACGT
			GTACATGCTCGCATGGCTTTCACCGAAA
			TTAAAGTACAGATGAGCGCAGCCTACGA
			TAACATTTACACATTTACCCCTGAAAAGA
			TTTATGGTCTCATTGCAAAGAAGCAATCT
			AATTTGTTCGGGGCAACACTCGTGAATG
			CAGACGCTAATTATCTGACAGGTTCTTTG
			ACCACATTTAACGGTGCTTACACACCTAC
			CAACTATGCCAATGTTCCTTGGTTGAGCC
			GTGATTACGTTGCACCTACCGCTGGTGC
			TCCTCAGGGCTTCTACGTATTAGAAAATG
			ACTACTCAGCTAACAGTGGAACTATTCAT
			CCGACAATCCTGTGTGTTTATGGCAAACT
			TCAGAAAAACGGAGCCGACCTGACGGGA
			ACCGATTTAGCAGCAGCTCAGGCCGCCA
			ATTGGGTGGATGCAGAAGGCAAG
99	P.	NA	ggcctcgagAACAAAGACAACGAAGCAGAAC
	cangingivalis		CCGTTGTAGAAGGTAACGCTACCATTAG
	B98 fimA		CGTAGTATTGAAGACCAGCAATCCGAAT
	polynucleotide		CGTGCTTTCGGGGTTGCAGATGACGAAG
	sequence		CAAAAGTGGCTAAACTGACTGTAATGGT
			CTACAAGGGTGAGCAGCAGGAAGCCATC
			AAATCAGCCGAAAATGCAATTAAGGTTGA
			GAACATCAAATGTGGTGCAGGCTCACGT
			ACGCTGGTCGTAATGGCCAATACGGGTG
			GAATGGAATTGGCTGGCAAGACTCTTGC
			AGAGGTAAAAGCATTGACAACTGAACTAA
			CTGCAGAAAACCAAGAGGCTACAGGTTT

SEQ ID N	O. Name	Target	DNA Sequence
			GATCATGACAGCAGAGCCTGTTGACGTA
			ACACTTGTCGCCGGCAATAACTATTATGG
			TTATGATGGAACTCAGGGAGGCAATCAG
			ATTTCGCAAGGTACTCCTCTTGAAATCAA
			ACGTGTTCATGCCCGTATTGCGTTCACC
			AAGATTGAAGTGAAGATGAGCGAGTCTT
			ATGTGAACAAATACAACTTTACCCCCGAA
			AACATCTATGCACTTGTGGCTAAGAAGAA
			GTCTAATCTATTCGGTACTTCATTGGCAA
			ATAGTGATGATGCTTATTTGACCGGTTCT
			TTGACGACTTTCAACGGTGCTTATACCCC
			TGCAAACTATACTCATGTCGTCTGGTTGG
			GAAGAGGCTACACAGCGCCTTCCAATGA
			TGCTCCACAAGGTTTCTATGTTTTGGAGA
			GTGCATACGCTCAGAATGCAGGTCTACG
			TCCTACCATTCTATGTGTAAAGGGTAAGC
			TGACAAAGCATGATGGTACTCCTTTGAGT
	!		TCTGAGGAAATGACAGCTGCATTCAATG
			CCGGCTGGATTGTTGCAAACAATGATCC
			TACGACCTATTATCCTGTATTAGTGAACT
	9		TTGAGAGCAATAATTACACCTACACAGGT
			GATGCTGTTGAGAAAGGGAAAATCGTTC
			GTAACCACAAGTTTGACATCAATCTGACG
			ATCACCGGTCCTGGTACGAATAATC
100	P. salivosa	NA	TGGCTAARTTGACTGTAATGGTTTATAAT
	B104 <i>fimA</i>		GGAGAACAGCAGGAAGCCATCRAATCAG
	polynucleotide		CCGAAAATGCGACTAAGRTTGARRAYAT
	sequence	• •	CAAATGTRGTGCAGGCCAACGTACGCTG
			GTCGTAATGGCCAATACGGGTGSAATGG
			AAYTGGYTGGCAAGACTCTTGCAGAGGT
			AAAAGCATTGACAACTGWACTGACTGMA
			GAAAACCAAGAGGCYRCAGGKTTGATCA
			TGACAGCAGAGCCAAAARCAATCGTTTT
			GAAGGCAGGCAAGAACTAYATTGGATAC
			RRTGGARCCGGAGAGGGYAAYCACATTG
			AGAATGMTCCTCTTRARATCAARCGTGT
			WCATGCTCGCATGGCTTTCACCGAAATT
			AAAGTRCARATGAGCGCAGCCTACGATA

-28-

SEQ ID N	O. Name	Target	DNA Sequence
			ACATTTACACATTYRYCCCTGAAAAGATT
			TATGGTCTCATTGCAAAGAAGCAATCTAA
			TTTGTTCGGGGCAACACTCGTRAATGCA
			GACGCTAATTATCTGACAGGTTCTTTGAC
			CACATTTAACGGTGCTTACACACCTRCCA
			ACTATGCCAATGTKCCTTGGYTGAGCCG
			TRATTACGTTGCACCTRCCGCYGRTGCT
			CCTCAGGGYTTCTACGTATTAGAAAATGA
			CTACTCAGCTAACRGTGGAACTATTCATC
			CGACAATCCTGTGTGTTTATGGCAAACTT
			CAGAAAAACGGAGCCGACYTGRCGGGA
			RCCGATTTAGCARCWGCTCAGGCCGCC
			AATTGGGTGGATGCAGAAGGCAAGACCT
			ATTACCCTGTATTRGTRAACT
101	P. denticanis	NA	TAATGGAGAACAGCAGGAAGCCATCGAA
	B106 fimA		TCAGCCGAAAATGCGACTAAGATTGAGA
	polynucleotide		ATATCAAATGTGGTGCAGGCCAACGTAC
	sequence		GCTGGTCGTAATGGCCAATACGGGTGGA
			ATGGAATTGGCTGGCAAGACTCTTGCAG
			AGGTAAAAGCATTGACAACTGTACTGACT
			GAAGAAAACCAAGAGGCCACAGGTTTGA
			TCATGACAGCAGAGCCAAAAGCAATCGT
1			TTTGAAGGCAGGCAAGAACTATATTGGAT
			ACGATGGAGCCGGAGAGGGCAACCACA
<u> </u>			TTGAGAATGCTCCTCTTGAAATCAAACGT
			GTACATGCTCGCATGGCTTTCACCGAAA
			TTAAAGTACAGATGAGCGCAGCCTACGA
			TAACATTTACACATTTACCCCTGAAAAGA
			TTTATGGTCTCATTGCAAAGAAGCAATCT
			AATTTGTTCGGGGCAACACTCGTGAATG
			CAGACGCTAATTATCTGACAGGTTCTTTG
			ACCACATTTAACGGTGCTTACACACCTAC
			CAACTATGCCAATGTTCCTTGGTTGAGCC
			GTGATTACGTTGCACCTACCGCTGGTGC
			TCCTCAGGGCTTCTACGTATTAGAAAATG
			ACTACTCAGCTAACAGTGGAACTATTCAT
			CCGACAATCCTGTGTGTTTATGGCAAACT
			TCAGAAAAACGGAGCCGACCTGACGGGA

SEQ ID NO.	Name	Target	DNA Sequence
			ACCGATTTAGCAGCAGCTCAGGCCGCCA
			ATTGGGTGGATGCAGAAGGCAAG
102	P.	NA	CAAGGGTGAGCAGCAGGAAGCCATCAAA
	endodontalis		TCAGCCGAAAATGCAATTAAGGTTGAGA
1	B114 <i>fimA</i>		ACATCAAATGTGGTGCAGGCTCACGTAC
	polynucleotide		GCTGGTCGTAATGGCCAATACGGGTGGA
	sequence		ATGGAATTGGCTGGCAAGACTCTTGCAG
			AGGTAAAAGCATTGACAACTGAACTAACT
			GCAGAAAACCAAGAGGCTACAGGTTTGA
			TCATGACAGCAGAGCCTGTTGACGTAAC
			ACTTGTCGCCGGCAATAACTATTATGGTT
			ATGATGGAACTCAGGGGAGGCAATCAGAT
			TTCGCAAGGTACTCCTCTTGAAATCAAAC
			GTGTTCATGCCGTATTGCGTTCACCAA
			GATTGAAGTGAAGATGAGCGAGTCTTAT
		1	GTGAACAAATACAACTTTACCCCCGAAAA
			CATCTATGCACTTGTGGCTAAGAAGAAGT
			CTAATCTATTCGGTACTTCATTGGCAAAT
			AGTGATGATGCTTATTTGACCGGTTCTTT
			GACGACTTTCAACGGTGCTTATACCCCT
			GCAAACTATACTCATGTCGTCTGGTTGG
			GAAGAGGCTACACAGCGCCTTCCAATGA
			TGCTCCACAAGGTTTCTATGTTTTGGAGA
			GTGCATACGCTCAGAATGCAGGTCTACG
			TCCTACCATTCTATGTGTAAAGGGTAAGC
			TGACAAAGCATGATGGTACTCCTTTGAGT
	}		TCTGAGGAAATGACAGCTGCATTCAATG
			CCGGCTGGATTGTTGCAAACAATGATCC
		<u> </u>	TACG

SEQ ID NO.	Name	Target	DNA Sequence
103	P. gulae	NA	MKKTKFFLLGLAALAMTACNKDNEAEPVV
	B43 FimA		EGNATISVVLKTSNPNRAFGVADDEAKVAK
	polypeptide		LTVMVYKGEQQEAIKSAENAIKVENIKCGA
	sequence		GSRTLVVMANTGGMELAGKTLAEVKALTT
			ELTAENQEATGLIMTAEPVDVTLVAGNNYY
			GYDGTQGGNQISQGTPLEIKRVHARIAFTKI
			EVKMSESYVNKYNFTPENIYALVAKKKSNL
			FGTSLANSDDAYLTGSLTTFNGAYTPANYT
			HVVWLGRGYTAPSNDAPQGFYVLESAYA
			QNAGLRPTILCVKGKLTKHDGTPLSSEEMT
			AAFNAGWIVANNDPTTYYPVLVNFESNNY
			TYTGDAVEKGKIVRNHKFDINLTITGPGTNN
			PENPITESANLNVNCVVAAWKGVVQNVIW
104	P.	NA	NGEQQEAIESAENATKIENIKCGAGQRTLV
	circumdentari		VMANTGGMELAGKTLAEVKALTTVLTEEN
	a		QEATGLIMTAEPKAIVLKAGKNYIGYDGAG
	B52 FimA		EGNHIENAPLEIKRVHARMAFTEIKVQMSA
	polypeptide		AYDNIYTFTPEKIYGLIAKKQSNLFGATLVN
	sequence		ADANYLTGSLTTFNGAYTPTNYANVPWLS
			RDYVAPTAGAPQGFYVLENDYSANSGTIH
			PTILCVYGKLQKNGADLTGTDLAAAQAAN
			WVDAEG
105	P. gulae	NA	MKKTKFFLLGLAALAMTACNKDNEAEPVV
	B69 FimA AA		EGNATISVVLKTSNPNRVFGVADDEAKVAK
			LTVMVYNGEQQEAIESAENATKIENIKCGA
			GQRTLVVMANTGGMELAGKTLAEVKALTT
			VLTEENQGATGLIMTAEPKAIVLKAGKNYIG
			YDGAGEGNHIENAPLEIKRVHARMAFTEIK
			VQMSAAYDNIYTFTPEKIYGLIAKKQSNLFG
			ATLVNADANYLTGSLTTFNGAYTPTNYANV
			PWLSRDYVAPTAGAPQGFYVLENDYSANS
			GTIHPTILCVYGKLQKNGADLTGTDLAAAQ
			AANWVDAEGKTYYPVLVNFNSNNYTYDN
			GYTPKNKIERNHKYDIKLTITGPGTNNPENP
			ITESAHLNVQCTVAEWVLVGQNATW

SEQ ID NO.	Name	Target	DNA Sequence
106	P.	NA	NGEQQEAIESAENATKIENIKCGAGQRTLV
	circumdentari		VMANTGGMELAGKTLAEVKALTTVLTEEN
	a		QEATGLIMTAEPKAIVLKAGKNYIGYDGAG
	B97 FimA		EGNHIENAPLEIKRVHARMAFTEIKVQMSA
	polypeptide		AYDNIYTFTPEKIYGLIAKKQSNLFGATLVN
	sequence		ADANYLTGSLTTFNGAYTPTNYANVPWLS
			RDYVAPTAGAPQGFYVLENDYSANSGTIH
	:	1	PTILCVYGKLQKNGADLTGTDLAAAQAAN
			WVDAEG
107	P.	NA	VVEGNATISVVLKTSNPNRAFGVADDEAKV
	cangingivalis		AKLTVMVYKGEQQEAIKSAENAIKVENIKC
	B98 FimA AA		GAGSRTLVVMANTGGMELAGKTLAEVKAL
			TTELTAENQEATGLIMTAEPVDVTLVAGNN
			YYGYDGTQGGNQISQGTPLEIKRVHARIAF
			TKIEVKMSESYVNKYNFTPENIYALVAKKKS
			NLFGTSLANSDDAYLTGSLTTFNGAYTPAN
			YTHVVWLGRGYTAPSNDAPQGFYVLESAY
			AQNAGLRPTILCVKGKLTKHDGTPLSSEEM
			TAAFNAGWIVANNDPTTYYPVLVNFESNN
			YTYTGDAVEKGKIVRNHKFDINLTITGPGTN
			NPENPITESANLNVNCVVAAWK
108	P. salivosa	NA	AXLTVMVYNGEQQEAIXSAENATKXXXIKC
	B104 FimA		XAGQRTLVVMANTGXMEXXGKTLAEVKAL
	polypeptide		TTXLTXENQEAXGLIMTAEPKXIVLKAGKNX
	sequence		IGYXGXGEGXHIENXPLXIXRVHARMAFTEI
			KVXMSAAYDNIYTXXPEKIYGLIAKKQSNLF
			GATLVNADANYLTGSLTTFNGAYTPXNYA
	i		NVPWXSRXYVAPXAXAPQGFYVLENDYSA
			NXGTIHPTILCVYGKLQKNGADXXGXDLAX
	Ē		AQAANWVDAEGKTYYPVXVN
109	P. denticanis	NA	NGEQQEAIESAENATKIENIKCGAGQRTLV
	B106 FimA		VMANŢGGMELAGKTLAEVKALTTVLTEEN
	polypeptide		QEATGLIMTAEPKAIVLKAGKNYIGYDGAG
	sequence		EGNHIENAPLEIKRVHARMAFTEIKVQMSA
			AYDNIYTFTPEKIYGLIAKKQSNLFGATLVN
			ADANYLTGSLTTFNGAYTPTNYANVPWLS
			RDYVAPTAGAPQGFYVLENDYSANSGTIH
			PTILCVYGKLQKNGADLTGTDLAAAQAAN

SEQ ID NO.	Name	Target	DNA Sequence
		1	WVDAEG
110	P.	NA	KGEQQEAIKSAENAIKVENIKCGAGSRTLV
	endodontalis		VMANTGGMELAGKTLAEVKALTTELTAEN
	B114 FimA		QEATGLIMTAEPVDVTLVAGNNYYGYDGT
	polypeptide		QGGNQISQGTPLEIKRVHARIAFTKIEVKMS
	sequence		ESYVNKYNFTPENIYALVAKKKSNLFGTSL
	·		ANSDDAYLTGSLTTFNGAYTPANYTHVVW
			LGRGYTAPSNDAPQGFYVLESAYAQNAGL
			RPTILCVKGKLTKHDGTPLSSEEMTAAFNA
			GWIVANNDPT
111	P. gulae	NA	ACATTCGTTGGAGCTATTGCACTGAATGC
	B43 oprF		AAGTGCACAGGAAAATACTGTACCGGCA
	polynucleotide		ACGGGTCAGTTACCCGCCAAAAATGTTG
	sequence		CTTTCGCTCGCAACAAGCAGGCAGCAA
			TTGGTTCGTAACACTGCAGGGCGGTGTT
			GCAGCGCAGTTCCTCAATGACAACAACA
			ACAAAGATTTTGTAGACCGCTTGGGTGC
			TGCCGGCTCTATTTCAGTTGGAAAATATC
			ACAATCCATTCTTTGCAACCCGTTTGCAA
5			ATTAACGGAGCTCAGGCACACGTTCC
			TTGGAAAAAATGCGGAACAAGAAATTAAG
			ACCAATTTTGGCGCAGCTCACTTTGACTT
			CATGTTCGATGTGGTTAATTACTTTGCGC
			CATATCGCGAAAATCGTTTCTTCCATTTA
			ATTCCATGGGTAGGTGTTGGTTACCAGC
			ATAAATTCATTGGCAGCAAATGGAGTAAA
			GACAATGTCGAGTCTCTGACTGCCAATC
			TGGGTGTTATGATGGCTTTCAGATTAGGA
			AAACGTGTAGACTTTGTGATCGAAGCAC
			AAGCAGCACCTCCAATCTCAACTTAAGC
			CGTGCTTTCAATGCCAAGCCGACTCCTA
			TTTTCCAGGATCAGGAAGGACGTTATTAC
			AATGGATTCCAAGGAATGGCGACAGCAG
			GTCTTAACTTCCGCTTGGGTGCTGTAGG
			CTTCAATGCCATCGAGCCCATGGACTAC
			GCGCTTATCAACGATCTGAATGGTCAGA
		L	

SEQ ID NO.	Name	Target	DNA Sequence
			TTAATCGCCTGCGCAGAGAAGTCGAAGA
			ACTCTCCAAGCGTCCTGTATCATGTCCC
			GAATGCCCCGACGTTACACCCGTTACCA
			AGACAGAAAACAAGCTAACCGAGAAGGC
			TGTACTCTTCCGTTTCGACAGCTATGTTG
			TAGACAAAGACCAGCTTATCAATCTGTAT
			GACGTAGCTCAGTTTGTAAAAGAAACCAA
			CGAGCCGATTACTGTTGTAGGCTATGCT
			GATCCTACGGGTGACACTCAGTACAACG
			AAAGATTGTCTGAGCGTCGCGCAAAAGC
			cg
112	P. cansulci	NA	ACATTGGCCGGGGTTTACGCCCTTTCAG
	B46 <i>oprF</i>		CCTCTGCTCAGCAGGAGAATATGCCACG
	polynucleotide		AATGGGGCAGACTCCCGCCAAGAATACC
	sequence		GCTTACGCTCGCTCTGAAGCCGGTGACA
			ATTGGTTTGTGACTTTGCAAGGAGGTGC
			TGCTATGCAGTTTGGGAAAGGTAACGAG
1			GATGCCGACTTCTTCGACCGCCAAACTG
			TTGCTCCCACTTTTGCCGTAGGTAAATGG
			CACAATCCTTTCTTCGGGACCAGATTGCA
			AATGGGCTTGGGGGTATCTCACGACTTC
			TCGAACAACGAAGCGAAATCCAAGTTGG
			AGATGAACCACGCTCGCTATGCTAACGC
			ACACTTTGACTTTATGTTTGATGTGATTAA
			CTACTTCAAGCCCTACAGTGAGGACCGC
			GTATTCCACCTTATTCCGTGGGTAGGTTT
			GGGTTACGATCACAAGTTTGAGAAAAAC
	:		AGCAACTTCAAGGTGGATGCTCTTACAG
			CCAACGCCGGTTTGATGTTTGCTTTCCGT
			GTGATGGAGCGTATGGACATTGTGTTGG
			AAAGCCAGGTAATGTATTCTGACTTCAAC
			CTCAACACAGCTCTGCCCGAGCCTCGCT
			ACACAGCTTGCTCCGGCATGCTCACTGC
			CGGTTTGAACTTCCGTATAGGAAATATCG
			GATGGAGCGAGATCCTACCAATGGATTG
			GGGCTTGGTAAATGACCTGAACGGACAA
			ATCAACGCCATGCGTGCTAAGAACGCAG

SEQ ID NO.	Name	Target	DNA Sequence
			AGTTGAGCAAGCGTCCCGTTTCTTGCCC
			CGAATGCCCGGAAGTTGAGCCTCGTGTA
			GAGCGTATCAATATGCTTTCGGACAAGT
			CTGTTCTTTTCCGTGCCGGCAAGACAAC
			TGTAGACAGCGATCAAATGGTAACGATC
			TTCGACGTAGCTCAGTTTGCAAAGAAGA
			ATGGCACACAGATCACCGTTACAGGCTA
			TGCAGACAAGAAGGGCAAAGAAAGCGAT
			CGCACCTCTGAACTTCGTGCAAAAGCCG
			TAGCCAAGATTCTCACCGACAAGTACGG
			TGTACCTT
113	P.	NA	TCTATAATGGGAGCTACAGCACTCTCCG
	circumdentari		CGAGTGCTCAACAATCTACGACACCTGA
	a		GACTCAAACTTTGCCAGCTCGCAAGACG
	B52 oprF		GCTTTTGACCGTTCCGCGGGTCACTGGT
	polynucleotide		TCTTGACTCTACAGGGTGGTGTAAATGC
	sequence		ACAGTTTTTGGAAGAAAACGAGTCTCAAG
			ACATCGTAAATCGTCTCCGTGTGATGCC
			AACTCTTTCTTTAGGAAAGTGGCACAATC
			CCTATTTTGCAACCCGTTTGCAAGTTTTT
			GGGGGCCAACCCCTACTTACTACAAGG
			AGGTTTCTGGGGAGGTTAAGACCCTAAA
			TACCGCCATGGCTGGAGCTCACTTTGAT
			TTTATGTTTGATGTAGTAAACTTCTATGCA
			AAGTATAATCCTAAACGAGTATTCCATTT
			GATTCCTTGGTTCGGTGTGGGATATGGT
			TTCAAATACTATAACGATTTTGCTGATTTA
			GCTGATATGATTCAGTTTAATGAACCCTT
			CCGTCACTCAGCAACTGCGAATGCTGGT
	1		TTGATGATGAGTTTTCGCTTGGCAAAACG
			TTTGGATTTGGTTCTGGAAGGGCAGGCT
			ATATATTCTAACTTGAATATTGTAAAGCAA
			GAGATAGATTATAAAGCCCCCATTATGCC
			CTATTCAAATATCTACAACGGATTGACAG
			GTGTCGTTACTGCAGGTCTCAACTTTAAT
			CTCGGTCGTGTTGCTTGGGAGTCCGTAA
E .			

SEQ ID NO.	Name	Target	DNA Sequence
			CTAAACGGACAAATTAACCGTTTGCGTTC
			TGAGAATACAGAGTTGAGAAAACGTCCA
			GTTTCTTGCCCAGAATGTCCTGAAGTTAC
			TGCAgAGACGGAAGTAGTTACTGAAAAC
			GTTTTAGGTGATAAGGCGATTGTTTCAA
			GTTTAATAGCGCAACTATTGACAAAGATC
			AACACATTGTTTTGCAGGATATCGCTGAC
			TTTGTTAAAGATGGCAACAAAGCTATTGT
			TGTAATAGGCTTCGCAGATACAACAGGT
			GATATTAATTACAATATGCATT
		<u> </u>	
114	P. gulae	NA .	ACATTCGTTGGAGCTATTGCACTGAATGC
	B69 oprF		AAGTGCACAGGAAAATACTGTACCGGCA
	polynucleotide		ACGGGTCAGTTACCCGCCAAAAATGTTG
	sequence		CTTTTGCCCGCAATAAAGCAGGCGGCAA
			TTGGTTTGTAACACTGCAAGGTGGTGTT
			GCAGCACAGTTCCTTAATGACAACAACAA
			CAAAGATCTAGTAGACCGCTTAGGAGCT
			ACCGGATCTATCTCCGTTGGAAAATATCA
			CAATCCATTCTTTGCGACTCGTTTGCAAA
			TTAACGGAGGTCAAGCACACGTTCCT
			TGGGAAGAATGCGGAACAAGAAATTAAC
			ACCAATTTTGGAGCAGCTCACTTTGACTT
		,	CATGTTCGATGTGGTTAACTACTTTGCGC
			CATATCGCGAAAACCGTTTCTTCCATTTA
			ATTCCATGGGTAGGTGTTGGTTACCAAC
			ACAAATTCATCGGTAGCGAATGGAGTAA
			AGACAACGTCGAGTCGCTGACCGCAAAC
			ATGGGTGTTATGATGGCTTTCAGATTAGG
			GAAGCGCGTGGACTTTGTGATCGAAGCA
			CAAGCTGCTCACTCCAATCTTAATTTAAG
			TCGCGCATTCAATGCCAAGAAAACTCCTA
			TTTTCCACGATCAAGAAGGTCGCTATTAC
			AATGGATTCCAAGGAATGGCTACAGCGG
			GTCTTAACTTCCGCTTAGGTGCTGTTGG
			CTTCAATGCCATCGAGCCAATGGACTAC
			GCGCTTATCAACGATCTGAATGGTCAGA
I		1	

SEQ ID NO.	Name	Target	DNA Sequence
			TTAACCGTTTGCGCAGAGAAGTTGAAGA
			GCTCTCTAAGCGTCCTGTATCATGCCCC
	!		GAATGTCCCGATGTAACACCCGTTACTAA
			GACAGAAAACAAGCTAACCGAGAAGGCT
			GTACTCTTCCGCTTCGACAGCTATGTTGT
			AGACAAAGACCAGCTGATCAATCTGTAT
			GACGTTGCTCAGTTCGTAAAAGAAACTAA
			CGAACCGATTACCGTTGTAGGTTATGCC
			GATCCTACGGGCAGCACTCAGTACAACG
			AAAGATTGTCTGAGCGTCGCGCAAAAGC
			cg
115	P.	NA	TCTGTTATGGGAGCTACAGCACTCACAG
	circumdentari		TTAGTGCTCAGCAACCTACTACACCTGA
	а		GACTCAGACATTGCCTGCTCATAAGACG
	B97 oprF		GCTTTTGACCGTTCTGCAGGACATTGGTT
	polynucleotide		CTTGACTCTCCAAGGTGGAGTTAGTGCT
	sequence		CAATTTTTAGAAGAAAATGAAAGTCAAGA
			AATCTTGAATCGTCTTCATGTTATGCCTA
			CAATCTCTTTAGGCAAGTGGCACAATCCT
			TATTTTGCAACTCGTTTGCAAGTGTTCGG
			AGGTCCTACTCCTACTTTTTATAAGAATG
			CTGCTGGTAAGGTGATGAAGGAAAATGC
		٠	GGCTATGGCTGGGGCTCACTTTGACTTT
į.	1		ATGTTTGATGTTGTGAACTACTTTGGTAA
			GTATAATCCAAAGAGAGTCTTTCATCTTG
			TGCCTTGGTTCGGTGTTGGATATGGCTTT
			AAATACCATAATGATTTCGCCGAAATGAG
			TGATATCATTAAGTTTAATGAGCCTTATC
			GCCATTCAGCAACAGCGAATGCAGGGTT
			GATGATGAGTTTCCGCTTAGCAAAACGT
			CTTGATTTAGTGCTTGAAGGACAGGCTAT
			ATATTCTAATTTGAATATTGTTAAGCAAGA
1			AATTGATTATAAAGCTCCTTCTACTCCTTA
			TTCTCCAAATTATAATGGGCTTTTGGGAG
			TTGTTACAGCAGGTCTTAACTTTAATCTT
			GGTCGTGTTGCTTGGGAGACTGTTACTC
			CCATGGATATGGATTTGATTAATGATCTT

SEQ ID NO.	Name	Target	DNA Sequence
			AATGGTCAAATCAATCGTTTGCGTTCTGA
			GAATACTGAGTTGAGAAAACGTCCTGTTT
!			CTTGTCCTGAATGCCCAGAAGTTTCTAAA
			GAAACAACTGTAGTTACAGAAAATGTATT
			GGGAGACAAAGCTATTGTTTTCAAATTTA
			ATAGTGCAACTATCAGCAAAGATCAACAT
			ATTGTTTTGCAAGACATTGCGGACTTTGT
			TAAGAATGGAAATAAGGGGGTTGCCGTG
			ATAGGTTTCGCAGATGTAACAGGAGATG
			CCAATTACAATATGCAAC
1			
116	P.	NA	GGTGGAGTTAGTGCTCAATTTTTAGAAGA
	cangingivalis		AAATGAAAGTCAAGAAATCTTGAATCGTC
	B98 oprF		TTCATGTTATGCCTACAATCTCTTTAGGC
	polynucleotide		AAGTGGCACAATCCTTATTTTGCAACTCG
	sequence		TTTGCAAGTGTTCGGAGGTCCTACTCCTA
			CTTTTTATAAGAATGCTGCTGGTAAGGTG
	ļ		ATGAAGGAAAATGCGGCTATGGCTGGGG
			CTCACTTTGACTTTATGTTTGATGTTGTG
			AACTACTTTGGTAAGTATAATCCAAAGAG
			AGTCTTTCATCTTGTGCCTTGGTTCGGTG
			TTGGATATGGCTTTAAATACCATAATGAT
			TTCGCCGAAATGAGTGATATCATTAAGTT
			TAATGAGCCTTATCGCCATTCAGCAACAG
			CGAATGCAGGGTTGATGATGAGTTTCCG
			CTTAGCAAAACGTCTTGATTTAGTGCTTG
			AAGGACAGGCTATATATTCTAATTTGAAT
			ATTGTTAAGCAAGAAATTGATTATAAAGC
			TCCTTCTACTCCTTATTCTCCAAATTATAA
			TGGGCTTTTGGGAGTTGTTACAGCAGGT
			CTTAACTTTAATCTTGGTCGTGTTGCTTG
			GGAGACTGTTACTCCCATGGATATGGAT
			TTGATTAATGATCTTAATGGTCAAATCAAT
			CGTTTGCGTTCTGAGAATACTGAGTTGA
			GAAAACGTCCTGTTTCTTGTCCTGAATGC
			CCAGAAGTTTCTAAAGAAACAACTGTAGT
			TACAGAAAATGTATTGGGAGACAAAGCTA

SEQ ID NO.	Name	Target	DNA Sequence
			TTGTTTTCAAATTTAATAGTGCAACTATCA
			GCAAAGATCAACATATTGTTTTGCAAGAC
Ì	Ì		ATTGCGGACTTTGTTAAGAATGGAAATAA
	ļ		GGGGGTTGCCGTGATAGGTTTCGCAGAT
	1		GTAACAGGAGATGCCAATTACAATATGCA
			ACTTTCTGAACGTCGTGCTAAGGCTGTT
			GCGGAAGCTCTTGTGAATCAATTC
117	P. salivosa	NA 	CATTGGTTCTTGACTCTCCAAGGTGGAG
	B104 oprF		TTAGTGCTCAATTTTTAGAAGAAAATGAA
	polynucleotide		AGTCAAGAAATCTTGAATCGTCTTCATGT
	sequence		TATGCCTACAATCTCTTTAGGCAAGTGGC
			ACAATCCTTATTTTGCAACTCGTTTGCAA
			GTGTTCGGAGGTCCTACTCTTTTA
			TAAGAATGCTGCTGGTAAGGTGATGAAG
			GAAAATGCGGCTATGGCTGGGGCTCACT
			TTGACTTTATGTTTGATGTTGTGAACTAC
	1		TTTGGTAAGTATAATCCAAAGAGAGTCTT
			TCATCTTGTGCCTTGGTTCGGTGTTGGAT
	}		ATGGCTTTAAATACCATAATGATTTCGCC
			GAAATGAGTGATATCATTAAGTTTAATGA
			GCCTTATCGCCATTCAGCAACAGCGAAT
			GCAGGGTTGATGATTTCCGCTTAG
			CAAAACGTCTTGATTTAGTGCTTGAAGGA
			CAGGCTATATATTCTAATTTGAATATTGTT
			AAGCAAGAAATTGATTATAAAGCTCCTTC
			TACTCCTTATTCTCCAAATTATAATGGGC
			TTTTGGGAGTTGTTACAGCAGGTCTTAAC
			TTTAATCTTGGTCGTGTTGCCTGGGAGA
			CTATTACTCCCATGGATATGGATTTGATT
			AATGATCTTAATGGTCAAATCAATCGTTT
1			GCGTTCTGAGAATACTGAGTTGAGAAAA
			CGTCCTGTTTCTTGTCCTGAATGCCCAGA
			AGTTTCTAAAGAAACAACTGTAGTTACAG
			AAAATGTATTGGGAGACAAAGCTATTGTT

-39-

SEQ ID NO.	Name	Target	DNA Sequence
			TTCAAATTTAATAGTGCAACTATCAGCAA
			AGATCAACATATTGTTTTGCAAGACATTG
			CGGACTTTGTTAAGAATGGAAATAAGGG
			GGTTGCCGTGATAGGTTTCGCAGATGTA
0.0			ACAGGAGATGCCAATTACAATATGCAACT
			TTCTGAACGTCGTGCTAAGGCTGTTGCG
			GAAGCTCTTGTGAATCAATTC
140		N1 A	
118		NA	GCTCATAAGACGGCTTTTGACCGTTCTG
	B106 oprF		CAGGACATTGGTTCTTGACTCTCCAAGG
	polynucleotide		TGGAGTTAGTGCTCAATTTTTAGAAGAAA
	sequence		ATGAAAGTCAAGAAATCTTGAATCGTCTT
			CATGTTATGCCTACAATCTCTTTAGGCAA
			GTGGCACAATCCTTATTTTGCAACTCGTT
			TGCAAGTGTTCGGAGGTCCTACTCCTAC
			TTTTTATAAGAATGCTGCTGGTAAGGTGA
			TGAAGGAAAATGCGGCTATGGCTGGGGC
			TCACTTTGACTTTATGTTTGATGTTGTGA
			ACTACTTTGGTAAGTATAATCCAAAGAGA
			GTCTTTCATCTTGTGCCTTGGTTCGGTGT TGGATATGGCTTTAAATACCATAATGATT
			TCGCCGAAATGAGTGATATCATTAAGTTT
			AATGAGCCTTATCGCCATTCAGCAACAG
			CGAATGCAGGGTTGATGATGAGTTTCCG
			CTTAGCAAAACGTCTTGATTTAGTGCTTG
			AAGGACAGGCTATATATTCTAATTTGAAT
			ATTGTTAAGCAAGAAATTGATTATAAAGC
			TCCTTCTACTCCTTATTCTCCAAATTATAA
			TGGGCTTTTGGGAGTTGTTACAGCAGGT
			CTTAACTTTAATCTTGGTCGTGTTGCTTG
			GGAGACTGTTACTCCCATGGATATGGAT
			TTGATTAATGATCTTAATGGTCAAATCAAT
			CGTTTGCGTTCTGAGAATACTGAGTTGA
			GAAAACGTCCTGTTTCTTGTCCTGAATGC
L			C. T. T. TOO TOO TO THE TOO TO AN TOO

-40-

SEQ ID NO.	Name	Target	DNA Sequence
			CCAGAAGTTTCTAAAGAAACAACTGTAGT
			TACAGAAAATGTATTGGGAGACAAAGCTA
		•	TTGTTTTCAAATTTAATAGTGCAACTATCA
			GCAAAGATCAACATATTGTTTTGCAAGAC
			ATTGCGGACTTTGTTAAGAATGGAAATAA
			GGGGGTTGCCGTGATAGGTTTCGCAGAT
			GTAACAGGAGATGCCAATTACAATATGCA
			ACTTTCTGAACGTCGTGCTAAGGCTGTT
			GCGGAAGCTCTTGTGAATCAATTCGGAG
			TTCCTTCTGATATGATTT
119	P.	NA	TCAGCACTGGGGGCTTTGGCACTTACAG
119	endodontalis		CTAGTGCTCAACAAACTACGAAACCAGC
	B114 oprF		GAATAGTATGCCCGCATTCAAGACTGCA
	polynucleotide		TTTGAACGCAGCGGCGGTCATTGGTTTC
	sequence		TGACAATTCAGGGTGGCCTGAGTGCTCA
	Sequence		ACTTTTGGGTGAAAATGAAAAGATGGACT
			TTGGCAAGCGTCTGCTACATGCTGCCAA
			GGCCAGTGACAACACCCAAACAGAGGCT
			AGCTACCTACGCATCATGCCCACGCTCT
			CTGTAGGTAAATGGCATAATCCCTACTTT
			GCTACTCGTGTACAGCTCTTCGGTGGTC
			TCACTCCTCTACAATACTGAGGGTGG
1			CGTTAATGTACACACCTACAACACTGCCA
			CGATCGGTGCCCACTATGATTTCATGTTT
			GATGTAGTAAACTATTTCGCCAAGTACAA
			CCCCAAACGTTTCTTCCACGTAATTCCTT
			GGGTGGGTCTTGGTTACAACTTCAAGTA
			TCATGATGTATTTGGATTCAAGGAGCCCT
			ATCGTCACTCTGTCACAGGTAACGCAGG
	Ì		CATGGAGTTTGCTTTCCGCCTCGGTAAG
			CGTGTAGACCTTGTACTCGAAGCTCAGG
			TAGTGTACAACAACCTGAACCTGATCAAG
			CAGGAAGTCGACTACGATGTAGTCACTA
			CTCCCTATGTACCTGCTGATACATACGCT
			GGTCTTATGACCATGTTTACTGCTGGTCT
			TAACTTCAATCTGGGCAAGGTTGAGTGG
I			

SEQ ID NO.	Name	Target	DNA Sequence
			GAAACTGTTGAGCCGATGGACTACCAGC
			TCATAAACGACTTGAACTCTCAGATCAGC
			CGTCTACGTAGCGAAAACGCAGAGCTTT
			CCAAGCGTCCTGCTTTCTGCCCCGAGTG
	<u> </u>		TCCCGAAGTAGAGGAAGATGTT
			GTTGTTGACCAGTATGTCCTCACCGACA
			AGGCTATCCTCTTCGACTTTGACAAGAG
			CAACATCCGCAAGGACCAACAAGCTCAG
			CTTGGTATGATTGCTGAATTCGTGAAGAA
			GTACAATACGCCTATCGTGGTAGTAGGC
			TATG
120	P. gulae	NA	TFVGAIALNASAQENTVPATGQLPAKNVAF
	B43 OprF		ARNKAGSNWFVTLQGGVAAQFLNDNNNK
	polypeptide		DFVDRLGAAGSISVGKYHNPFFATRLQING
	sequence		AQAHTFLGKNAEQEIKTNFGAAHFDFMFD
			VVNYFAPYRENRFFHLIPWVGVGYQHKFIG
			SKWSKDNVESLTANLGVMMAFRLGKRVD
			FVIEAQAAHSNLNLSRAFNAKPTPIFQDQE
			GRYYNGFQGMATAGLNFRLGAVGFNAIEP
			MDYALINDLNGQINRLRREVEELSKRPVSC
			PECPDVTPVTKTENKLTEKAVLFRFDSYVV
			DKDQLINLYDVAQFVKETNEPITVVGYADP
			TGDTQYNERLSERRAKAVVDVLTGKYGVP
			SELISVEWKGDTTQPFNKKAWN
121	P. cansulci	NA	TLAGVYALSASAQQENMPRMGQTPAKNT
	B46 OprF		AYARSEAGDNWFVTLQGGAAMQFGKGNE
	polypeptide		DADFFDRQTVAPTFAVGKWHNPFFGTRLQ
	sequence		MGLGVSHDFSNNEAKSKLEMNHARYANA
			HFDFMFDVINYFKPYSEDRVFHLIPWVGLG
			YDHKFEKNSNFKVDALTANAGLMFAFRVM
			ERMDIVLESQVMYSDFNLNTALPEPRYTAC
			SGMLTAGLNFRIGNIGWSEILPMDWGLVN
			DLNGQINAMRAKNAELSKRPVSCPECPEV
			EPRVERINMLSDKSVLFRAGKTTVDSDQM
			VTIFDVAQFAKKNGTQITVTGYADKKGKES
			DRTSELRAKAVAKILTDKYGVPSDRISIEWK
			GVSEQVYDNRDWNRVV
L		<u> </u>	<u> </u>

SEQ ID NO.	Name	Target	DNA Sequence
122	P.	NA	SIMGATALSASAQQSTTPETQTLPARKTAF
	circumdentari		DRSAGHWFLTLQGGVNAQFLEENESQDIV
	а		NRLRVMPTLSLGKWHNPYFATRLQVFGGP
	B52 OprF		TPTYYKEVSGEVKTLNTAMAGAHFDFMFD
	polypeptide		VVNFYAKYNPKRVFHLIPWFGVGYGFKYY
	sequence		NDFADLADMIQFNEPFRHSATANAGLMMS
			FRLAKRLDLVLEGQAIYSNLNIVKQEIDYKA
			PIMPYSNIYNGLTGVVTAGLNFNLGRVAWE
4			SVTPMDMDLINDLNGQINRLRSENTELRKR
			PVSCPECPEVTAETEVVTENVLGDKAIVFK
	:		FNSATIDKDQHIVLQDIADFVKDGNKAIVVI
			GFADTTGDINYNMHLSERRAKAVAEALVN
			KFGVSSDMISVEWQGETEQFNPRAWN
123	P. gulae	NA	TFVGAIALNASAQENTVPATGQLPAKNVAF
	B69 OprF		ARNKAGGNWFVTLQGGVAAQFLNDNNNK
	polypeptide		DLVDRLGATGSISVGKYHNPFFATRLQING
	sequence		GQAHTFLGKNAEQEINTNFGAAHFDFMFD
			VVNYFAPYRENRFFHLIPWVGVGYQHKFIG
			SEWSKDNVESLTANMGVMMAFRLGKRVD
	9		FVIEAQAAHSNLNLSRAFNAKKTPIFHDQE
			GRYYNGFQGMATAGLNFRLGAVGFNAIEP
			MDYALINDLNGQINRLRREVEELSKRPVSC
			PECPDVTPVTKTENKLTEKAVLFRFDSYVV
			DKDQLINLYDVAQFVKETNEPITVVGYADP
			TGSTQYNERLSERRAKAVVDVLTGKYGVP
			SELISVEWKGDSTQPFNKKAWN
124	P.	NA	SVMGATALTVSAQQPTTPETQTLPAHKTA
	circumdentari		FDRSAGHWFLTLQGGVSAQFLEENESQEI
	а		LNRLHVMPTISLGKWHNPYFATRLQVFGG
	B97 OprF		PTPTFYKNAAGKVMKENAAMAGAHFDFMF
	polypeptide		DVVNYFGKYNPKRVFHLVPWFGVGYGFK
	sequence		YHNDFAEMSDIIKFNEPYRHSATANAGLM
			MSFRLAKRLDLVLEGQAIYSNLNIVKQEIDY
			KAPSTPYSPNYNGLLGVVTAGLNFNLGRV
			AWETVTPMDMDLINDLNGQINRLRSENTEL
			RKRPVSCPECPEVSKETTVVTENVLGDKAI
			VFKFNSATISKDQHIVLQDIADFVKNGNKG
			VAVIGFADVTGDANYNMQLSERRAKAVAE

SEQ ID NO.	Name	Target	DNA Sequence
			ALVNQFGVPSDMISVEWQGETELFEARAW
			N
			The second secon
125	P.	NA	GGVSAQFLEENESQEILNRLHVMPTISLGK
	cangingivalis		WHNPYFATRLQVFGGPTPTFYKNAAGKV
	B98 OprF		MKENAAMAGAHFDFMFDVVNYFGKYNPK
	polypeptide		RVFHLVPWFGVGYGFKYHNDFAEMSDIIKF
	sequence		NEPYRHSATANAGLMMSFRLAKRLDLVLE
	ii		GQAIYSNLNIVKQEIDYKAPSTPYSPNYNGL
			LGVVTAGLNFNLGRVAWETVTPMDMDLIN
			DLNGQINRLRSENTELRKRPVSCPECPEV
			SKETTVVTENVLGDKAIVFKFNSATISKDQH
			IVLQDIADFVKNGNKGVAVIGFADVTGDAN
			YNMQLSERRAKAVAEALVNQF
126	P. salivosa	NA	HWFLTLQGGVSAQFLEENESQEILNRLHV
	B104 OprF		MPTISLGKWHNPYFATRLQVFGGPTPTFY
	polypeptide		KNAAGKVMKENAAMAGAHFDFMFDVVNY
	sequence		FGKYNPKRVFHLVPWFGVGYGFKYHNDF
			AEMSDIIKFNEPYRHSATANAGLMMSFRLA
			KRLDLVLEGQAIYSNLNIVKQEIDYKAPSTP
			YSPNYNGLLGVVTAGLNFNLGRVAWETITP
			MDMDLINDLNGQINRLRSENTELRKRPVSC
			PECPEVSKETTVVTENVLGDKAIVFKFNSA
			TISKDQHIVLQDIADFVKNGNKGVAVIGFAD
į			VTGDANYNMQLSERRAKAVAEALVNQF
127	P. denticanis	NA	AHKTAFDRSAGHWFLTLQGGVSAQFLEEN
	B106 OprF		ESQEILNRLHVMPTISLGKWHNPYFATRLQ
	polypeptide		VFGGPTPTFYKNAAGKVMKENAAMAGAH
	sequence		FDFMFDVVNYFGKYNPKRVFHLVPWFGV
	·		GYGFKYHNDFAEMSDIIKFNEPYRHSATAN
			AGLMMSFRLAKRLDLVLEGQAIYSNLNIVK
			QEIDYKAPSTPYSPNYNGLLGVVTAGLNFN
			LGRVAWETVTPMDMDLINDLNGQINRLRS
			ENTELRKRPVSCPECPEVSKETTVVTENVL
			GDKAIVFKFNSATISKDQHIVLQDIADFVKN
			GNKGVAVIGFADVTGDANYNMQLSERRAK
L		<u> </u>	

SEQ ID NO.	Name	Target	DNA Sequence
			AVAEALVNQFGVPSDMISVEWQGET
128	P.	NA	SALGALALTASAQQTTKPANSMPAFKTAFE
	endodontalis		RSGGHWFLTIQGGLSAQLLGENEKMDFGK
	B114 OprF		RLLHAAKASDNTQTEASYLRIMPTLSVGKW
	polypeptide		HNPYFATRVQLFGGLTPLYNTEGGVNVHT
	sequence		YNTATIGAHYDFMFDVVNYFAKYNPKRFFH
			VIPWVGLGYNFKYHDVFGFKEPYRHSVTG
			NAGMEFAFRLGKRVDLVLEAQVVYNNLNLI
[KQEVDYDVVTTPYVPADTYAGLMTMFTAG
			LNFNLGKVEWETVEPMDYQLINDLNSQISR
			LRSENAELSKRPAFCPECPEVEEVEDVVV
			DQYVLTDKAILFDFDKSNIRKDQQAQLGMI
			AEFVKKYNTPIVVVGYADPTGKSKYNMELS
			KRRAQAVVNELTNRHGVPADLITMEWEGA
			TNKFTPPTAWN
129	P. gulae B43	NA	ACNKDNEAEPVV
	FimA		
	polypeptide		
	fragment		
	sequence #1		
130	P. gulae B43	BNA	YPVLVNFESNNYTYTGDAVEK
	FimA		
	polypeptide		
	fragment		
	sequence #2		
131	P. gulae B43	BNA	TGPGTNNPENPITESA
	FimA		
	polypeptide		
	fragment		
	sequence #3		
132	P. gulae B43	RNA	NDNNNKDFVDRLGA
102	OprF	1"	
	•		
	polypeptide		
	fragment		

-45-

SEQ ID NO.	Name	Target	DNA Sequence
	sequence #1		
			0
133	P. gulae B43	NA	DLNGQINRLRREVEELSKRPVSCPECPDV
	OprF	:	
	polypeptide		
	fragment		
	sequence #2		
134	P. gulae B43	NA	ADPTGDTQYNERLSERRAKAV
	OprF		
	polypeptide		
	fragment		
	sequence #3		
135	pBAD-HisA	NA	MGGSHHHHHHGMASMTGGQMGRDLYDD
	Amino-		DDKDRWGSELEICSQYHMGI
	terminal		,
	polypeptide		
	sequence		·
136	pBAD-TOPO	NA	MGSGSGDDDDKLALM
	Amino-		
	terminal		
	polypeptide		
	sequence		
137	I vector	NA	MGTTTTTSLHM
	Amino-		
	terminal		
	polypeptide		
	sequence		

Note: Lower case nucleotides are not present in the target DNA sequence. They are added to the 5' region of the primer to aid in cloning. NA, Not applicable

The following companion animal periodontal isolates were deposited with the American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, VA, 20110, USA, on August 9, 2001: *P. gulae* B43 (PTA-3618), *P. cansulci* B46 (PTA-3619), *P. circumdentaria* B52 (PTA-3620), *P. gulae* B69 (PTA-3621), *P. circumdentaria* B97 (PTA-3622), *P. cangingivalis* B98 (PTA-3623), *P. salivosa* B104 (PTA-3624), *P. denticanis* B106 (PTA-3625), and *P. endodontalis* B114 (PTA-3626). In a preferred embodiment of the

5

-46-

invention, an isolated polynucleotide molecule of the present invention has a nucleotide sequence selected from the group consisting of SEQ ID NOS: 86 to 102 and 111 to 119. The preferred polypeptides of the present invention have amino acid sequences selected from the group consisting of SEQ ID NOS: 103 to 110 and 120 to 128.

Cloning of Porphyromonas Nucleotide Sequences

5

10

15

20

25

30

35

There are several known methods or techniques that can be used to clone the *Porphyromonas* nucleotide sequences of the present invention. For example, the sequences can be isolated as restriction fragments and cloned into cloning and/or expression vectors, the sequences can be PCR amplified and cloned into cloning and/or expression vectors, or the sequences can be cloned by a combination of these two methods.

Standard molecular biology techniques known in the art and not specifically described can be generally followed as described in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, New York (1989); Ausubel et al., *Current Protocols in Molecular Biology*, John Wiley and Sons, Baltimore, Maryland (1989); Perbal, *A Practical Guide to Molecular Cloning*, John Wiley & Sons, New York (1988); Watson et al., *Recombinant DNA*, Scientific American Books, New York; Birren et al (eds) *Genome Analysis: A Laboratory Manual Series, Vols. 1-4* Cold Spring Harbor Laboratory Press, New York (1998); and methodology set forth in United States Patent Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057. Polymerase chain reaction (PCR) is carried out generally as described in *PCR Protocols: A Guide To Methods And Applications*, Academic Press, San Diego, CA (1990).

Examples of methods useful in cloning and sequencing the polynucleotides of the present invention are provided in the Example.

fimA and oprF-ENCODED POLYPEPTIDES AND PROTEINS

The present invention encompasses the use of prokaryotic and eukaryotic expression systems, including vectors and host cells, which may be used to express both truncated and full-length (native protein) forms of the recombinant polypeptides expressed by the nucleotide sequences of the present invention.

In a preferred embodiment of the invention, an isolated polynucleotide molecule of the present invention has a nucleotide sequence selected from one of the sequences of SEQ ID NO:95 to 102 and 111 to 119 or degenerate variants thereof; and encoding a corresponding polypeptide selected from the amino acid sequences of SEQ ID NO:103 to 110 and 120 to 128, respectively.

A variety of host-expression vector systems may be utilized to express the polypeptides of the present invention. Such host-expression systems also represent vehicles by which the coding sequences of interest may be cloned and subsequently purified. The present invention further provides for host cells which may, when transformed or transfected with the appropriate vector or nucleotide sequence, express the encoded polypeptide gene product of the invention. Such host cells, include but are not limited to, microorganisms such

-47-

as bacteria (e.g., E. coli, B. subtilis) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing coding sequences; yeast (e.g., Saccharomyces, Pichia) transformed with recombinant yeast expression vectors containing the gene product coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing the coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing coding sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter).

5

10

15

20

25

30

35

In a preferred embodiment, the expression system is a bacterial system. A number of expression vectors may be advantageously selected depending upon the use intended for the product being expressed. For example, when a large quantity of such a polypeptide is to be produced, for the generation of vaccine compositions or for raising antibodies, for example, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Preferably, the vectors contain promoters that direct inducible gene expression. Suitable vectors include, but are not limited to, the E. coli pET expression vectors (Studier and Moffatt, 1986, J. Mol. Biol. 189:113; Rosenberg et al., 1987, Gene 56:125-135; Novagen, Madison, Wisconsin), in which the coding sequence can be fused inframe to a sequence encoding multiple (e.g., 6) histidine residues; pBAD vectors (Guzman et al., 1995, J. Bact. 177:4121-4130), from which a heterologous protein can be expressed under the control of an arabinose inducible protein; and pGEX vectors (Pharmacia Biotech, USA), used to express heterologous polypeptides as fusion proteins with glutathione Stransferase (GST). The fimA or oprF sequences of the present invention can be cloned into a λ expression vector and expressed in λ bacterial strains. In a preferred mode, the bacterial strain is E. coli BL21 (Gibco-BRL, USA). Preferably, the vectors that can be used include, but are not limited to, pLEX expression vectors (LaVallie et al., 1992, Bio/Technology 11:187-193; Mieschendahl et al., 1986, Bio/Technology 4:802-808; Invitrogen) and pRIT2T expression vectors (Nilsson et al., 1985, EMBO 4:1075; Zabeau and Stanley, 1982, EMBO 1:1217; Pharmacia Biotech). Other vectors and bacterial strains can be used and are known to those skilled in the art.

Antibody Production

Antibodies may either be monoclonal, polyclonal, or recombinant. Conveniently, the antibodies may be prepared against the immunogen or portion thereof, for example, a synthetic peptide based on the sequence, or prepared recombinantly by cloning techniques or the natural gene product and/or portions thereof may be isolated and used as the immunogen. Immunogens can be used to produce antibodies by standard antibody production technology well known to those skilled in the art as described generally in Harlow

-48-

and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1988 and Borrebaeck, *Antibody Engineering - A Practical Guide*, W.H. Freeman and Co., 1992. Antibody fragments may also be prepared from the antibodies and include Fab, F(ab')₂, and Fv by methods known to those skilled in the art.

5

10

15

20

25

30

35

In the production of antibodies, screening for the desired antibody can be accomplished by standard methods in immunology known in the art. Techniques not specifically described are generally followed as in Stites et al.(eds), Basic and Clinical Immunology (8th Edition), Appleton & Lange, Norwalk, CT (1994) and Mishell and Shiigi (eds), Selected Methods in Cellular Immunology, W.H. Freeman and Co., New York (1980). In general, ELISAs and Western blotting are the preferred types of immunoassays. Both assays are well known to those skilled in the art. Both polyclonal and monoclonal antibodies can be used in the assays. The antibody can be bound to a solid support substrate or conjugated with a detectable moiety or be both bound and conjugated as is well known in the art (for a general discussion of conjugation of fluorescent or enzymatic moieties see Johnstone & Thorpe, Immunochemistry in Practice, Blackwell Scientific Publications, Oxford, 1982.) The binding of antibodies to a solid support substrate is also well known in the art (see for a general discussion, Harlow & Lane Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Publications, New York, 1988 and Borrebaeck, Antibody Engineering - A Practical Guide, W.H. Freeman and Co., 1992). The detectable moieties contemplated for use in the present invention can include, but are not limited to, fluorescent, metallic, enzymatic and radioactive markers such as biotin, gold, ferritin, alkaline phosphatase, bgalactosidase, peroxidase, urease, fluorescein, rhodamine, tritium, 14C and iodination.

Where appropriate, other immunoassays such as radioimmunoassays (RIA) can be used as known in the art. Available immunoassays are extensively described in the patent and scientific literature. See, for example, United States Patent Nos. 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 4,879,219; 5,011,771; and 5,281,521, as well as Sambrook et al, *Molecular Cloning: A Laboratory Manual*, Cold Springs Harbor, New York, 1989.

Detection, Diagnostic, and Prevention Kits

The present invention further provides kits for the detection of *Porphyromonas* spp. The kit includes reagents for analyzing a sample for the presence of *Porphyromonas* organisms, polypeptides, or *Porphyromonas* nucleotide sequences of the present invention, wherein the presence of the nucleotide sequence is indicative of the presence of the organism. This method is valuable because disease can be diagnosed prior to the existence of symptoms and can therefore prevent the onset of the disease prior to the occurrence of damage to the patient. The presence of the *Porphyromonas* spp. Bacteria, polypeptides, or nucleotide sequences can be determined using antibodies, PCR, hybridization, and other detection methods known to those of skill in the art.

In one embodiment, the kit provides reagents for the detection of antibodies against *Porphyromonas*. In certain embodiments, the kit can include a set of printed instructions or a label indicating that the kit is useful for the detection of *Porphyromonas* spp. Minimally, the kit comprises in at least one container a protein having an amino acid sequence comprising at least 30 contiguous amino acids of any of the polypeptides of SEQ ID NO:103 to 110 and 120 to 128. In one embodiment, the kit further comprises a secondary antibody. In a preferred embodiment, the secondary antibody is conjugated to a detectable moiety, such as, e.g., an enzyme that catalyzes a colorimetric or chemiluminescent reaction, such as alkaline phosphatase or horseradish peroxidase. In a further embodiment, the kit comprises reagents for carrying out a colorimetric or chemiluminescent assay.

5

10

15

20

25

30

35

In another embodiment, the kit provides reagents for the detection of *Porphyromonas* nucleic acids. In one embodiment, the kit provides reagents for the PCR detection of *Porphyromonas* nucleic acids and comprises in at least one container a first isolated DNA molecule comprising a fragment of at least about 15, 20, 25 or 30 nucleotides, which fragment hybridizes under stringent conditions to a DNA molecule encoding a polypeptide comprising a sequence of at least 5, 10, 15, 20, 25, or 30 contiguous amino acids, or the complete amino acid sequence, of any of the polypeptides of SEQ ID NO:xx-yy, and a second isolated DNA molecule comprising a fragment of at least 15, 20,25, or 30 nucleotides, which fragment hybridizes under stringent conditions to a DNA molecule complementary to a DNA molecule encoding a polypeptide having a sequence of at least 5 10, 15, 20, 25, or 30 contiguous amino acids, or the complete amino acid sequence, of any of the polypeptides of SEQ ID NO:xx-yy, which first and second DNA molecules can be used to specifically amplify a *Porphyromonas* spp. nucleic acid encoding a 16S rRNA which 16S rRNA is encoded by a DNA molecule selected from the group consisting of SEQ ID NOS: 1-9.

In an further embodiment, the present invention provides a kit comprising in at least one container an isolated DNA molecule comprising a nucleotide sequence of at least about 15 contiguous nucleotides selected from any of SEQ ID NOS: 86 to 94, 95 to 102, and 111 to 119 which hybridizes under highly stringent conditions to the complement of any of the nucleotide sequences depicted in SEQ ID NOS: 86 to 94, 95 to 102, and 111 to 119, and a second isolated DNA molecule comprising in a second container an isolated DNA molecule comprising a nucleotide sequence of at least about 15 contiguous nucleotides selected from the complement of any of the nucleotide sequences depicted in SEQ ID NOS: 86 to 94, 95 to 102, and 111 to 119 which hybridizes under highly stringent conditions to any of the nucleotide sequences depicted in SEQ ID NOS: 86 to 94, 95 to 102, and 111 to 119, wherein the kit further comprises a set of instructions indicating that the kit is useful for the detection of *Porphyromonas* spp.

Vaccine Formulation and Method of Administration

The vaccine of the present invention can be is administered to a companion animal in an effective amount such that the vaccine therapeutically treats or confers resistance to or

-50-

prevents periodontal disease in the companion animal. The vaccine of the present invention is useful in the control of bacteria that cause periodontal disease. The vaccines of the present invention can, in particular, be used in the field of veterinary medicine to treat companion animals and for the maintenance of public health against those bacteria described herein which are known to cause periodontal disease.

5

10

15

20

25

30

35

The vaccines of the present invention are of value in the control of bacteria that are injurious to, or spread or act as vectors of disease in man and companion animals, for example those described herein. The vaccines of the present invention are particularly useful in controlling bacteria that are present in companion animals for which purpose they can be administered using any known methods of administration, including, but not limited to, oral, parenteral, intranasal, subcutaneous, or topical.

According to a further aspect of the present invention, there is provided a composition comprising a vaccine of the present invention, in admixture with a compatible adjuvant, diluent or carrier. In a preferred embodiment, the vaccine formulation of the present invention is composed of an aqueous suspension or solution containing at least one bacteria of the present invention and/or at least one subunit protein, preferably buffered at physiological pH, in a form ready for injection.

The present invention further provides a method of treating or preventing a bacterial infection, which comprises treatment with an effective amount of a vaccine or vaccine formulation of the present invention. It is to be appreciated that reference to treatment includes prophylaxis as well as the alleviation of established symptoms of a bacterial infection.

The vaccines and vaccine formulations of the present invention can used to induce a response that prevents the pathological changes characteristic of periodontal disease caused by periodontal disease-causing bacteria. In a vaccine formulation, an immunogenic amount of the bacteria, purified protein, nucleic acid, or combinations thereof is desirably mixed with a suitable conventional vaccine adjuvants and physiologic vehicles, for use in mammals.

A vaccine formulation for preventing periodontal disease in companion animals can be produced using at least one of the isolated and purified inactivated or attenuated bacteria, purified polypeptides (such as native proteins, subunit proteins, or polypeptides, and admixing one or more or these with a compatible adjuvant, diluent, or carrier. Preferably, the polypeptide sequences are subunit proteins selected from the group including FimA (SEQ ID NOS: 103 to 110 and OprF (SEQ ID NOS: 120 to 128).

Examples of fragments of FimA and OprF that can be used for diagnostic polypeptides or for vaccine preparations include, but are not limited to ACNKDNEAEPVV, YPVLVNFESNNYTYTGDAVEK, TGPGTNNPENPITESA, NDNNNKDFVDRLGA, DLNGQINRLRREVEELSKRPVSCPECPDV, and ADPTGDTQYNERLSERRAKAV (SEQ ID NOS: 129-134). The subunit protein can be recombinantly expressed, either alone or fused to another polypeptide sequence or protein. The other polypeptide sequence or protein can

include, but is not limited to, a poly-His tag, MBP, thioredoxin, or GST, for example. Also provided by the present invention are the polynucleotide sequences or genes that encode any of the above mentioned subunit proteins. The polynucleotide sequence of the bacteria can be selected from *fimA* and *oprF* or a fragment or variant thereof which fragment or variant exhibits at least about 90%, 95%, or 99% homology thereto, or a complementary polynucleotide sequence which hybridizes under high stringency conditions, or a combination of both. Preferably, the polynucleotide sequences of the present invention can be used to amplify a *fimA* or *oprF* DNA molecule of the present invention, or encodes an amino acid fragment than can be used to raise antibodies against FimA or OprF.

5

10

15

20

25

30

35

For DNA-based therapy, a vehicle capable of delivering or transferring heterologous nucleic acid into a host cell may be used. The expression vehicle may include elements to control targeting, expression and transcription of the nucleic acid in a cell selective manner as is known in the art. The expression vehicle can include a promoter for controlling transcription of the heterologous material and can be either a constitutive or inducible promoter to allow selective transcription. Enhancers that may be required to obtain necessary transcription levels can optionally be included.

Vectors can be introduced into cells or tissues by any one of a variety of known methods within the art. Such methods can be found generally described in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Springs Harbor Laboratory, New York (1989, 1992); Ausubel et al., *Current Protocols in Molecular Biology*, John Wiley and Sons, Baltimore, Maryland (1989); Chang et al., *Somatic Gene Therapy*, CRC Press, Ann Arbor, MI (1995); Vega et al., *Gene Targeting*, CRC Press, Ann Arbor, MI (1995); R.L. Rodriguez *Vectors: A Survey of Molecular Cloning Vectors and Their Uses*, Butterworths, Boston MA (1988) and include, for example, stable or transient transfection, lipofection, electroporation and infection with recombinant viral vectors.

The present invention further provides for combinations vaccines having at least one of the inactivated or attenuated bacteria, nucleotide sequences, or polypeptide sequences of the present invention, in combination with one or more additional immunogenic components. Such a combination vaccine may produce in the vaccinated animal a surprisingly greater effect than that expected by simply adding the effects of each component administered separately. Thus, a combination vaccine may stimulate a synergistic production of antibody in animals.

Vaccines of the present invention can be prepared by combination of at least one of the inactivated or attenuated bacteria, nucleotide sequences, or polypeptide sequences of the present invention, with a pharmaceutically acceptable carrier, an preferably, an adjuvant.

Suitable preparations of the vaccines of the present invention include injectables, either liquid solutions or suspensions. Solid forms suitable for solution in, or suspension in, a liquid pharmaceutically acceptable carrier prior to injection may also be prepared. The vaccine preparation may be emulsified. The active immunogenic component, is preferably

-52-

mixed with an adjuvant which is pharmaceutically acceptable and compatible with the active immunogenic component. Suitable adjuvants include, but are not limited to: mineral gels, e.g., aluminum hydroxide; surface active substances such as lysolecithin; glycosides, e.g., saponin derivatives such as Quil A or GPI-0100 (United States Patent No. 5,977,081); cationic surfactants such as DDA, pluronic polyols; polyanions; non-ionic block polymers, e.g., Pluronic F-127 (B.A.S.F., USA); peptides; mineral oils, e.g. Montanide ISA-50 (Seppic, Paris, France), carbopol, Amphigen (Hydronics, Omaha, NE USA), Alhydrogel (Superfos Biosector, Frederikssund, Denmark) oil emulsions, e.g. an emulsion of mineral oil such as BayolF/Arlacel A and water, or an emulsion of vegetable oil, water and an emulsifier such as lecithin; alum, cholesterol, rmLT, cytokines and combinations thereof. The immunogenic component may also be incorporated into liposomes, or conjugated to polysaccharides and/or other polymers for use in a vaccine formulation. Additional substances that can be included in a product for use in the present methods include, but are not limited to one or more preservatives such as disodium or tetrasodium salt of ethylenediaminetetracetic acid (EDTA), merthiolate, and the like.

5

10

15

20

25

30

35

The subject to which the vaccine is administered is preferably a companion animal, most preferably, a dog or cat.

It is preferred that the vaccine of the invention, when in a vaccine formulation, be present in unit dosage form. For purposes of this invention, an immunogenic amount, when administered comprises about 1 x 10⁴ - 1 x 10¹³ inactivated bacterial cells, 0.1 μ g – 1 mg of purified protein, or 0.1 μ g – 10 mg of nucleic acid. In a vaccine formulation containing multiple components, the same or lesser immunogenic amounts can usefully be employed.

Appropriate therapeutically effective doses can be determined readily by those of skill in the art based on the above immunogenic amounts, the condition being treated and the physiological characteristics of the animal. Accordingly, a vaccine preparation provides a dosage of a sterile preparation of an immunogenic amount of the active ingredient(s), where the active ingredient is at least one bacteria, protein, nucleic acid, or any combination thereof. In the presence of additional active agents, these unit dosages can be readily adjusted by those of skill in the art.

A desirable dosage regimen involves administration of at least one dose of desired vaccine composition, where the antigenic content of each fraction is as stated above. Effective doses (immunizing amounts) of the vaccines of the invention may also be extrapolated from dose-response curves derived from model test systems. The mode of administration of the vaccines of the invention can be any suitable route that delivers the vaccine to the host. These include but are not limited to oral, intradermal, intramuscular, intraperitoneal, subcutaneous, intranasal routes, and via scarification (scratching through the top layers of skin, e.g., using a bifurcated needle). However, the vaccine is preferably administered subcutaneously or by intramuscular injection. Other modes of administration

-53-

can also be employed, where desired, such as intradermally, intravenously, intranasally, or intratonsillarly.

Studies have shown that, for each of the above described vaccine compositions, a primary immunization of young animals (after 8 weeks of age) is desirably initiated, with booster doses administered at 12 weeks and 16 weeks of age. Annual re-vaccination is recommended.

5

10

15

20

25

30

35

The vaccine of the present invention is administered and dosed in accordance with good medical practice, taking into account the clinical condition of the individual subject, the site and method of administration, scheduling of administration, subject age, sex, body weight and other factors known to medical practitioners.

The invention further provides kits for the prevention periodontal disease in companion animals. In one embodiment, the kit provides a container comprising a therapeutically effective amount of a composition which prevents periodontal disease in companion animals. Also provided in the same or different container is a pharmaceutically acceptable carrier that may be used in the composition. The kit can additionally include an adjuvant that can be used to aid in creating the response to the composition of the present invention. Also, the kit can include a dispenser for dispensing the composition, preferably in unit dosage form. The dispenser can, for example, comprise metal or plastic foil, such as a blister pack. The kit can be accompanied by a label or printed instructions describing administration of the composition to prevent periodontal disease in a companion animal. Compositions comprising a vaccine composition of the present invention formulated in a pharmaceutically acceptable carrier can also be prepared, placed in an appropriate container, and labeled for treatment of the indicated periodontal condition.

Determination of Vaccine Efficacy

The specific mechanism of protection induced by the vaccines and vaccine compositions compositions of the present invention is the induction of the antibody and/or cellular immune response in vaccinated animals, as indicated by the *in vivo* animal tests described below.

The bacteria, polynucleotides, polypeptides, vaccines, and vaccine compositions of the present invention may be useful in treating or preventing companion animal periodontal disease, bovine foot rot, coronary heart disease (dogs), or systemic infections (dogs). In addition, the compositions of the present invention may also be useful in treating or preventing certain illnesses in companion animals corresponding to similar illnesses in humans such as coronary heart (or vascular or artery) disease, parotitis, oral maloder, gingivitis, periodontitis, stroke, atherosclerosis, hyperlipidemia, increased incidence of preterm delivery of low birth weight infants, bacterial vaginosis and intrauterine growth retardation (IUGR).

The present invention is further illustrated by the following non-limiting example and accompanying figures.

-54-

Example

Companion Animal Crevicular Fluid Sample

Microbial samples were taken from dogs and cats examined at veterinary clinics for periodontal treatment, or dogs examined at either Pfizer Terre Haute or Pfizer Sandwich facilities for normal check-ups. Dogs with periodontal pockets >3mm and cats with periodontal pockets >2mm were included in this study. Dental indices (gingival index and periodontal index) and the periodontal pocket depths were recorded. Individual coarse absorbent paper points (Henry Schein; Melville, NY) were aseptically inserted into the periodontal pocket. Upon removal, the paper points were immediately inserted into vials containing Pre-Reduced Anaerobically Sterile (PRAS) Anaerobic Dental Transport (ADT) Medium (Anaerobe Systems; Morgan Hills, CA).

Vials were transferred into a Bactron IV anaerobic chamber (Sheldon Manufacturing, Cornelius, OR) and processed under 90% N_2 , 5% H_2 , 5% H_2 . The paper points were aseptically placed into 50 μ l of PRAS Brain Heart Infusion (BHI) medium (Anaerobe Systems) and vortexed for 30 seconds. Dilutions of 1:100 and 1:1000 were prepared in BHI medium. Aliquots of 100 μ l of the 1:100 and 1:1000 dilutions were spread on PRAS Burcella Blood Agar (BRU) plates (Anaerobe Systems). The plates were incubated at 37°C in the anaerobic chamber for five to seven days. The total number of bacterial colonies and the number of Black Pigmented Anaerobic Bacteria (BPAB) colonies were counted. Individual BPAP colonies were transferred to new BRU plates and re-incubated as above.

Clinical Isolate Characterization

Each clinical isolate was subjected to a number of biochemical analyses and 16S rRNA DNA sequence analysis, using primers D0056 and D0057 (Seq. ID No. 1 and Seq. ID No. 2; Table 1), to determine genus and species. Individual isolates were streaked on BRU plates. Kanamycin, Vancomycin, and Colistin disks (Anaerobe Systems) were placed on the agar surface to determine the KVC resistance patterns of each isolate. Purified colonies were also subjected to the indole and catalase tests (Anaerobe Systems). Individual isolates were transferred to Egg Yolk Agar (EYA) plates (Anaerobe Systems) in order to determine lipase and lecithinase production patterns. This data is shown in Table 2.

25

5

10

15

20

Table 2. Canine and feline BPAB isolate characterization

Genus/species	1	T]				T	Γ			Π	Γ		
by 16S rRNA	si,	si,	lis.			[F			si,						٠,-
sequence	Porphyromonas gingivalis	Porphyromonas gingivalis	Porphyromonas gingivalis			Porphyromonas salivosa	lia		Porphyromonas gingivalis	gulae	lae	lae	gulae	gulae	Porphyromonas cansulci
	s gir	s gir	s gir	ဖွာ		s sa	теа	Ş	s gir	ng s	ng s	s gu	s gu	s gu	s ca
	лопа	nona	юпа	nona	taria	nona	inter	orali	nona	nona	nona	nona	nona	nona	non
	yron	yron	yron	yron	nden	yron	tella	tella	yron	yron	yron	yron	yron	yron	yron
	orph	orph	orph	Porphyromonas	circumdentaria	orph	Prevotella intermedia	Prevotella oralis	orph	Porphyromonas	Porphyromonas gulae	Porphyromonas gulae	Porphyromonas	Porphyromonas	orph
Catalase	1	1	1		<u> </u>	<u> </u>	-	<u> </u>		1	1			-	7
	9	9	9	9		2	2	9	Se	Ъ	ட	Se	۵.	<u>a</u>	Ne
Lecith.	>	>	>	z		z	N/X	N N	>	>	ND Q	ND	ND ND	N Q	ND
Lipase	z	z	z	z		z	>	ND ND	z	z	z	z	z	z	ND
Indole		_	<u> </u>												
Col	>	>_	>_	2		2	>	2	2	9	2	2	2	2	9
Col	22	2	<u>~</u>	2		9	တ	9	22	œ	22	8	OZ.	<u>د</u>	œ
Vanc	S	S	S	<u>P</u>		Q.	2	Q.	S	8	<u>m</u>	S	S	တ	S
Kan	<u>~</u>	2	2	Ð		9	œ	2	S	2	22	S	S	S	S
Hemolysis	>	>	>	z		Z	>	<u>R</u>	>	>	<u>N</u>	S	<u>R</u>	<u>R</u>	z
Pigment															
	├	>	>	Light		Tan	_	>	>	>-	>-			>	
Gingivitis index	S S	S S	S S	2		9	9	2	2	2	2	2	Ð	2 S	2
Periodontal index	2 2	S	S S	9		2	9	2 2	S S	2	2	S S	2	2	2
Pocket depth	S	<u>R</u>	S	9		2	S S	S S	2	2	문	N N	2	2	
Tooth				_		=				_	_	_	_		4_
sampled	ΑN	NA	NA NA	A A		NA A	NA	¥ Y	ND	S S	<u>P</u>	Q.	٥	S S	URP4
sex		1											<u>R</u>		
Age	AN A	A A	AN NA	AN A		Δ V	NA NA	۸N	QN C	2	2	QN C	<u>Q</u>	QN C	<u>ь</u>
Breed	Ϋ́	¥	ž	₹ Z		¥.	¥	¥.	8	9	2	2	8	9	4.5
, ,	NA A	NA	NA	AN		A A	NA	NA	2	N N	N Q	Q.	QN Q	2	YRKT
Dog/Cat	NA N	NA A	N A	A A		AN AN	A A	N A N					Z O	<u>ک</u> ن	<u>≻</u>
Source											Ω	Ω	 		_
	ATCC	ATCC	ATCC	ATCC		ATCC	ATCC	ATCC	NCTC	Pfizer	Pfizer	Pfizer	Pfizer	Pfizer	VHUP1B
Bact. Log #	9 A					3 A			2 0	ı				5 P	9
	B0029	B0030	B0031	B0032		B0033	B0034	B0035	B0040	B0041	B0042	B0043	B0044	B0045	B0046

Canualanacias		1	Г	Γ	Τ			Γ		Γ_		Г		Γ			
Genus/species																Į	
by 16S rRNA	ij.	Sa	io,	Sa	<u>i:</u>]						Į]	
sequence	Porphyromonas cansulci	Porphyromonas salivosa	Porphyromonas cansulci	Porphyromonas salivosa	Porphyromonas cansulci			į									
	s ca	s sa	s ca	s sa	s ca	60		60		S		S		S		S	
	ona	na	na	ona	Sua	Porphyromonas	aria										
	шо	Omo	ошо	ошо	ошо	шо	ente	шо	enta	ŭ.	ent	шо	ent	ша	enta	JUO.	ent
	hy	hy	hyr	hyr	hyr	hyr	рш	hyr	рш	hy	pur	th.	pur	ly y	puir	hy	pur
	Joc	Jo.	201	ζ do	20ct	207	circumdentaria	207	circumdentaria	207	circumdentaria	20rg	circumdentaria	Jog To	circumdentaria	207	circumdentaria
Catalase	-	-															
	Se	<u> </u>	Д.	Se	Ne	_		_		۵		۵_		۵		ட	
Lecith.																	
	9	2	z	z	9	9		2		9		9		2		2	
Lipase																	
	9	<u> </u>	2	2	2	2		2		2		2		2		2	
Indole	Ð	S	9	Ð	2	9		S		9		9		9		S	
Col	1	2	2	1		_		2		1		1		-		2	
	2	ĸ	<u>K</u>	<u>~</u>	2	œ		<u>~</u>		œ		PK.		ద		œ	
Vanc					Q.												
 Kan	꼰	12	<u> </u>	<u>~</u>		S		S	_	S		S		S	·	S	
	2	2	2	ဟ	2	ဟ		တ		ဟ		ဟ		ဟ		ဟ	
Hemolysis	₽	z	9	9	9	2		2		₽		9		2		9	
Pigment	Ĭ				 -												
	≻	<u> </u>	<u>></u>	>_	<u> ></u> _	<u> </u>		<u> </u> >_		≻_		>		>		<u> </u>	
Gingivitis index	2	2	2	2	2	8		က		က		က		m		က	
Periodontal index				2.				_		_		_				8	
Pocket depth	7	2	2	2	2	<u>(C)</u>		က		8		(n)		8			
Tooth	4	4	4	4	4	ιΩ		ſΩ		ιC		ro		13		2	
	4	4	4	4	4	4		4		4		4		4		4	
sampled	URP4	URP4	URP4	URP4	URP4	URP4											
sex																	
Age	10	10	10	10	π.	Σ		≥		Σ		Σ		<u>N</u>		Σ	
	4.5	5.4	4.5	4.5	4.	2.5		2.5		2.5		2.5		2.5		2.5	
Breed	도	노	노		A	¥		DSHA									
	YRKT	YRKT	YRKT	YRKT	YRKT	DSHA		SO		DS		DS		DS		Sa	
Dog/Cat	Ω				۵	U		ပ		ပ		U		ပ		ပ	
Source		$\overline{}$			—											_	
	È	VHUP1E	VHUP1G	UP	J.	IN IN		P.		IP.		JP.		VHUP2E		VHUP2F	
	¥	_	XH	VHUP1H	VHUP11	VHUP2A		VHUP2B		VHUP2C		VHUP2D					
Bact. Log #	B0047 VHUP1D	48	49	20	1	52		B0053				B0055		26		157	
	<u>8</u>	B0048	B0049	B0050	B0051	B0052		B00		B0054		B00		B0056		B0057	
																	

Genus/species	1	T	Π	1					T	_					.છ		
by 16S rRNA						S	S	S							ntal	ļ	
sequence	Porphyromonas gulae	Bacteroides acidofaciens	Bacteroides acidofaciens	Bacteroides acidofaciens	Porphyromonas	circumdentaria	Bacteroides fragilis	Porphyromonas	circumdentaria	Porphyromonas gulae	Porphyromonas endodontalis	Porphyromonas gulae	Pasteurella canis				
Catalase			а.	۵		Ne	Ne	Ne	۵		Ne	Ne		۵	_		_ _
Lecith.	>	>	>	Z	z	>	>	>	z		z	z	_	z	z	z	z
Lipase	z	z	z	z	z	z	z	z	>		<u></u>	z	***	>	≻	z	z
Indole	e S	SN SN	2	9	2	z	z	z	 ≻		۵	z	****	z	z	z	z
Col	<u>ر</u> الا	2	2	2	<u>د</u>	2	2	2	2		S	2		2	2	2	<u>د</u>
Vanc	2	2	~	œ.	æ	<u>n</u>	S	S	S	•	2	2	-	S	S	S	S
Kan	2	æ	2	nz.	2	S	S	œ	ex.		R	2		S	2	S	œ
Hemolysis	2	Q	9	2	2	>	>	z	z		z	z		>_	z	>	>
Pigment				-		yellow	yellow	yellow			brown	obadne		dk brn	It brn	dk brn	dk brn
Gingivitis index	>	>_	>	>	<u> </u>	<u>×</u>	🖔	<u>\$</u>	풁		ā	0		ਰ	=_	8	ਰ
Periodontal index	7	2	2	2	2	2	2	2	က		3	က		8	2	2	2
Pocket depth	_	-	-	<u>_</u>	-	က	က	က	က		က	က		ო_	QN.	2	2
Tooth	2	2	2	2	2	27	7.	5	9		9	9		9	က	က	8
sampled	ULC	OLC	ULC	nrc	OLC	ULP4	ULP4	ULP4	URCAN		URCAN	URCAN		URCAN	LRCAN	LRCAN	LRCAN
sex	≥	≥	≥	Σ	Σ	ட	ш	LL.	u.		ᄔ	u.,		 LL_	Σ	Σ	Σ
Age	12.5 M	5	5	5	15		15	15		15	6	6	6				
Breed	DSHA	DSHA	DSHA	DSHA	DSHA	QN	2	QN	TPOO		TP00	TP00		TPOO	SSHZ	SSHZ	SSHZ
Dog/Cat	S	U	U_	U	U			Ω	Ω				_		۵	۵	۵
Source	VHUP3A (VHUP3B (VHUP3C (VHUP3D (VHUP3E	VHUP4A	VHUP4C	VHUP4F I	DAH1A [DAH1C I	DAH1D [DAH1F I	DAH2A [DAH2C [
Bact. Log#	N 69008	B0070	B0071 \	B0072 \	B0073 \	B0078 \	B0080 \	B0083 \	B0084 [B0086	B0087		B0089	B0090	B0092 [B0093 DAH2D

Genus/species					is Si												is l
by 16S rRNA	1				gival	_		a	Ø	sini	sinis	ļ. <u>.</u>	a	В	æ	sini	onta
sequence	ae	gulae			Porphyromonas cangingivalis	Streptococcus bovis JB		Porphyromonas salivosa	Porphyromonas salivosa	Porphyromonas denticanis	Porphyromonas denticanis	Porphyromonas cansulci	Porphyromonas salivosa	Porphyromonas salivosa	Porphyromonas salivosa	Porphyromonas denticanis	Porphyromonas endodontalis
	Porphyromonas gulae	gan	(0		s cal	bovi		ssal	ssal	s de	s de	s cal	s sal	s sal	s sa	s de	s en
	ona	Porphyromonas	Porphyromonas	aria	ona	Sns		ona	ona	ona	ona	ona	ona	ona.	ona	ona	ona
	топ	Loui	rom	circumdentaria	rom	000		rom	rom	rom	rom	rom	rom	rom	rom	rom	rom
	phy	rphy	rphy	mı	phy	epto		phy	rphy	rphy	rphy	rphy	rphy	rphy	rphy	rphy	rphy
	Po	Pol	Po	circ	Po	Str		Pol	Po	9	Po	90	8	Po	<u>g</u>	90	Po
Catalase		_	П		_	Ne		<u>_</u>	_	Se .	Ne	_		<u>_</u>	Д.	Se	Ne
Lecith.	- -		-					1	_								
	z	>_	z		z	<u> </u>		>_	<u> </u>	z	z	>_	>_	>	<u> </u>	z	z
Lipase	z	z	z		Z	z		>	>	z	z	>-	>	>	>	z	z
Indole	-	-	_														
	z	z	z		Z	z	_	z	Z	Z_	Z	<u>a</u>	Z	۵.	<u>a</u>	<u> </u>	Z
Col	<u>~</u>	2	2		l _c	2		<u>~</u>	<u>~</u>	S	S	2	2	S	တ	S	
Vanc			_														
	ဟ	ဟ	2		ဟ	ဟ		꼰	OC.	8	꼰	ဟ	四	<u> </u>	S	꼰	
Kan	œ	<u>~</u>	<u>~</u>		တ	ဟ		<u>R</u>	R.	ဟ	<u>~</u>	တ	ĸ	တ	œ	22	
Hemolysis	>	_	z		Z	>		>	>	>	>	z	z	z	>	>	
Pigment				-			_										>
	쏡	동	쏡		pun	blk/wt	fans	pru	pru	쏡	쑮	dk brn	pru	prn	prn	쏡	yellow
Gingivitis index	<u> </u>		_			1	- 7 2		1			L	1	1			
Periodontal index	2	9	2		2	2		2	2	2	2	2	2	2	2	2	<u>R</u>
	呈	9	2		2	2		2	2	2	2	2	2	2	2	2	Q.
Pocket depth	က	က	3		8	4		4	4	4	4	4	4	4	4	4	4
Tooth	z						_									١.	
sampled .	LRCAN	RPM4	RPM4		RPM4	LM1		LM1	LM1	LM1	LM1	LPM4	LPM4	LPM4	LPM4	LPM4	LPM4
sex	무	IK.	18		185	-					-	-	┼	-	-	<u> </u>	-
	Σ	Σ	Σ		Σ	Σ_		Σ	≥	Σ	Σ	Σ	Σ	Σ	≥	Σ	Σ
Age	6	2	2		2	2		8	2	2	2	2	2	2	2	2	2
Breed	SSHZ																
Dog/Cot	SS	2	2		2	2		2	2	2	2	2	2	2	2	2	<u>N</u>
Dog/Cat								Ω									
Source	2F	₩.	<u>a</u>		ပ္ထ	B		ပွ	6	끧	F	<u>B</u>	ပ္ထ	<u> 유</u>	끭	L.	ဖြူ
	DAH2F	TH1aA	TH1aB		TH1aC	TH1bB		TH1bC	TH1bD	TH1bE	TH1bF	TH2aB	TH2aC	TH2aD	TH2aE	TH2aF	TH2aG
Bact. Log #	35					13								-			-
	B0095	B0096	B0097		B0098	B0103		B0104	B0105	B0106	B0107	B0109	B0110	B0111	B0112	B0113	
	144	141	lш		111	101		لتا	1111	101	<u> </u>	<u> 141</u>	<u> 141</u>	لبدر	141	144	لــــــــــــــــــــــــــــــــــــــ

Genus/species	S					S	S		S								
by 16S rRNA	ntali,	_	<u> </u> -			ntali	ntali	_	ntali	nis		isi	-		,,,	С.	nis
sequence	Porphyromonas endodontalis	salivosa		Porphyromonas cansulci	cansulci	Porphyromonas endodontalis	Porphyromonas endodontalis	Porphyromonas salivosa	Porphyromonas endodontalis	Porphyromonas denticanis	Porphyromonas salivosa	Porphyromonas denticanis	Porphyromonas salivosa	Porphyromonas cansulci	Porphyromonas salivosa	Porphyromonas salivosa	Porphyromonas denticanis
	enc	sall	эchу	can	can	enc	enc	sall	enc	der	sall	der	sal	car	sall	sali	der
	onas	onas	n br	onas	onas	onas	onas	onas	onas	onas	onas	onas	onas	onas	onas	onas	onas
	rom	J W Q	eriur	rom	roma	rom	1011	rom	rom	rom	rom	rom	rom	rom	rom	rom	rom
	rphy	Porphyromonas	Eubacterium brachy	rphy	Porphyromonas	rphy	rphy	rphy	rphy	rphy	rphy	rphy	rphy	rphy	rphy	rphy	rphy
	Po	g.	En	8	8	9	Po	Po	9	Po	9	Po	Po	9	Po	P ₀	Po
Catalase	Se	۵.	Se	Ne	Se	_	Ne	<u>d</u>	Ne	Ne	۵.	Ne	<u>_</u>	Ne	<u></u>	ட	Ne
Lecith.																	
	>_	z	<u>></u>	>_	z	>_	>_	>	>_	z	>_	z_	<u>></u>	z	z_	Z_	z
Lipase	z	>	z	z	z	>	z	>	z	z	z	z	z	z	 >	>	z
Indole																	
Col	Z	Z	Z	Z	Z	Z	Z	Z	Z	Z	Z	Z	Z	Z	<u>α</u>	П	<u>В</u>
	꼰	22	<u>m</u>	DC_	区	lac.	<u>~</u>	DC.	깥	လ	nc nc	တ	lac.	匹	တ	တ	တ
Vanc	<u>د</u>	er.	S	2	တ	l m	S	2	S	œ	OZ.	œ.	2	S	CC	2	2
Kan	<u>ب</u>	2	الا الا	<u>~</u>	S	2	2	2	2	2	比	2	2	2	R.	2	2
Hemolysis															z	z	
Pigment	<u>></u>) 	Z	Z	Z	<u> </u>	Z	<u> </u>	Z	<u> </u>	<u> ></u>	<u> ></u> _	>	>	_	_	<u>></u>
	dk bm	opaque	yellow	 -	~	It brn	~	dk brn	~	~	brn	~	prn	حد	prn	brn	~
Gingivitis index				품	플		쑮	$\overline{}$	쑮	충		출		훒	1		쑮
	2	2	2	2	2	2	2	8	2	2	9	2	2	2	2	2	2
Periodontal index	2	2	2	2	9	2	2	2	2	2	문	2	2	2	2	2	2
Pocket depth	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
Tooth														_	e .	, m	က
sampled	LM1	LM1	LM1	LM1	RM1	RM1	RM1	RM1	RM1	RM1	RM1	RM1	RM1	RPM3	RPM3	RPM3	RPM3
sex	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	∑	≥	Σ	Σ	Σ	≥	≥	Σ
Age	Ð	9	9	2	<u>N</u>	R	B	Q.	2	9	R	9	Ð	2	Q.	Q.	9
Breed	广	_	_	-			_			<u> </u>		-	-	<u> </u>			
	S	S N	Q.	N N	Q.	N N	9	S	2	Q.	S	2	<u>R</u>	2	S	2	9
Dog/Cat		Q				Ω		۵			Ω				۵		Ω
Source																	
	TH2bA	TH2bD	TH2bE	TH2bF	TH2cB	TH2cC	TH2cD	TH2cE	TH2cF	TH3aA	TH3aC	TH3aD	TH3aF	TH3bA	TH3bB	ТНЗЬС	TH3bD
Bact. Log#	B0114	1													1	B0134	B0135
	90 B0	B0117	B0118	B0119	B0121	B0122	B0123	B0124	B0125	B0126	B0128	B0129	B0131	B0132	B0133	B0.	80

Genus/species																	
by 16S rRNA	α ₂	nis	(m			_		nis	nis	nis		a	nis	nis		siui	siuis
sequence	Porphyromonas salivosa	Porphyromonas denticanis	Porphyromonas salivosa	Eubacterium brachy	Porphyromonas gulae	Enterococcus gallinarum	Porphyromonas cansulci	Porphyromonas denticanis	Porphyromonas denticanis	Porphyromonas denticanis	Bacteroides forsythus	Porphyromonas salivosa	Porphyromonas denticanis	Porphyromonas denticanis	Eubacterium brachy	Porphyromonas denticanis	Porphyromonas denticanis
Catalase	۵	Ne	Ф	Ne	Д,	Ne	Ne	Ne	Ne	Ne	Д.	Ъ	Ne	Ne	Ь	<u>a</u> .	Ne
Lecith.	z	>	>	z	z	z	z	z	z	z	z	z	z	z	>	z	>
Lipase	>	>	>	z	>	>	>	z	z	z	>	>	z	\	\	z	z
Indole	۵	z	z	۵	а.	z		Д	z	z	z	Ъ	z	z	Ь	z	z
Col	S	2	œ	QN	œ	S	S	S	S	S	တ	S	တ	S	S	S	S
Vanc	<u>~</u>	<u>~</u>	œ	9	ဟ	S	<u>~</u>	m.	œ	œ	22	2	œ	œ	S	œ	œ
Kan	<u>K</u>	2	ď	2	S	S	<u>~</u>	R	<u>~</u>	22	꼰	2	œ	œ	တ	<u>~</u>	œ
Hemolysis	z	z	_	>_	>	z	z	>	<u></u>	 ≻_	z	>	>	<u>></u>	z	>	>
Pigment	brn	왕	obadne	wht	bk	lt brn	It brn	ρk	blk	bk	brn	brn	bk	Š	brn	bk	blk
Gingivitis index	9	2	Q.	S S	QN Q	9	₽ P	9	S S	2	Q.	S	2	S	S S	2	QN N
Periodontal index	2	2	9	2	2	S	B	S	2	2	2	2	2	S.	2	2	S S
Pocket depth	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	7	7
Tooth																-	
sampled	RPM3	LM1	LM1	LM1	RM1	RM1	RM1	LM3	LM1	LM1	LM1	LM1	LM1	LPM4	LPM4	RPM4	RPM4
sex	Σ	Σ	Σ	Σ	≥	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ
Age	Q	QN	9	9	2	2	9	문	g	2	9	문	2	2	2	2	2
Breed	ND	ON	QN	ND ND	ND ND	N N	ND	N ON	N O	N S	9	P P	9	ND ND	2	QN	ND ND
Dog/Cat					۵						۵						
Source	TH3bE [TH3cC I	TH3cE I	TH3cF I	TH4aB	TH4aC	ТН4аЕ	TH4bA	TH4bB	TH4bC	TH4bD	TH4bE	ТН46F	TH5bB	TH5bC	ТН6аD	ТН6аЕ
Bact. Log #	B0136 T	B0140 T	B0142	B0143 T	B0145 T	B0146 T	B0148 T	B0150 T	B0151 T	B0152 T	B0153 T	B0154	B0155 T	B0163 7	B0164	B0171	B0172

Genus/species			6					Γ						S			
by 16S rRNA	is	sic	Porphyromonas endodontalis				_			_		_		Porphyromonas cangingivalis			_
sequence	Porphyromonas denticanis	denticanis	lopo	oris	S	Porphyromonas salivosa	Porphyromonas salivosa	ļ		salivosa	æ	Campylobacter sputorum	g	ging	Porphyromonas cansulci	e e	Porphyromonas cansulci
	den	den	end	Porphyromonas canoris	alocis	salii	salii			salii	gulae	put	gulae	can	can	gulae	can
	nas	nas	nas	nas	Im a	nas	nas	nas	ria	nas	nas	ter s	nas	nas	nas	nas	nas
	omc	Porphyromonas	omc	omo	Fusobacterium	omo	omo	Porphyromonas	circumdentaria	Porphyromonas	Porphyromonas	pac	Porphyromonas	omo	ошс	Porphyromonas	omc
	hyr	hyrc	hyre	hyra	pac	hyra	hyra	hyra	mde	hyr	hyra	pylc	hyra	hyra	hyr	hyra	hyra
	Porp	good	Porp	Porp	Eusc	Porp	Porp	Porp	sirc	Porp	Porp	Cam	Porp	Porp	Porp	Porp	Porp
Catalase																	
*****	<u>R</u>	<u>e</u>	2	>_	Se	۵.	<u>a</u>	Se		▄	<u>a</u>	Se Se	۵.	<u> </u>	Se	۵.	Ne
Lecith.	Ì																
1:	Z_	z_	<u> </u>	Z	z_	>_	>	>_		>_	Z	Z	Z	Z	Z	>	Z
Lipase	z	z	z	z	z	>	>	>		>	>	z	>	z	>	z	_
Indole	_							<u> </u>					ĺ				
	<u>a</u>	z	Z	z	z	z	z	ட		ட	<u>a</u>	z	z	z	z	z	z
Col	တ	S	2	œ	œ.	œ	œ	l m		S	œ	ဟ	2	တ	œ	œ	<u>م</u>
Vanc	<u>"</u>	-	-			<u> </u>)				0,		<u> </u>	
	<u>~</u>	8	<u>~</u>	2	တ	ద	2	တ		ద	ဟ	∝	ဟ	ဟ	ద	깥	ъ.
Kan	œ	2	œ	œ	œ	22	œ	2		œ	œ	ĸ	2		œ	œ	<u>~</u>
Hemolysis	>	>	z	>	z	>	>	>		z	>	>	 -	z	z	>	z
Pigment	_									<u> </u>				<u> </u>	_		_
	ᅩ	opaque	blk/brn	Ę	opaque	Ę		~		lt brn	Ę	ᅩ	dk brn	_	~	pru	<u>~</u>
Gingivitis index	흦		1	ᇣ	1	LIQ 0	¥ K	풁		T	prn	충		tau	흜		훒
	2	2	9	2	9	2	2	2		Q N	2	<u>N</u>	2	2	2	<u>N</u>	2
Periodontal index	9	9	9	9	2	9	2	2		9	9	9	2	문	9	2	9
Pocket depth	6.5	2.5	4	4	4	4	4	8		4	4	4	4	က	3	8	3
Tooth				<u> </u>			_										
sampled	LM1	RPM4	<u>1</u>	F	F	₽	F	₹		LPM3	LPM3	LPM3	LPM3	RPM3	RPM3	RPM3	RPM3
		<u>~</u>	LM1	LM 1	LM1	LM1	LM1	RM1		<u> </u>	二		<u> </u>		<u> </u>	<u> </u>	<u> </u>
sex	≥	Σ	Σ	Σ	Σ	Σ	Σ	Σ		≥_	Σ	≥	Σ	Σ	Σ	Σ	Σ_
Age	₽	9	9	9	9	윤	₽	2		₽	9	9	9	9	9	9	9
Breed																	
	Q Q	R	S	S	N N	S	S	S		N D	S	Q.	S	g	g	2	9
Dog/Cat _																	Ω
Source						Ω	Δ			Ω	Ω_						
	TH6bA	TH7aD	TH7bA	TH7bB	TH7bC	TH7bE	TH7bF	TH8aD		ТН9аА	TH9aB	TH9aD	ТН9аF	TH9bA	ТН9ЪВ	ТН96С	Dq6
	_						픋					芦					固
Bact. Log #	B0174	B0183	B0186	B0187	B0188	B0190	B0191	B0195		B0198	B0199	B0201	B0203	B0204	B0205	B0206	В0207 ТН9bD
	B0	80	8 8	B0	<u>8</u>	B0	B0	B0		B0	B	B0.	B0.	B0	8	B0	80

Genus/species	ŝ																
by 16S rRNA	jival	2			ļ	ļ		01					a		a		ļ
sequence	Porphyromonas cangingivalis	Campylobacter sputorum			ae			sp.			Porphyromonas canoris		Porphyromonas salivosa	Sn	Porphyromonas salivosa		
	car	nds			gulae	,,		Peptostreptococcus	; <u>;</u>	: <u>=</u>	scal	g	sal	Bacteroides forsythus	sal	60	
	onas	cter	Porphyromonas	aria	Porphyromonas	Porphyromonas	aria	000	Bacteroides levii	Bacteroides levii	ona	Klebsiella oxytoca	ona	s for	onas	Porphyromonas	aria
	ī D D	loba	10	circumdentaria	rom	rom	circumdentaria	trept	ide	ide	rom	lla c	rom	ide	rom	rom	circumdentaria
	phy	mpy	rphy	mı	yhd	rhy	ш	soto	cterc	cterc	phy	bsie	rphy	cterc	rphy	phy	m
	Po	S	Po	circ	9	Po	_cir	Pel	Ba	Ba	_S	<u>\$</u>	8	Ba	Po	Po	circ
Catalase		0)						_D	a	a)				0		a	
Lecith.	<u>~</u>	g	<u> </u>		<u> </u>	<u>_</u>		Se	Se	Se	α_	۵.	<u> </u>	Se	Ω.	Se Se	
Leon.	z	z	z		>	>		>	z	z	z	z	>	>	>	>-	
Lipase	z	z	z		z	z	-	>	>	>	z	>	>	z	>	>-	
Indole																	
	Z	z	z		Z	z		z	z	Z	<u></u>	٥	۵.	z	z	Z	
Col	~	S	œ		2	 Y		S	2	22	S	2	CC.	<u> </u>	2	S	
Vanc	<u> </u>	-	Ē	100					-			=					
17	တ	配	R.		8	<u>K</u>		တ	<u>~</u>	2	ဟ	တ	တ	꼰	꼰	လ	
Kan	比	œ	R.		2	区		22	<u>~</u>	8	22	<u>~</u>	区	8	~	22	
Hemolysis	z	z	z		>	Z		z	>	z	z	_	>	z	z	>	
Pigment		\vdash		,									_				
	tan	opaque	崇		lt brn	blk/brn		yellow	쑭	쑮	It bm	brn	mixed	yellow	lt bm	쏡	
Gingivitis index		-											T -	1	ł		
Periodontal index	2	2	2	-	2	2		2	8	2	9	2	2	2	2	2	{
	2	2	문		2	2		2	2	2	2	2	2	2	9	2	
Pocket depth	က	4	4		4	4		4	4	4	2	2	4	4	4	4	
Tooth		1	1										-	-		*	
sampled	RPM3	RM1	RM1		RM1	RM1		LM1	RM1	RM1	LPM3	LPM3	RPM4	RPM4	RPM4	RPM4	
sex		IL.	IL.		IL.	<u> </u>		-	ILE.	IK.		-	ILE.	I.	<u> </u>	<u> </u>	
	Σ	Σ	Σ		Σ	Σ		Σ	Ц.	11_	ш.	ш	<u> L</u>	ц.	止	Ц.	
Age	2	2	9		9	2		2	S S	2	9	2	2	2	<u>N</u>	2	
Breed									_	_] _		_	_		
	2	2	2		2	2		2	2	9	2	2	2	2	2	S N	
Dog/Cat	Ω	Ω	Ω		Ω	Ω		۵	Ω		Ω	Ω	٥	۵		Ω	
Source	Ш	aA	Γ						Ye	G		PF	AB AB	$\overline{}$	Г	1	
	TH9bE	TH10aA	H10		TH10aC	TH10aD		TH10bC	TH11aA	TH11aD	TH11bE	TH11bF	TH12aA	TH12aB	TH12aC	TH12aE	
Bact. Log#	8		B0211 TH10aB			3		$\overline{}$		_		1			_		\dashv
	B0208	B0210	021		B0212	B0213		B0218	B0222	B0225	B0232	B0233	B0234	B0235	B0236	B0238	
L	ш	ΙШ	lω		Ш	Ω		lω	<u>m</u>	100	M	ĪΘ	Tω	<u> m</u>	m	100	

Genus/species		Ĩ		Ś		į	ķ										
by _. 16S rRNA	S	တ	10	ntal	<i>a</i>	ntal	ntal	<i>a</i>	nis	nis	10	nis	nis		ĺ		
sequence	cien	acidofaciens	sb.	todc	salivosa	opoj	lodo	salivosa	tica	ıtica	sb.	ıtica	itica	ae	ае	ae	ae
	lofa	lofa	sno	end	sali	ena	enc	sali	der	der	sno	der	der	gulae	gal	gulae	gnl
	acic	acic	2000	nas	nas	nas	nas	nas	nas	nas	000	nas	nas	nas	nas	nas	nas
	des	des	eptc	onc 0	0110	0110	ouc	omc	omc	omo	epto	ошс	omo	omo	omo	omc	omo
	eroi	erol	ostr	hyr	hyra	hyre	hyr	hyr	hyr	hyr	tosti	hyra	hyr	hyre	hyr	hyr	hyr
	Bacteroides acidofaciens	Bacteroides	Peptostreptococcus sp. D1	Porphyromonas endodontalis	Porphyromonas	Porphyromonas endodontalis	Porphyromonas endodontalis	Porphyromonas	Porphyromonas denticanis	Porphyromonas denticanis	Peptostreptococcus sp.	Porphyromonas denticanis	Porphyromonas denticanis	Porphyromonas	Porphyromonas gulae	Porphyromonas	Porphyromonas gulae
Catalase										<u> </u>							
	Ne	Re	Ne	Se	а.		مـ	<u>a</u>	Se	8	e B	<u>e</u>	ட	<u>a</u>	ட	ட	<u>a</u>
Lecith.																ł	
	Z	z	z	z	<u>≻</u>	>_	Z	<u> </u>	z	Z	z_	z	2	>_	>_	<u>></u>	>
Lipase	z	>	z	z	>	 	z	>	z	z	z	z	9	z	z	z	z
Indole	_			-								-	 - -	_		<u> </u>	
	а_	۵	۵_	z	z	z	z	ட	z	z	ட	z	z	z	z	z	z
Col	~	S	2	œ	S	S	S	S	er.	2	EK.	B	œ	œ	æ	CL	
Vanc																	
	ဟ	DC.	တ	တ	깥	œ	တ	S	ဟ	2	တ	2		<u>~</u>	<u>n</u>	ဟ	S
Kan	တ	22	ဟ	œ	တ	22	œ	œ	တ	22	တ	22	CC	œ	nz.	<u>ac</u>	2
Hemolysis	z	z	z	 	z	>	z	z	>	>	>	z	z	>	>	>	_
Pigment														ĺ			
	[⊭	ے	yellow	7	It brn	It brn	يدا	dk brn	~	~	yellow	~	\ <u>×</u>	ے	۽	gry brn	~
Gingivitis index	Whit	ng .	7	충	1	i	충	1	출	훒	7	흥	출	LIQ (ng 0		SK SK
	2	2	9	2	2	2	2	2	2	2	8	2	2	2	2	2	문
Periodontal index	문	9	9	9	2	9	9	9	9	2	2	9	2	9	9	9	9
Pocket depth	4	4	4	2	2	2	72	5	2	2	2	2	2	4	4	4	4
Tooth													T^{-}				
sampled	ULPM4	ULPM4	ULPM4	RPM4	RPM4	URPM2	URPM2	URPM2	ULCAN	ULCAN	ULCAN	ULCAN	ULCAN	RM1	RM1	RM1	RM1
	<u> </u> 5	트	5	区	<u> </u>	5_	5_	5	5	=_	5	5	15	<u>2</u>	₩.	<u>~</u>	Ē.
sex	止	ш	ட	≥	Σ	Σ	Σ	Σ	Σ	≥	Σ	Σ	≥	≥	≥	Σ	≥
Age	ND D	S	S	9	2	9	9	9	2	9	S	2	9	9	9	9	9
Breed		 - -															
	문	S S	문	9	9	S	S	S	2	2	Q.	9	Q.	9	S	9	2
Dog/Cat				۵													
Source		0		_	\Box	1	$\overline{}$		A D		0		T	T	$\overline{}$		
Ì	TH12bB	TH12bC	TH12bD	TH13aC	TH13aF	TH14aA	TH14aB	TH14aC	TH14bA	TH14bB	TH14bC	TH14bD	TH14bF	TH15aA	TH15aB	TH15aC	TH15aD
	1	_	$\overline{}$	_	匡	_	-		-	1		臣	-	$\overline{}$	픋		
Bact. Log #	B0241	B0242	B0243	B0248	B0251	B0258	B0259	B0260	B0264	B0265	B0266	B0267	B0269	B0270	B0271	B0272	B0273
	B0,	B0,	80°	B0;	<u>80</u>	<u>80</u>	B0,	B0;	BO.	BO.	BO.	80	B0.	B0	B0,	80	B0.

Genus/species		S					-									E	
by 16S rRNA		ntali	į	_	_								ļ		L	eriu	Si
sequence	Porphyromonas gulae	Porphyromonas endodontalis	Porphyromonas cansulci	Unidentified eubacterium	Unidentified eubacterium	Porphyromonas gulae	Porphyromonas	circumdentaria	Porphyromonas	circumdentaria	Porphyromonas gulae	Porphyromonas	circumdentaria	Porphyromonas gulae	Unidentified eubacterium	Unidentified rumen bacterium	Bacteroides acidofaciens
Catalase	٦	<u></u>	Ь	_	Ne	ட	<u>a</u>		Ne		۵.	<u>a</u>		ட	Д.	<u>a</u> .	Ne
Lecith.	>	z	>	z	z	>	z		z		>	z		>	z	z	z
Lipase	z	<u> </u>	z	z	z	z	z		z		z	z		z	z	z	z
Indole	z	z	z	z	z	z	z		<u>a</u>		z	z		z	z	z	<u>a</u>
Col	~	œ	Ж	S	တ	S	œ		22		2	<u>~</u>		œ	S	S	တ
Vanc	တ	တ	S	S	တ	S	S		S		တ	S		S	တ	တ	œ
Kan	<u>~</u>	CC	<u>K</u>	S	တ	ဟ	R.		2		ĸ	ĸ		œ	တ	S	S
Hemolysis	≻	>	2	2	9	2	₽		2		2	>		>	z	>	z
Pigment	dkbrn	DK	brn	쑮	쏡	brn	brn		쏡		dk brn	쑭		brn	於	blk	yellow
Gingivitis index	₽ P	2	2	2	9	Q.	9		2		Q.	2		3	3	3	2
Periodontal index	Ð	2	9	9	R	9	£		9		Ð	2		3	3	က	က
Pocket depth	4	2	4	4	4	4	4		2	_	2	4		9	9	9	5
Tooth sampled	RM1	LM1	RM1	RM1	RM1	RM1	RM1		LPM4		LPM4	URCAN		URCAN	URCAN	URCAN	LM1
sex	Σ	Σ	ш	ш	 L		ப_		L		L	L		ഥ	ഥ	止	≥_
Age	9	2	2	N N	N N	QN.	2		9		N N	9		9	5	19	7.5 M
Breed	QN	ND	S	Q.	ND	ND ND	QN	!	ND		Q.	DSHA		COLI	COLI	COLI	SCOT
Dog/Cat			۵		۵		٥				۵	O		۵	D	۵	Ω
Source	TH15aE	TH15bD	TH16aB	TH16aC		\neg	TH16aF		TH16bC		TH16bD	VHUP5F		DAH6A	1	DAH6F	B0342 VHUP6A D
Bact. Log #	B0274		B0283 1	B0284 1			_		B0290 -		B0291	B0323		B0336		B0341	B0342

Convelencies	1					<u> </u>					$\neg \neg$	Т		sis		T	
Genus/species								ွှ	S.	S.		Į.		iens			Si
by 16S rRNA						_	sa	cani	cani	cani		can		gon		osa	ican
sequence	Bacteroides forsythus	Porphyromonas	circumdentaria	Bacteroides forsythus	Peptostreptococcus	Porphyromonas gulae	Porphyromonas salivosa	Porphyromonas denticanis	Porphyromonas denticanis	Porphyromonas denticanis	Porphyromonas gulae	Porphyromonas denticanis	Bacteroides forsythus	Tessaracoccus bendigoniensis	Bacteroides levii	Porphyromonas salivosa	Porphyromonas denticanis
Catalase	Se	۵.		۵	Ne	ட	Ne	Ne	Ne	Ne	Ь	Ne	Ne Ne	Д	Ne	Ne	Ne
Lecith.	z	z		>	z	z	>	z	z	z	z	z	z	>	z	z	z
Lipase	 ≻	>		>	z	z	>	z	z	z	z	z	z	>_	z	z	z
Indole	۵	z		z	Д	Z	<u>a</u>	<u>a</u>	م	<u>a</u>	z	۵.	z	z	z	<u>a</u>	<u>a</u>
Col	<u>~</u>	2		S	œ	2	တ	S_	တ	တ	တ	ဟ	တ_	2	œ	2	œ
Vanc	S	9		S	တ	2	S	<u>«</u>	2	22	r.	<u>~</u>	တ	တ	œ	2	<u>~</u>
Kan	ĸ	2		œ.	တ	2	တ	8	R.	<u>a</u>	2	<u>~</u>	8	<u>K</u>	<u>~</u>	9	<u>~</u>
Hemolysis	z	z		z	z	>_	z	 	>_	>	>	>_	z	z	z	z	z
Pigment	lt brn	왕		brn	yellow	blk	brn	쏡	ÞĶ	D K) 남	황	yel	lt brn	治	prn	wt
Gingivitis index					2	2	8	8	8	8	8	2	3	9	2	33	2
Periodontal index	3 2	3 2		3 2	-	2	8	т т	8	е г	m	m	2	2	2	_	-
Pocket depth	5	5		5	9	6	9	9	3	3	က	8	9	z	ဖ	5	<u> -</u>
Tooth						z	44	44					AN		_	M3	M3
sampled	LM1	LM1		LM1	ULP2	ULCAN	URPM4	URPM4	ULM1	ULM1	ULM1	LRM1	URCAN	2	LRM1	URPM3	ULPM3
sex	Σ	Σ		Σ	Σ	Σ	Σ	Σ	ш	ட	ш	Σ	Σ	Σ	Σ	Σ	ш
Age	7.5	7.5		7.5	1-	11	6	စ	19	10	9	=======================================		17	문	17	2
Breed	SCOT	SCOT		SCOT	CKSP	YRKT	YRKT	YRKT	DACH	DACH	DACH	MIXB	DSHA	DSHA	2	DACH	DSHA
Dog/Cat	0									٥	Ω	Ω	ပ	ပ			ပ
Source	VHUP6B I	VHUP6C I		VHUP6E I	VHUP7A	DAH8B	1				DAH20D	DAH24D	DAH37E	CSU1B	DAH39C	UCD2A	UF1A
Bact. Log #	B0343 V	R0344 V		B0346 V			_				B0367				B0256		

Genus/species	1								Ι					ш		
by 16S rRNA			artië					.s						eriu	S)	is.
sequence	rum		eri p			osa	(n)	can	₀	ds.		osa	osa	Sact	ican	ican
sequence	onto		varn	ori		aliv	gulae	lenti	gulae	anla		saliv	saliv	9.7	dent	dent
	er s	as .	กรก	ongc	o.	as s	as c	as c	ias (ias (ď.	as a	as (ass	nas (ias (
	bact	mom	30CC	lla b	ls un	mon	mor	mor	mor	mor	ella s	mor	mo	Mou	mo	ioui
	olyc	oyk	olytic Springer	one	ridiu	hyro	hyro	hyro	hyrc	hyrc	icate	hyrc	hyrc	s at	hyrc	hyrc
	Campylobacter sputorum	Porphyromonas	ori curringina Staphylococcus warneri partia	Salmonella bongori	Clostridium sp.	Porphyromonas salivosa	Porphyromonas	Porphyromonas denticanis	Porphyromonas	Porphyromonas gulae	Globicatella sp.	Porphyromonas salivosa	Porphyromonas salivosa	Marine snow assoc. bacterium	Porphyromonas denticanis	Porphyromonas denticanis
 Catalase	1	-	3 0)	7	T	Ť					<u> </u>					
	Se	ட		<u>a.</u>	<u>R</u>	ட	_	<u>e</u>	<u> </u>	<u>a</u>	Se	<u>a</u>	<u>a</u>	Se	<u>8</u>	Se
Lecith.																
	z	z	Z	Z	z	>	Z	Z	z	Z	z	>_	<u> ></u> _	Z	Z	Z
Lipase	z	z	z	z	z	>	z	z	z	z	z	>	>	z	z	z
Indole				1	1											
	<u> -</u>	ட	<u>a</u>	<u>a</u>	ட	z	z	<u>a</u>	山	Z	<u>a</u>	۵.	₽	<u>a</u> _	<u> </u>	凸
Col	ြွ	2	2	9	2	တ	2	CZ.	9	2	2	S	S	2	2	2
Vanc					<u>_</u>											
Kan	꼰	<u>~</u>	2		2	S	S	2	2	S	S	S	ဟ	S	<u>K</u>	꼰
	<u>~</u>	တ	2	2	2	<u>R</u>	œ	œ	2	ဟ	ဟ	ဟ	ဟ	2	<u>R</u>	R
Hemolysis	z	z	>	>	z	z	>_	z	>	z	z	z	z	z	z	z
Pigment				u			ے		_	ے	=	=	ے	E		E
	lt brn	prn	dk brn	dk brn	prn	lt brn	dk brn	yel	dk brn	dk brn	dk brn	grybrn	grybrn	brnfan	yel	grybrn
Gingivitis index	╬	13.7		1		 -				_						
Periodontal index	2	-		-	-	-	-	_	-	-	2	2	2	2	2	2
	_	-		<u> </u>		 -	-	 -	-	-	-	 -	-	_	7	7
Pocket depth	<u>-</u>	0.5	0.5	0.5	0.5	_	<u>~</u>	<u></u>	_	<u> -</u>	<u> </u>	<u></u>	<u> -</u>	_	2	2
Tooth	िह	43	<u>8</u>	¥3	M3	M3	M3	M33	M3	M3	₩3	M3	₩3	M3	M3	M3
sampled	ULPM3	ULPM3	H PM3	ULPM3	ULPM3	ULPM3	ULPM3	URPM3	URPM	URPM3	ULPM3	ULPM	ULPM3	ULPM3	ULPM3	ULPM
sex	╁	 	_=		 	1										
Age	止	<u> L</u>	<u> </u>	<u>. L.</u>	<u> L</u>	<u> </u>	<u> </u>	11.	<u>ц</u>	11_	<u> L</u>	ш	и.	ш	<u> </u>	<u>L</u>
	7	~	4	\neg	~	2	2	2	2	2	rO	ιC	ις.	5	2	2
Breed	DSHA	DSHA	DSHA	DSHA	DSHA	DSHA	DSHA	DSHA	DSHA	DSHA	DSHA	DSHA	DSHA	DSHA	DSHA	DSHA
Dog/Cat	U U	O	ان		U U	S	S	S	S	S	υ υ	S	U U	U	C	S
Source	╁	1	1		 	1	╁	 	1	1	Ť		 	† <u> </u>		
	一	2C	2	UF2E	UF2F	UF3B	UF3F	UF4C	UF4D	UF4E	UF7A	UF7B	UF7D	UF7F	UF9A	UF9B
	UF1E	UF2C	I IF2D													<u>#</u> _
Bact. Log #	B0385	B0389	B0390	B0391	B0392	B0394	B0398	B0401	B0402	B0403	B0411	B0412	B0414	B0416	B0417	B0418
	8	<u></u>	8	8	<u> </u> 8	8	B0	<u> </u> 28	<u>B</u>	BC	<u> </u> 2	<u> </u> 2	<u> </u>	<u>M</u>	<u> </u>	<u> </u>

								,—			т—				т —		
Genus/species						42											
by 16S rRNA	sini	nis				Veillonella sp. oral clone X042											
sequence	Porphyromonas denticanis	denticanis	36	ae ae	ae	lone	}		}								
	dei	der	gal	gal	gal	īa	ia 	пае	sinis	ra sp.			,		(0		
	nas	nas	nas	onas	nas	<i>b</i> . o	non	ıs rir	Sns	hag	Suas	aria	nas	aria	Suas	aria	onas
	шо	ошо,	шо	отс	JUO.	ella s	llao	cillu	200	ytor	JWO.	lenta	comc	lenta	omo.	lenta	omo.
	phyl	Porphyromonas	Porphyromonas gulae	Porphyromonas gulae	Porphyromonas gulae	llone	Prevotella oulora	Lactobacillus rimae	Streptococcus suis	Capnocytophaga	Porphyromonas	circumdentaria	Porphyromonas	circumdentaria	Porphyromonas	circumdentaria	Porphyromonas
	Por	Por	Por	Por	Por	Vei	Pre	Lac	Stre	Cay	Por	circ	Por	circ	Por	circ	Por
Catalase				}							}						
	Se	Se	<u>a</u>	<u></u>	<u></u>	Se	Ş	8	Se	Se	<u></u>		α.		۵_		<u>а</u>
Lecith.			_	-			_	9	_	욷	Z		_		_		
Lipase	Z	Z	Z_	Z	Z	Z	Z		Z		_		Z		Z		Z
	Z	z	>_	z	<u> </u>	z	z	2	z	2	z	·-	z		z		z
Indole			1		1												
Col	<u></u>	<u> </u>	Z	Z	Ω.	Δ_	Z	2	Z	<u>a</u>	Z		а.		<u> </u>		<u>a</u>
001	~	22	œ	9	nz.	S	9	9	S	9	DZ.		ဟ		œ		<i>رب</i>
Vanc								9		P							
Kan	꼰	R	S	2	꼰	S	2		S		S		S		S		တ
	꼰	<u>R</u>	S	2	12	S	9	2	ဟ	9	<u>~</u>		2	_	œ		2
Hemolysis	z	z	>	z	z	>	z	9	>_	9	z		z		z		z
Pigment	_					٦											
	grybrn	붉	쓹	쏡	쓹	brnfan	yel	It brn	lt brn	2	Itbrn		쓹		쏡		brn
Gingivitis index	6	10	12	<u> </u>	<u> </u>	10	>	=	╫	-	▐ <u></u>		9		Ω_		9
Periodontal index	2	7	2	2	2	2	2	2	2	2	2		2		2		2
	7	7	2	2	2	2	2	2	2	2	2		2		2		2
Pocket depth	2	2	2	2	2	2	2	9	9	m	9		2		9		9
Tooth	5	2	<u>π</u>	<u>n</u>	<u> </u>												
sampled	ULPM3	ULPM3	ULPM3	ULPM3	ULPM3	LLM1	LLM1	LLM1	LLM1	UR!	LRM1		LRM1		LRM1		LRM1
sex	-	-	-	-	-			ᆜ	 -		1		<u></u>				
	ய	ட	<u> 11</u>	止	ш.	ட	ഥ	<u> L</u>	<u> </u>	ட	≥		Σ		Σ		Σ
Age	9	문	2	2	9	4	4	4	4	12	2		2		2	-,	2
Breed	₹	1	4	4	4	HZ	7	무		1	1		1		ł		1 1
	DSHA	DSHA	DSHA	DSHA	DSHA	MSHZ	MSHZ	MSHZ	MSHZ	BOXE	DSHA		DSHA		DSHA		DSHA
Dog/Cat	O	U	U	ပ	U	۵	۵	۵			S		ပ		ပ		U
Source																	
ľ	UF9E	UF9F	UF10A	UF10E	UF10F	UCD4C	UCD4D	UCD4E	UCD4F	UCD5B	UCD6A		UCD6B		OCD6C) 1907
D-414					•												B0449 UCD6D
Bact. Log #	B0421	B0422	B0423	B0427	B0428	B0437	B0438	B0439	B0440	B0442	B0446		B0447		B0448		1449
	B0	8	<u>8</u>	B0	8	B0	8	8	8	8	8		8		8		<u>8</u>

												,					-
Genus/species											ļ —	ļ		1			ļ
by 16S rRNA		1		{				nis	nis	2	}	S	S	ည	a	a	
sequence	1							ntice	ntica	scier	s sp.	scier	acier	acier	ivos	livos	
		S		S		6		Porphyromonas denticanis	Porphyromonas denticanis	Bacteroides acidofaciens	Peptostreptococcus sp.	Bacteroides acidofaciens	Bacteroides acidofaciens	Bacteroides acidofaciens	Porphyromonas salivosa	Porphyromonas salivosa	}
	aria	Porphyromonas	aria	Porphyromonas	aria	Porphyromonas	aria	ona	ona	s ac	toco	s ac	s ac	s ac	ona	ona	}
	circumdentaria	rom	circumdentaria	rom	circumdentaria	rom	circumdentaria	ron	rom	ojde	trep	oide	oide	oide	rom	rom	0
	mn	rphy	m	rphy	шn	rphy	m	rphy	rphy	cter	ptos	cten	cter	cter	rphy	rphy	ative
	circ	_Q	circ	Po	circ	Po	circ	9	8	Ba	Pe	Ba	Ba	Ba	8	8	Neg
Catalase		Ne		<u>_</u>		<u>_</u>		_	Ne	Se	_	Ne	Ne	Se		Se	Ne,
Lecith.	+	_				-		-	_	1	<u> </u>		_	_	 -	-	tive;
		z		z		z		z	z	z	>_	9	9	9	2	9	Posi
Lipase		z		z		z		z	z	z	z	S	9	₽	9	9	le; ND, Not determined; M, Male; F, Female; Y, Yes; N, No; P, Positive; Ne, Negative
Indole																	ž
0-1		z		<u>a</u>		z		Z	<u>a</u>	<u>a</u>	ᇟ	<u>α</u>	<u> </u>	<u>a</u>		ը_	Yes;
Col	ļ	2		2		2		S	S	nc.	œ	S	S	œ	2	CZ.	>
Vanc																	nale
Kan		ဟ		ဟ		တ		꼰	K	S	လ	CC.	2	区	<u>R</u>	区	Fer
		<u>K</u>		2		2		깥	<u>~</u>	<u>K</u>	တ	CC_	2	<u>m</u>	R	<u>K</u>	T.
Hemolysis		z		z		z		z	z	z	z	z	z	z	>	>	Mak
Pigment																	Ž,
	ļ	brn		쑮		쑮		쑮	PLUQ	yei	prn	wht	wyel	wht	FIG	Щą	ined
Gingivitis index	1							2	2	QN	2						erm
Periodontal index	\dashv	2		2		2		1-	1		Z	2	2	2	2	2	tdet
	_	2		2		2		2	2	2	=	2	2	2	2	2	12
Pocket depth	_	2		9		2		9	9	2	9	6	8	8	က	<u>m</u>	2
Tooth	ì	_		_		_		A	A	N/		4	4	4	4	4	
sampled		LRM1		LRM1		LRM1		URCA	URCAN	URCAN	LLP4	URP4	URP4	URP4	URP4	URP4	plic
sex		Σ		Σ		Σ		L.	ш	ш.	Σ	Σ	Σ	Σ	Σ	Σ	lot a
Age												1					Ž,
Breed		4		4		4		8	0 8	8	9	5	5	5	7	5	at; 2
		DSHA		DSHA		DSHA		POOD	POOD	POOD	DLHA	WHWT 10	WHWT 10	WHWT 10	WHWT 10	WHWT 10	Abbreviations: D, Dog; C, Cat; NA, Not applicab
Dog/Cat		S		U		S		a	0	0	O	۵	Ω			۵	Dog;
Source		T^{-}						В									Ω,
	ļ	UCD6E		DODD0		ПСБЕН		UCD7B	UCD7C	UCD7D	UCD8C	UCD10A	UCD10B	UCD10D	UCD10E	UCD10F	ions
Bact. Log#		12		12		3			1							8	viat
	Ì	B0450		B0452		B0453		B0456	B0457	B0458	B0463	B0473	B0474	B0476	B0477	B0478	bbre
L		m		ĮΦ		ΙŌ		JΩ	lω	lω	<u> </u>	M	lω	lω	lω	lw.	J∢

The isolates were typed based on their 16S rRNA DNA sequence. Individual, well-isolated colonies were utilized as template for polymerase chain reactions (PCR) amplification of the 16S rRNA region using primers D0056 and D0057 (Seq. ID No. 1 and Seq. ID No. 2; Table 1) in triplicate. The PCR was carried out in 50 μl reaction volumes containing 1 x PCR buffer (Life Technologies; Rockville, MD), 1.0 mM MgCl₂, 1.25 μM each primer, 300 μM each deoxy-NTP, and 2.5 U Platinum *Pfx* DNA Polymerase (Life Technologies). The following PCR cycle conditions were utilized: a two minute denaturation step at 94°C; 30 cycles of denaturation at 94°C for 40 seconds, annealing at 60°C for 40 seconds, and extension at 72°C for one minute; a final extension step at 72°C for two minutes; and a final cooling step to 4°C. A GeneAmp 9700 thermocycler (Perkin Elmer Applied Biosystems; Foster City, CA) was utilized for all PCR amplifications.

5

10

15

20

25

30

The resulting PCR products were purified using the PCR preps kits (Promega Corp.; Madison, WI) and pooled by isolate. The purified PCR products were then desalted by drop analysis against 25 ml sterile water using a 0.025 µm nitrocellulose filter (Millipore Corp.; Bedford, MA). The purified, desalted PCR products were subjected to DNA sequence analysis using the DyeDeoxy termination reaction on an ABI automated DNA sequencer (University of Texas Genetics Core Facility, Houston, TX and Lark Technologies Inc., Houston, TX). Synthetic oligonucleotide primers D0056, D0057, PFZ175-AP1, PFZ175-AP2, and PFZ175-AP3 (Seq. ID No. 1-5, respectively; Table 1) were used to obtain double stranded DNA sequence. The resulting DNA sequences were used to search publicly available DNA databases using a BLAST-N program publicly available from The National Center for Biotechnology Information, USA.

The bacterial isolates were typed based on the closest match identified by database searches. The B106 isolates did not have a precise match. The nearest match was with an uncultured bacterial type that was identified by random PCR of human periodontal pocket material. This isolate was referred to as *Porphyromonas denticanis* strain B106. A complete listing of all the isolates and their respective characteristics is located in Table 2. The top nine most frequently isolated strains are exemplified by the following isolates: *P. gulae* B43 (dog sample Sandwich 4), *P. cansulci* B46 (dog sample VHUP 1B), *P. circumdentaria* B52 (cat sample VHUP 2A), *P. gulae* B69 (cat sample VHUP 3A), *P. circumdentaria* B97 (dog sample TH 1bC), *P. cangingivalis* B98 (dog sample TH 1aC), *P. salivosa* B104 (dog sample TH 1bC), *P. denticanis* B106 (dog sample TH 1bE), and *P. endodontalis* B114 (dog sample TH 2bA).

The distribution of isolates is shown in Table 3.

Table 3. Summary of the number of dogs and cats identified to harbor indicated bacterial species.

Isolate	# dog	#	% positive	# cat	#	% positive
	isolates	dogs	dogs	isolates	cats	
Porphyromonas gulae	27	16	31	8	6	38
Porphyromonas salivosa	27	17	33	3	2	13
(macacae)						
Porphyromonas denticanis	24	15	29	0	0	0
Porphyromonas cansulci	12	8	15	0	0	0
Porphyromonas	11	8	15	0	0	0
endodontalis						
Porphyromonas	10	8	15	15	4	25
circumdendaria						
Bacteroides acidofaciens	10	5	10	0	0	0
Bacteroides forsythus	4	3	6	1	1	6
Porphyromonas	3	2	4	0	0	0
cangingivalis						
Bacteroides levii	3	2	4	0	0	0
Eubacterium brachy	3	3	6	0	0	0
ATCC33089						
Peptostreptococcus sp. D1	3	4	8	1	1	6
Unidentified eubacterium	3	2	4	0	0	0
Porphyromonas canoris	2	2	4	0	0	0
Campylobacterium sputorum	2	2	4	1	1	6
Porphyromonas gingivalis	1	1	2	0	0	0
Bacteroides fragilis	1	1	2	0	0	0
Uncultured bacterium SHA-	. 1	1	2	0	0	0
54						
Uncultured bacterium SHA-	. 1	1	2	0	0	0
219						
Pasteurella canis	1	1	2	0	0	0
Streptococcus bovis JB1	1	1	2	0	0	0
Enterococcus gallinarum	1	1	2	0	0	0
Fusobacterium alocis	1	1	2	0	0	0
Klebsiella oxytoca	1	1	2	0	0	0
Unidentified rumer	1	1	2	0	0	0

Isolate	# dog isolates	# dogs	% positive dogs	# cat isolates	# cats	% positive
bacterium						
Uncultured bacterium	0	0	0	6	3	19
AF132259						
Prevotella oulora	0	1	2	0	0	0
Tessatacoccus	0	0	0	1	1	6
bendigoniensis						
Staphyloccus warneri	0	0	0	1	1	6
Salmonella bongori	0	0	0	1	1	6
Clostridium sp.	0	0	0	1	1	6
Globicatella sp.	0	0	0	1	1	6
Marine snow associated	0	0	0	1	1	6
bacterium						
Veillonella sp. oral clone	0	1	2	0	0	0
X042						
Lactobacillus rimae	0	1	2	0	0	0
Streptococcus suis	0	1	2	0	0	0
Capnocytophaga sp.	0	1	2	0	0	0

The isolates listed above represent those species that were most frequently identified and present in the highest percentages of dogs or cats.

The following companion animal periodontal isolates were deposited with the American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, VA, 20110, USA, on August 9, 2001: *P. gulae* B43 (PTA-3618), *P. cansulci* B46 (PTA-3619), *P. circumdentaria* B52 (PTA-3620), *P. gulae* B69 (PTA-3621), *P. circumdentaria* B97 (PTA-3622), *P. cangingivalis* B98 (PTA-3623), *P. salivosa* B104 (PTA-3624), *P. denticanis* B106 (PTA-3625), and *P. endodontalis* B114 (PTA-3626).

5

10

15

CULTURE CONDITIONS FOR PORPHYROMONAS SP.

Since the standard growth media for *Porphyromonas sp.* (Brain Heart Infusion (BHI) and Chopped Meat Carbohydrate (CMC) media) contain animal product, which are not amenable for vaccine production, a growth medium that does not contain these ingredients was sought. Various media compositions, with and without the addition of hemin and vitamin K, were tested for their ability to support growth equivalent to that of growth of BHI or CMC. Both the PYG-complete medium and ME-complete medium supported the growth of *P. gulae* B43 (PTA-3618) to a level equivalent to that of BHI (Figure 1). The PYG-complete medium was chosen as the *P. gulae* B43 (PTA-3618) growth medium due to its ability to yield high

10

15

20

25

30

35

density cultures during fermentation. This medium contains the following ingredients: 3% phytone (Becton Dickinson; Cockeysville, MD), 0.3% yeast extract (Becton Dickinson), 0.3% glucose (Sigma Corp.; St. Louis, MO), 0.05% sodium thioglycollate (Becton Dickinson), 0.5% sodium chloride (Sigma Corp.), 5μ g/ml hemin (Sigma Corp.) (added after autoclaving), 0.5 μ g/ml menadione (Sigma Corp.) (added after autoclaving), and 0.2% sodium bicarbonate (Sigma Corp.), pH 7.0.

 $P.\ gulae\$ B43 (PTA-3618) was routinely cultivated on Brucella blood agar plates (Anaerobe Systems) or in complete PYG medium or BHI at 37°C in a Bactron IV anaerobic chamber (Shel Labs; Cornelius, OR) under 90% N_2 , 5% CO_2 for three to five days (plates) or 24 to 48 hours (liquid cultures). For whole cell bacterin preparation, $P.\ gulae\$ B43 (PTA-3618) was cultivated in a BioFlo 3000 Bioreactor using 5 liters of PYG complete medium. The culture medium in the vessel was rendered anaerobic by sparging with 95 – 99.5% N_2 and 0.5 – 5% CO_2 immediately after autoclaving. The reduced culture medium was seeded with 0.02% of $P.\ gulae\$ B43 (PTA-3618) stock and cultivated at 37°C with an agitation rate of 100 rpm and the pH maintained at 7.0 by the automatic addition of NaOH. During cultivation, the vessel was periodically sparged with both N_2 and CO_2 . The bacterial cells were collected after 36 to 48 hours at an OD_{600} of 2.0 to 3.5 while cells were still undergoing logarithmic growth.

Pathogenicity Testing of Clinical Isolates

The nine isolates (P. gulae B43, P. cansulci B46, P. circumdentaria B52, P. gulae B69, P. circumdentaria B97, P. cangingivalis B98, P. salivosa B104, P. denticanis B106, and P. endodontalis B114) were tested for their pathogenicity in the mouse periodontal bone loss model. Three-week-old, age-matched male Balb/c CyJ mice (Jackson Laboratories; Bar Harbor, ME) with estimated weights of 14-15 grams were utilized for this study. The animals were housed in positive pressure, barrier cage units. Food pellets, standard for the species, and water were provided ad libitum throughout the experiment. The bedding utilized was granular Bed O'Cobbs to minimize impaction in the gingival tissues. Following receipt, all animals were acclimatized for five to seven days. To reduce competing oral flora, animals were placed on a mixture of sulfamathoxazole and trimethoprim (10 ml drinking water; approximately 2 mg and 0.4 mg/ml, respectively) for ten days followed by a five-day washout period. Serum samples were taken from each mouse tail vein bleed. The animals were infected with 0.5 ml suspension of approximately 1 X 1010 cfu/ml of the appropriate bacterial strain in 1% carboxymethylcellulose by gavage. Additional drops were placed in the oral cavity. This infection was repeated two more times for a total of three times (Monday, Wednesday, and Friday).

Day 1 of the experiment was defined as the Tuesday following the first infection. All animals were sacrificed on Day 2. Post-infection serum was collected, as were microbial

samples. The jaws of each mouse were defleshed, stained, and scored for horizontal bone loss microscopically. The scoring was repeated three times to reduce operator error. The average bone loss is expressed as the average bone loss/site/jaw in mm. Statistical analysis of the resulting data was done with Systat (version 9), SigmaStat (version 2), and SigmaPlot (version 2000) available from SPSS Science Inc. (Chicago, IL). Table 4 shows the numerical results for the top nine isolates.

Table 4. Summary of the mouse periodontal disease pathogenicity trial.

5

10

15

20

Isolate	Number of	Source of	Mean Bone	Std.	SEM
	mice	bacteria	Loss (mm)	Deviation	
Sham	32	N/A	0.0843	0.0118	0.00211
P. gingivalis 53977	16	Human	0.106	0.0139	0.00347
P. gingivalis W50	16	Human	0.0948	0.0116	0.0029
P. gingivalis B40 A	16	Dog	0.106	0.0138	0.00357
P. gingivalis B40 B	16	Dog	0.115	0.0114	0.00284
P. gulae B43	16	Dog	0.112	0.0163	0.00407
P. cansulci B46	16	Dog	0.101	0.014	0.00362
P. circumdentaria B52	16	Cat	0.0924	0.00836	0.00209
P. gulae B69	16	Cat	0.114	0.0129	0.00322
P. circumdentaria B97	16	Dog	0.0855	0.0143	0.00368
P. cangingivalis B98	16	Dog	0.111	0.0136	0.0034
P. salivosa B104	16	Dog	0.102	0.0107	0.00286
P. denticanis B106	16	Dog	0.124	0.0167	0.00417
P. endodontalis B114	16	Dog	0.0994	0.0223	0.00557

Each of these yielded statistically significant bone loss in this model.

Figure 2 graphically shows the net bone loss. The mean alveolar bone levels (cementoenamel junction – alveolar bone crest) were obtained at 14 maxillary sites in mm, and the mean value for each jaw was determined. For each experimental group, the mean values for each jaw were summed and the group mean derived by dividing by the total number of animals in that group.

Figure 3 graphically shows the comparison of net bone loss. The mean alveolar bone levels (cementoenamel junctions – alveolar bone crest) were obtained at 14 maxillary sites in mm, and the mean value for each jaw was determined. For each experimental group, the mean values for each jaw were summed and the group mean derived by dividing by the total number of animals in that group. The net bone loss was determined by subtracting the sham infected mean values from each experimental groups. The data is presented as a percentage

10

15

20

25

30

35

of the positive control group (*P. gingivalis* 53977) which is set at 100%. *P. gingivalis* W50 is a poorly fimbrinated strain that has reduced virulence in this animal model.

These data indicate that the following clinical isolates are capable of producing high levels of bone loss in the mouse model of periodontal disease: *P. gulae* B43 (PTA-3618), *P. gulae* B69 (PTA-3621), *P. cangingivalis* B98 (PTA-3623) and *P. denticanis* B106 (PTA-3625). The following clinical isolates yielded moderate bone loss in the mouse periodontal model: *P. cansulci* B46 (PTA-3619), *P. salivosa* B104 (PTA-3624), and *P. endodontalis* B114 (PTA-3626). The following clinical isolates yielded minimal bone loss in the mouse periodontal model: *P. circumdentaria* B52 (PTA-3620) and *P. circumdentaria* B97 (PTA-3622). While varying amounts of bone loss were observed between the clinical isolates, it should be noted that in each case, the amount of bone loss observed was well above what was observed in the sham infected mice. Based on these data, it can be concluded that each of the top nine clinical isolates is capable of causing periodontal disease either alone or in concert with other bacteria.

PREPARATION OF BACTERIAL CELLS AND GENOMIC DNA

Porphyromonas spp. were anaerobically cultivated in BHI or complete PYG at 37°C for 48 hours. Cells from a 1-3 ml culture were pelleted by centrifugation, washed once in an equal volume of anaerobic PBS, re-centrifuged, and re-suspended in 1/10 volume anaerobic PBS.

Genomic DNA was purified from 5 ml cultures of *Porphyromonas spp.* that were anaerobically cultivated in BHI or complete PYG at 37°C for 48 hours. The Wizard Genomic DNA Extraction kit (Promega Corp.) was utilized for all genomic DNA preparations.

CLONING OF THE FIMBRIAL GENE FROM CLINICAL ISOLATES

The *fimA* gene was PCR amplified from genomic DNA isolated from the top ten clinical isolates using combinations of the following PCR primers D0067 (forward; Seq. ID No. 6), D0078 (forward; Seq. ID No. 8), D0097 (forward; Seq. ID No. 9), D0068 (reverse; Seq. ID No. 7) and D0098 (reverse; Seq. ID No. 10). The PCR was carried out in 50 ul reaction volumes containing 1x PCR buffer (Life Technologies), 1.0 mM MgCl₂, 1.25 μM each primer, 300 M each deoxy-NTP, and 2.5 U Platinum *Pfx* DNA Polymerase (Life Technologies). The following PCR cycle conditions were utilized: a two minute denaturation step at 94°C; 30 cycles of denaturation at 94°C for 40 seconds, annealing at 60°C for 40 seconds, and extension at 72°C for 1.5 minutes; a final extension step at 72°C for five minutes; and a final cooling step to 4°C. A GeneAmp 9700 thermocycler (Perkin Elmer Applied Biosystems; Foster City, CA) was utilized for all PCR amplifications. The amplified products were visualized on a 1.2% E-gel (Invitrogen; Carlsbad, CA).

The PCR products were A-tailed using 10 units of KlenTaq polymerase (Ab Peptides, Inc.; St. Louis, MO) for five minutes at 72°C. The resultant products were immediately T-tail

10

15

20

25

30

35

cloned into the pCR2.1-TOPO vector (Invitrogen) using the manufacturer's protocol and transformed into *E. coli* Top10F' (Novagen; Madison, WI). Transformants harboring recombinant plasmids with the correct insert DNA were identified by a combination of colony PCR, restriction enzyme digestion, and DNA sequence analysis using DyeDeoxy termination reactions on an ABI automated DNA sequence (Lark Technologies, Inc.). Synthetic oligonucleotide primers (Seq. ID No. 6, 7, 8, 11-42) were used to obtain double stranded DNA sequence.

CLONING OF THE P. GULAE B43 FIMA GENE INTO EXPRESSION PLASMIDS

For the purpose of high-level protein expression, the *P. gulae* B43 (PTA-3618) *fimA* gene was cloned into the pBAD/HisA expression vector (Invitrogen). Genomic DNA was purified from a 5 ml culture of *P. gulae* B43 in BHI incubated at 37°C for two days anaerobically using the genomic DNA extraction kit (Promega Corp.). The *fimA* gene was PCR amplified using primers D0097 and D0098 (Seq. ID No. 9 and Seq. ID No. 10) in triplicate. The PCR was carried out in 50 ul reaction volumes containing 1 X PCR buffer (Life Technologies), 50 ng *P. gulae* B43 genomic DNA, 1.0 mM MgCL₂, 1.25 µM each primer, 300 µM each deoxy-NTP, and 2.5 U Platinum *Pfx* DNA Polymerase (Life Technologies, USA).

The following PCR cycle conditions were utilized: a two minute denaturation step at 94°C; five cycles of denaturation at 94°C for 40 seconds, annealing at 58°C for 40 seconds, and extension at 72°C for 1.5 minutes; 30 cycles of denaturation at 94°C for 40 seconds, annealing at 65°C for 40 seconds, and extension at 72°C for 1.5 minutes; a final extension step at 72°C for five minutes; and a final cooling step to 4°C. A GeneAmp 9700 thermocycler (Perkin Elmer Applied Biosystems) was utilized for all PCR amplifications. The PCR products were purified using PCR prep kits (Promega Corp.). The purified PCR products and pBAD/HisA were double digested with HindIII and XhoI for three hours at 37°C. Half way through the digestion, five units of shrimp alkaline phosphatase (SAP) (Amersham Pharmacia Biotech, Inc.: Piscataway, NJ) were added to the vector digestion. The digested DNA's were purified using the DNA Clean-Up kit (Promega Corp.). The purified HindllI/Xhol digested PCR products were ligated into HindIII/XhoI digested, SAP treated pBAD/HisA with the T4 DNA Ligase enzyme (Life Technologies) in the presence of 1 X T4 DNA ligase buffer at 16°C for 18 hours. A portion of the resulting ligation mixture was transformed into competent E. coli Top10F' cells (Novagen). A recombinant plasmid, pBAD:B43fimA4, was found to contain the fimA gene in the correct orientation. The resulting recombinant FimA contains a terminal, vector-encoded sequence

(MGGSHHHHHHGMASMTGGQMGRDLYDDDDKDRWGSELEICSQYHMGI, SEQ ID NO: 135), followed by the mature portion of FimA beginning at asparagine-20. This plasmid was transformed into competent *E. coli* BL21 cells (Novagen) for further protein expression analysis.

EXPRESSION AND PURIFICATION OF THE RECOMBINANT FIMA PROTEIN

A frozen working stock of the *E. coli* BL21/pBAD:B43fimA4 was thawed, seeded at a 1:5000 dilution into Luria broth containing 100 μg/ml ampicillin (1% tryptone, 0.5% yeast extract, 0.5% NaCl), and grown in a 5 liter working volume BioFlo 3000 Bioreactor (New Brunswick Scientific; Edison, NJ) at 37°C with a 100 rpm agitation rate until A₆₂₅ was 2.5-3.5. L-arabinose was then added to the culture at a final concentration of 0.1% to induce FimA expression. The culture was incubated for an additional three hours. Expression of the recombinant FimA was detected by SDS-PAGE and Western blot analysis using anti-Express serum (Invitrogen) (Figure 4). The recombinant FimA protein had a predicted molecular mass of 45 kDa.

5

10

15

20

25

30

35

Wet cells of the *E. coli* BL21 transformant expressing recombinant FimA from the 5 liter fermentation were harvested by centrifugation and re-suspended in phosphate-buffered saline. The cells were mechanically lysed. Following centrifugation, the pellet was discarded. The supernatant was passed over a Ni²⁺ -affinity column, and eluted off using an imidazole gradient. Fractions containing the recombinant protein were pooled, dialyzed to remove the imidazole, and filter-sterilized using a 0.2 µm filter.

CLONING OF THE OPRF GENE FROM CLINICAL ISOLATES

Based on sequences of the *P. gingivalis* strain W50 *oprF* homolog, gene PG32 (Genbank accession number AF175714), oligonucleotide primers D0086 (SEQ ID No. 43), D0087 (SEQ ID NO. 44), and KWK-Pg-03 (SEQ ID NO. 45) were designed and synthesized (Life Technologies). For PCR, primer D0086 (SEQ ID NO. 43) was used in conjunction with either D0087 (SEQ ID NO. 44) or KWK-Pg-03 (SEQ ID NO. 45) in 1 X PC2 buffer (Ab Peptides), 200 μM each dNTP, 7.5 U Klen *Taq*1 (Ab Peptides) and 0.15 U cloned *Pfu* (Stratagene; La Jolla, CA) thermostable polymerases in a 50 μl final sample volume. Reactions were performed in triplicate using either a washed cell suspension or purified genomic DNA as template from *P. gulae* B43, *P. cansulci* B46, *P. circumdentaria* B52, *P. gulae* B69, *P. circumdentaria* B97, *P. cangingivalis* B98, *P. salivosa* B104, *P. denticanis* B106, and *P. endodontalis* B114. Amplification was carried out as follows: denaturation (94°C, 9 minutes); 30-40 cycles of denaturation (94°C, 30 seconds), annealing (55-60°C, 30 seconds), and polymerization (72°C, 1.5 minutes); followed by a final extension at 72°C for seven minutes.

For polymerase chain amplification of the *oprF* homolog from *P. cangingivalis* B98, primer KWK-Ps-04b (SEQ ID No. 81) was used in conjunction with KWK-Ps-06b (SEQ ID No. 83). For amplification of the homolog from *P. salivosa* B104, primer KWK-Ps-04b (SEQ ID No. 81) was used with KWK-Ps-05b (SEQ ID No. 82). For amplification of the gene from *P. denticanis* B106, primer KWK-Ps-02 (SEQ ID No. 79) was used with KWK-Ps-03 (SEQ ID No. 80). Reactions were performed in triplicate using purified chromosomal DNA as template

10

15

20

25

30

35

-77-

from strains *P. cangingivalis* B98, *P. salivosa* B104, and *P. denticanis* B106. Amplification was carried out as follows: denaturation (94°C, 9 minutes); 30-35 cycles of denaturation (94°C, 30 seconds), annealing (61-72°C, 30 seconds), and polymerization (72°C, 1.5 minutes); this was followed by a final extension at 72°C for 7 minutes.

The PCR amplified gene products were visualized by separation on a 1.0% agarose gel (Sigma). The PCR products were purified using a QIAquick™ PCR Purification kit (Qiagen; Valancia, CA), and each set of triplicate samples pooled. These fragments were then sequenced directly in an attempt to avoid the introduction of sequence artifacts due to mutations that arise during PCR amplification and subsequent cloning steps. The pooled mixtures were then subjected to direct sequence analysis using DyeDeoxy termination reaction on an ABI automated DNA sequencer (Lark Technologies). Synthetic oligonucleotide primers (SEQ ID NO. 46-75) were used to sequence both DNA strands of the amplified products.

The nucleotide sequences encoding the OprF homolog from *P. gulae* B43, *P. cansulci* B46, *P. circumdentaria* B52, *P. gulae* B69, *P. circumdentaria* B97, *P. cangingivalis* B98, *P. salivosa* B104, *P. denticanis* B106, *P. cangingivalis* B98, *P. salivosa* B104, *P. denticanis* B106, and *P. endontalis* B114 are depicted in SEQ ID NO. 111 to 119. Sequence corresponding the 5' and 3' primers used for PCR amplification of each gene was removed, as it may not represent the actual sequence of the gene in each of the respective strains. The ORFs encoded by SEQ ID NO.111 to 119 are shown in SEQ ID No. 120 to 128, respectively. For each of the encoded ORFs, the amino terminal sequence, even when that encoded by the 5' primer was excluded, still maintained characteristics of a prokaryotic signal sequence (von Heijne, 1985, J. Mol. Biol. 184:99-105; Nielsen, H., Engelbrecht, J., Brunak, S., and von Heijne, G., 1997 Protein Engineering, 10: 1-6). Each ORF was compared against existing nucleotide and protein databases using the Basis Local Align Search Tool (BLAST) programs (Altschul, S.F., Gish, W., Miller, W., Myers, E.W., Lipman, D.J., 1990, J. Mol. Biol. 215:403-410). The entry with which each shared the greatest homology was PG32 from *P. gingivalis*.

CLONING OF THE P. GULAE B43 OPRF GENE INTO EXPRESSION PLASMIDS

For the purpose of recombinant protein expression, the gene encoding OprF was cloned with the sequence encoding its signal peptide. *OprF* was amplified from *P. gulae* B43 using oligonucleotide primers KWK-Pg-06 (SEQ ID NO. 76) and KWK-Pg-03 (SEQ ID NO. 45). For polymerase chain amplification, duplicate 50µl reactions were set up containing chromosomal DNA as template, 1 X PC2 buffer, 200 µM each dNTP, 50 pMol each primer, 7.5 U Klen*Taq*1 and 0.15 cloned *Pfu* thermostable polymerase. Amplification was carried out as follows: denaturation (94°C, nine minutes); 30 cycles of denaturation (94°C, 30 sec), annealing (60°C, 30 sec), and polymerization (72°C, 1.5 min), followed by a final extension at

72°C for 7 minutes. Following amplification, the samples were purified (QIAquick™ PCR Purification kit) and pooled. The purified PCR product was cloned directly into the TA cloning site of both pBAD-TOPO and pBAD/Thio-TOPO (Invitrogen). The ligand products were transformed into Max Efficiency *E. coli* DH5α cells. The predicted amino terminal sequence of the encoded protein expressed from pBAD-TOPO:OprF consists of the vector-encoded sequence MGSGSGDDDDKLALM (SEQ ID NO: 136) followed immediately by the sequence beginning at glutamine-13 of OprF (SEQ ID No. 120). A clone containing the appropriate plasmid was identified, and purified plasmid was isolated from a small-scale broth culture using a QIAprep Spin Miniprep kit (Qiagen). This plasmid was transformed into *E. coli* BL21 cells (Novagen), and a clone was identified that contained the appropriate plasmid.

5

10

15

20

25

30

35

The predicted amino terminal sequence of the encoded fusion protein expressed from pBAD/Thio-TOPO: *oprF* should consist of the thioredoxin protein and a 14 amino acid residue linker followed immediately by the sequence beginning at glutamine-13 of OprF (SEQ ID NO. 120). A clone containing the appropriate plasmid was identified, and purified plasmid was isolated from a small-scale broth culture using a QIAprep Spin Miniprep kit. This plasmid was transformed into *E. coli* BL21 cells, and a clone was identified that contained the appropriate plasmid.

The oprF gene lacking the sequence encoding the signal peptide was also cloned into two different λ expression plasmids. Both of these plasmids encode the temperaturesensitive λ repressor c/857, which inhibits expression from λ promoters at 30°C. At 42°C, the repressor is inactivated and expression from the $\boldsymbol{\lambda}$ promoter is enabled, yielding high-level transcription and translation. For cloning into these vectors, oprF was amplified from P. gulae B43 using oligonucleotide primers KWK-Pgu-14 (SEQ ID NO. 77) and KWK-Pgu-15 (SEQ ID NO. 78). For polymerase chain amplification, duplicate 50 μl reactions were set up containing washed P. gulae B43 cells as template, 1 X PC2 buffer, 200 μM each dNTP, 50 pMol each primer, 7.5 U Klen Taq1 and 0.15 U cloned Pfu thermostable polymerases. Amplification was carried out as follows: denaturation (94°C, nine minutes); 45 cycles of denaturation (94°C, 30 seconds), annealing (55°C, 30 seconds), and polymerization (72°C, 1.5 minutes), followed by a final extension at 72°C for seven minutes. Following amplification, the samples were pooled and digested with restriction enzymes, generating overhangs compatible with the plasmids which had also been linearized using the same enzymes. Following restriction digestion, the PCR fragment and plasmids were purified (QIAquick™ PCR Purification kit; Qiagen Corp.), ligated, and transformed into E. coli DH5α cells (Novagen). The predicted amino terminal consisted of the vector-encoded sequence MGTTTTTSLHM (SEQ ID NO: 137) followed immediately by the sequence beginning at Glutamine-13 of OprF (SEQ ID NO. 120). The protein expressed from the second plasmid would consist only a vector-encoded Met followed by Glutamine-13 of OprF (SEQ ID NO: 120). Clones containing the appropriate plasmids were identified, and plasmids were isolated from small-scale broth cultures using QIAprep Spin Miniprep kits (Qiagen Corp.). These plasmids were transformed into *E. coli* BL21 cells, and separate clones were identified that contained the appropriate plasmids.

EXPRESSION AND PURIFICATION OF THE RECOMBINANT OPRF PROTEIN

5

10

15

20

25

30

35

 $E.\ coli$ BL21 cells that express recombinant OprF (fused at its N-terminus to SEQ ID NO: 137) were utilized for expression studies. A frozen stock was thawed, seeded at a 1:5000 dilution into 2 X YT medium containing 50 μg/ml kanamycin sulfate (1.6% tryptone, 1% yeast extract, 0.5 NaCL), and grown in a 5 liter working volume BioFlo 3000 Bioreactor (New Brunswick Scientific; Edison, NJ) at 29°C with a 100 rpm agitation rate until A_{625} was 2.5-3.5. The cultures were then shifted to 42°C to induce OprF expression. The culture was incubated for an additional 3 hours. Aliquots were removed at various time points, centrifuged, and re-suspended in reducing sample buffer. All samples were analyzed on a 10% NuPAGE gel (Invitrogen, USA) (Figure 5).

Wet cells of the *E. coli* BL21 transformant expressing recombinant OprF from the 5 liter fermentation were harvested by centrifugation and re-suspended in phosphate-buffered saline. The cells were mechanically lysed. Following centrifugation, the pellet was discarded. The supernatant was passed over an ion exchange column, and eluted off using a NaCl gradient. Fractions containing the recombinant protein were pooled, dialyzed to remove the NaCl, and filter-sterilized using a 0.2 µm filter.

WHOLE CELL BACTERIN PREPARATION

A 5 liter batch of P. gulae B43 was grown in a fermentor as described above and split into 1 liter portions. The cells in each 1 liter fraction (4.4 \times 10¹² total P. gulae B43 cells) were inactivated by the following treatments: exposure to 0.4% formalin for 24 hours at 23°C, exposure to 10 mM binary ethylene-imine (BEI) at pH 8.5 for 48 hours at 37°C, heating to 60°C for 30 minutes on two consecutive days, and exposure to air for 48 hours. Following the BEI treatment, the BEI was inactivated by treatment with 50 mM sodium thiosulfate. The cells were collected by centrifugation. The resultant cells pellets were re-suspended in 220 ml PBS yielding a final concentration of 2 \times 10¹⁰ cells per ml. Seven ml of each of the inactivated cells was mixed with 7 ml of MPL + TDM adjuvant (Sigma Corp.) yielding a final concentration of 1.0 \times 10¹⁰ cells per ml.

Whole cell bacterin preparations of the other eight top clinical isolates (*P. cansulci* B46, *P. circumdentaria* B52, *P. gulae* B69, *P. circumdentaria* B97, *P. cangingivalis* B98, *P. salivosa* B104, *P. denticanis* B106, and *P. endodontalis* B114) or other pigmented anaerobic bacteria can be prepared in an identical fashion.

HOMOLOGOUS VACCINE EFFICACY

In homologous vaccine efficacy studies, mice were immunized with two injections of 0.2 ml each of the above mentioned inactivated *P. gulae* B43 cells in MPL + TDM adjuvant

three weeks apart. The mice were infected as previously described with *P. gulae* B43 two weeks following the booster immunization. Forty-two days following the infection, the mice were sacrificed and processed as previously described. Table 5 shows the numerical results of bone loss measurements.

Table 5. Mouse homologous vaccine efficacy study results.

Group	Vaccinogen	Challenge	Mean	Std.	SEM	Net	%	%
			bone	Dev.		bone	bone	bone
			loss			loss	loss (a)	loss (b)
А	PBS with RIB	None	0.0686	0.00862	0.00216	0	NA (c)	NA
	MPL+TDM							
	adjuvant							
В	PBS with RIB	l Pg 53977	0.112	0.0107	0.00266	0.0434	100	NA
	MPL+TDM							
	adjuvant							
С	PBS with RIB	I Pg B43	0.093	0.0188	0.00471	0.0244	NA	100
	MPL+TDM							
	adjuvant							
D	Formalin	Pg 53977	0.098	0.0146	0.00364	0.0294	67.7	NA
	inactivated F) .						
	gingivalis							
	53977							
	with Freund	S						
	adjuvant			0.0400	0.00074	0.0046	EC 7	NA
Е	Formalin	Pg 53977	0.0932	0.0109	0.00271	0.0246	56.7	INA
		P.						
	gingivalis							
	53977	N.						
	with RIE	31						
	MPL+TDM							
-	adjuvant Formalia	Pg B43	0.082	0.0128	0.00319	0.0134	NA	54.9
F	Formalin inactivated <i>I</i>	Py 643	0.002	0.0120	0.00010	0.0101		
	gulae B43	•						
	with RI	31 -						
	MPL+TDM	- ,						
	adjuvant							
G	BEI inactivate	ed Pa B43	0.107	0.0151	0.0039	0.0384	NA	157.4
_	<u></u>		5.151					

-81-

Group	Vaccinogen	Challenge	Mean	Std.	SEM	Net	%	%
			bone	Dev.		bone	bone	bone
			loss			loss	loss (a)	loss (b)
	P. gulae B43		. "					
	with RIE	31						
	MPL+TDM							
	adjuvant							
Н	Heat	Pg B43	0.0845	0.0113	0.00281	0.0159	NA	65.2
	inactivated F	٥.						
	gulae B43							
	with RIE	31						
	MPL+TDM							
	adjuvant							
1	aeration	Pg B43	0.0746	0.00691	0.00173	0.006	NA	24.6
	inactivated I	Ρ,						
	gulae B43							
	with RII	BI						
	MPL+TDM							
	adjuvant				•			

(a) Percentage calculated based on group B as the positive control group.

(b) Percentage calculated based on group C as the positive control group.

(c) NA = Not applicable.

5

10

15

Figures 6, 7, and 8 graphically display these results. Figure 7 shows the percent bone loss for the control experiment. Vaccines containing formalin-inactivated *P. gingivalis* 53977 and either Freund's complete/incomplete or MPL + TDM adjuvants reduced the bone loss induced by infection with *P. gingivalis* 53977 by approximately 32% and 43%, respectively. Figure 8 shows the percent bone loss for the test experiment. Vaccines containing either formalin-, heat-, or air-inactivated *P. gulae* B43 and MPL + TDM adjuvant reduced the bone loss induced by infection with *P. gulae* B43 by approximately 45%, 35%, and 75%, respectively. Based on these data, it can be concluded that the formalin-, air-, and heat-inactivated *P. gulae* B43 vaccines were efficacious in their ability to reduce bone loss induced in this superinfection model. Extrapolating this data into the clinical setting, these three vaccines would likely be efficacious in the prophylactic prevention of periodontal disease and may well prove efficacious in the therapeutic treatment of periodontal disease.

HETEROLOGOUS VACCINE EFFICACY STUDY

In heterologous vaccine efficacy studies, mice were immunized with two injections of 0.2 ml each of either formalin-inactivated *P. gulae* B43 or formalin-inactivated *P. salivosa* B104 and *P. denticanis* B106 cells in MPL + TDM adjuvant three weeks apart. The mice were infected as previously described with either *P. gulae* B43, *P. gulae* B69, *P. salivosa* B104, or *P. denticanis* B106 two weeks following the booster immunization. Forty-two days following the infection, the mice were sacrificed and processed as previously described. Table 6 shows the numerical results of bone loss measurements.

.83

Table 6. Mouse heterologous vaccine efficacy study results.

Group	Group Vaccinogen	Inactivation Chall	Challenge	Mean	Std.	SEM	Net	%	%	%	%
		method		pone	Dev.		bone	pone	pone	pone	pone
				loss			loss	loss ^a	loss ^b	lossc	loss ^d
A	PBS	NA	None	0.088	0.0112	0.00299	0	0	0	0	0
В	PBS	NA	P. gulae B43	0.101	0.0103	0.00266	0.013	100	NA®	N A	AN
ပ	PBS	ΝΑ	P. gulae B69	0.115	0.0112	0.00289	0.027	A A	100	NA	ΝΑ
۵	PBS	NA	P. salivosa B104	0.101	0.0132	0.00352	0.013	A A	NA	100	ΝΑ
ш	PBS	NA	P. pfizerii B106	0.0994	0.0135	0.0035	0.0114	N A	NA	N A	100
ш.	P. gulae B43	Formalin	P. gulae B43	0.0901	0.016	0.00412	0.0021	16.15	NA	NA	٧×
Ŋ	P. gulae B43	Formalin	P. gulae B69	0.104	0.0166	0.00443	0.016	A A	59.26	NA	ΝΑ
I	P. gulae B43	Formalin	P. salivosa B104	0.0926	0.0119	0.00319	0.0046	A A	NA	35.38	ΝΑ
_	P. gulae B43	Formalin	P. pfizerii B106	0.102	0.0124	0.00333	0.014	A A	NA	NA	122.8
7	P. salivosa B104/	Formalin	P. gulae B69	0.102	0.0124	0.00333	0.014	NA	51.85	NA	NA
	P. denticanis B106										
	a										

^a Percentage bone loss is calculated for the P. gulae B43 infected mice.

^b Percentage bone loss is calculated for the *P. gulae* B69 infected mice.

^c Percentage bone loss is calculated for the *P. salivosa* B104 infected mice.

^d Percentage bone loss is calculated for the *P. denticanis* B106 infected mice.

e NA, not applicable.

Ŋ

-84-

Figures 9, 10, 11, 12, and 13 graphically display these results. Figure 9 shows the net bone loss for these experiments. Figure 10 shows the percent bone loss for the P. gulae B43 infected groups. Formalin-inactivated P. gulae B43 and MPL + TDM adjuvant reduced the bone loss induced by infection with P. gulae B43 by approximately 84%. Figure 11 shows the percent bone loss for the P. gulae B69 infected groups. The formalin-inactivated P. gulae B43 and formalin-inactivated P. salivosa B104/P. denticanis B106 vaccines containing MPL + TDM adjuvant reduced the bone loss induced by infection with P. gulae B69 by approximately 40% and 49%, respectively. Figure 12 shows the percent bone loss for the P. salivosa B104 infected groups. Formalin-inactivated P. gulae B43 and MPL + TDM adjuvant reduced the bone loss induced by P. salivosa B104 by approximately 65%. Figure 13 shows the percent bone loss for the P. denticanis B106 infected groups. Formalin-inactivated P. gulae B43 with MPL + TDM adjuvant failed to cross protect against challenge with P. denticanis B106. Based on these data, it can be concluded that the formalin-inactivated P. gulae B43 vaccine adjuvanted with MPL + TDM was capable of providing protection not only from homologous challenge, but also from heterologous challenge with P. gulae B69. Moreover, protection was observed between two Porphyromonas species as the P. gulae B43 vaccine protected against P. salivosa B104 challenge. Extrapolating this data into the clinical setting, a multivalent vaccine would likely be efficacious in the prophylactic prevention of periodontal disease and may well prove efficacious in the therapeutic treatment of periodontal disease.

Recombinant FimA and OprF mouse serological study

In subunit vaccine serology studies, mice were immunized with two injections of 0.2 ml each of either recombinantly expressed, purified *P. gulae* B43 FimA or recombinantly expressed, purified *P. gulae* B43 OprF in QuilA/Cholesterol adjuvant three weeks apart. The mice were bled prior to the first vaccination and two weeks following the booster immunization. Table 7 shows the numerical results while figures 14 and 15 show the results graphically.

25

5

10

15

20

Table 7. Mouse subunit vaccine serology study.

			rFimA ELISA	r	OprF ELISA
Group	Vaccinogen	Pre-	Post-	Pre-	Post-
•		vaccination	vaccination	vaccination	vaccination
A	Saline	50	50	50	50
В	rFimA + QAC	50	138889	NA	NA
C	rOprF + QAC	NA	NA	50	118

Throughout this application, various patent and scientific publications, including United States patents, are referenced by author and year and patents by number. The disclosures of these publications and patents are hereby incorporated by reference in their entireties into this application in order to more fully describe the state of the art to which this invention pertains.

WO 03/054755

5

10

15

20

25

30

35

CLAIMS


- 1. An isolated pigmented anaerobic bacteria having a 16S rRNA DNA sequence comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS: 86 to 94, provided that the bacteria is not a strain of *Porphyromonas gingivalis* designated as dog 20B.
- 2. An isolated pigmented anaerobic bacteria which causes, either directly or in combination with other pathogenic agents, periodontal disease in companion animals, wherein the bacteria can be used to prepare a vaccine for treating or preventing periodontal disease in companion animals, wherein the vaccine comprises an immunologically effective amount of the bacteria which has been inactivated or attenuated, provided that the bacteria is not a strain of *P. gulae* sp. nov. designated ATCC 51700.
- 3. The bacteria according to claim 2 having a 16S rRNA DNA sequence at least about 95% homologous to any of the sequences depicted in SEQ ID NOS: 86 to 94.
- An isolated polynucleotide molecule comprising a nucleotide sequence isolated from a bacteria selected from the group consisting of a bacterium having the identifying characteristics of *Porphyromonas gulae* B43, *P. cansulci* B46, *P. circumdentaria* B52, *P. gulae* B69, *P. circumdentaria* B97, *P. cangingivalis* B98, *P. salivosa* B104, *P. denticanis* B106 and *P. endodontalis* B114 provided that the bacteria is not a strain of *P. gulae* sp. nov. designated ATCC 51700.
- 5. The isolated polynucleotide according to claim 4 wherein the polynucleotide encodes for a polypeptide.
- 6. The isolated polynucleotide according to claim 4 wherein, the polynucleotide encodes ribosomal RNA or transfer RNA.
- 7. An isolated polynucleotide molecule comprising any of the nucleotide sequences selected from the group consisting of SEQ ID NOS: 86 to 94 and homologues having at least 95% homology thereto, provided that the nucleotide sequence is not the 16S rRNA DNA from bacteria *P. gulae* sp. nov. designated ATCC 51700.
- 8. An isolated polynucleotide molecule comprising any of the nucleotide sequences depicted in SEQ ID NOS: 95 to 102 and 111-119 or fragments or variants thereof, which sequence encodes a polypeptide immunologically effective as a vaccine for preventing or treating periodontal disease in companion animals, or complements thereto.
- 9. isolated polynucleotide molecule comprising a nucleotide sequence which hybridizes under conditions of high stringency to any of the sequences depicted in SEQ ID NOS: 95 to 102 and 111-119, or complements thereto.
- 10. A recombinant expression vector comprising a polynucleotide selected from the group consisting of any of the nucleotide sequences SEQ ID NOS: 95 to 102 and 111 to 119, fragments or variants thereof, operably linked to a promoter sequence.

11. A plasmid comprising a polynucleotide selected from the group consisting of any of the nucleotide sequences SEQ ID NOS: 95 to 102 and 111 to 119, fragments or variants thereof, operably linked to a promoter sequence.


5

10

- 12. A host cell comprising the isolated polynucleotide sequence according to claim 4, 7, or 8.
- 13. A method for the production of recombinant FimA, OprF, selected from any of the sequences depicted in SEQ ID NOS: 103 to 110 or 120 to 128, or fragments or variants thereof, said method comprising (1) growing the cells of claim 36 under conditions in which a polypeptide comprising FimA, or OprF, or fragments or variants thereof is expressed, and (2) recovering said polypeptide.
- 14. An isolated polypeptide immunologically effective as a vaccine for preventing or treating periodontal disease in companion animals comprising an amino acid sequence depicted in SEQ ID NOS: 103 to 110 and 120 to 128.
- 15. A recombinantly expressed polypeptide, which polypeptide is selected from15 the group consisting of FimA (SEQ ID NOS: 103 to 110) and OprF (SEQ ID NOS: 120 to 128).










FIG.

4/14




Fig. 161

5 λ Insol

1 λ Insol

5 λ Sol

1 λ Sol

Std

Ind

Std

- 161

- 87

- 87


- 87


- 88

- 88


FIG. 5

T=0 T=1 T=2 T=3



































FIG. 12



14/14





SEQUENCE LISTING

<110> Pfizer Product Inc.	
<120> VACCINE FOR PERIODONTAL DISEASE	
<130> PC11864A	
<140>	
<141>	
<160> 137	
<170> PatentIn Ver. 2.1	
<210> 1	
<211> 21	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: D0056	
<400> 1	21
ggattagata ccctggtagt c	21
<210> 2	
<211> 19 <212> DNA	
<213> Artificial Sequence	
(215) /11 (111 (21 (11 (11 (11 (11 (11 (11 (11	
<220>	
<223> Description of Artificial Sequence: D0057	
<400> 2	
cccgggaacg tattcaccg	19
<210> 3	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<pre><220> <223> Description of Artificial Sequence: PFZ175-AP1</pre>	
<400> 3	

1

WO 03/054755	PCT/IB02/05539

ggcttaagtg ccataacgag 20

<210> 4 <211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PFZ175-AP2

<400> 4

ctggcgtctt acgacggctg 20

<210> 5

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PFZ175-AP3

<400> 5

tgtcgtcagc tcgtgccgtg 20

<210> 6

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:D0067

<400> 6

gcgcagcaag gccagcccgg 20

<210> 7

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:D0068

<400> 7

VO 03/054755	PCT/IB02/0553
// U U3/U34 /33	PU 1/10/2/0555

gagcgaaccc	cgctccctgt	20
------------	------------	----

<210>	8	
<211>	23	
<212>	DNA	
<213>	Artificial Sequence	
<220>		
<223>	Description of Artificial Sequence: D0078	
<400>	8	
gcgaco	gctat atgcaagaca atc	23
<210>	9	
<211>	33	
<212>	DNA	
<213>	Artificial Sequence	
	•	
<220>		
<223>	Description of Artificial Sequence: D0097	
<400>	9	
ggccto	cgaga acaaagacaa cgaagcagaa ccc	33
<210>	10	
<211>	34	
<212>	DNA	
<213>	Artificial Sequence	
<220>		
<223>	Description of Artificial Sequence: D0098	
<400>	10	
ggcaag	gotta ocaaataaca ttitgtacaa cacc	34
<210>	11	
<211>	20	
<212>		
<213>	Artificial Sequence	
<220>		
<223>	Description of Artificial Sequence:PFZ185-AP1	

<400> 11

VO 03/054755	PCT/IB02/0553

tcatccgaca	atcctgtgtg	20	

- <210> 12
- <211> 20
- <212> DNA
- <213> Artificial Sequence
- <2205
- <223> Description of Artificial Sequence:PFZ185-AP2
- <400> 12
- agcagctgct aaatcggctc

- <210> 13
- <211> 20
- <212> DNA
- <213> Artificial Sequence
- <220>
- <223> Description of Artificial Sequence:PFZ185-AP3
- <400> 13
- ttggcaagac tcttgcagag

20

- <210> 14
- <211> 20
- <212> DNA
- <213> Artificial Sequence
- <220>
- <223> Description of Artificial Sequence:PFZ185-AP4
- <400> 14
- ctgcagtcag ttcagttgtc

20

- <210> 15
- <211> 20
- <212> DNA
- <213> Artificial Sequence
- <220>
- <223> Description of Artificial Sequence: PFZ186-AP1
- <400> 15

WO 03/054755	PCT/IB02/05539
tacgtcaaca ggctctgctg	20
<210> 16	
<211> 20	
<212> DNA <213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence:PFZ186-AP2	
<400> 16	20
gacaactgaa ctaactgcag	20
<210> 17	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: PFZ186-AP3	
<400> 17	20
aacatagaaa ccttgtggag	20
<210> 18	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: PFZ186-AP4	
<400> 18	20
tgtcgtctgg ttgggaagag	20

<210> 19
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:PFZ186-AP5
<400> 19

WO 03/054755	PCT/IB02/05539
aatctgattg cctccctgag	20
<210> 20	

<210>	20	
<211>	20	
<212>	DNA	
<213>	Artificial Sequence	
<220>		
<223>	Description of Artificial Sequence: PFZ187-AP1	
<400>		20
gggaac	ccgat ttagcagcag	20
<210>	21	
<211>		
<212>	DNA	
<213>	Artificial Sequence	
<220>		
<223>	Description of Artificial Sequence:PFZ187-AP2	
<400>		20
ccaata	acagg gtaataggtc	20
<210>	22	
<211>		
<212>		
<213>	Artificial Sequence	
<220>		
<223>	Description of Artificial Sequence:PFZ187-AP3	
<400>		
gttgt	caatg cttttacctc	20
<210>	23	
<210>		
<212>		
	Artificial Sequence	
	-	
.000.		

<223> Description of Artificial Sequence:PFZ187-AP4 <400> 23

WO 03/054755	PCT/IB02/05539
W O 05/054/33	PCT/IB02/0553

gattgagaat atcaaatgtg	2	0
<210> 24		
<211> 20		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> Description of Artificial Sequence:PFZ187-AP5		
<400> 24		
ttaggcgtat aaccattgtc	2	0
-210. 25		
<210> 25 <211> 20		
<212> DNA		
<213> Artificial Sequence		
2137 ALCITICIAL DOGACIICO		
<220>		
<223> Description of Artificial Sequence:PFZ187-AP6		
-		
<400> 25		
atttaacggt gcttacacac	2	0
<210> 26		
<211> 20		
<212> DNA		
<213> Artificial Sequence		
<220>		
<pre><223> Description of Artificial Sequence:PFZ187-AP7</pre>		
Total Carta		
<400> 26		
ccaattggcg gcctgagctg	2	0
<210> 27		
<211> 20		
<212> DNA		
<213> Artificial Sequence		
-220		
<220>		
<223> Description of Artificial Sequence:PFZ187-AP8		
<400> 27		

tggcatagtt ggtaggtgtg	20
<210> 28 <211> 20	
<212> DNA <213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence:PFZ187-AP9	
<400> 28 tgtaagcacc gttaaatgtg	20
<210> 29	
<211> 20	
<212> DNA <213> Artificial Sequence	
(213) Altificial begacines	
<220>	
<223> Description of Artificial Sequence:PFZ187-AP11	
<400> 29	
ctgacaggtt ctttgaccac	20
<210> 30	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: PFZ187-AP12	
<400> 30	
tgttccttgg ttgagccgtg	20
<210> 31	

```
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PFZ187-AP13

<400> 31
```

VO 03/054755	PCT/IB02/05539

		20
ataatcaaaa	aacctgtcag	20

- <210> 32
- <211> 20
- <212> DNA
- <213> Artificial Sequence
- <220>
- <223> Description of Artificial Sequence:PFZ187-AP14
- <400> 32
- cataaacaca caggattgtc

20

- <210> 33
- <211> 20
- <212> DNA
- <213> Artificial Sequence
- <220>
- <223> Description of Artificial Sequence:PFZ187-AP15
- <400> 33
- ttgcttcttt gcaatgagac

20

- <210> 34
- <211> 20
- <212> DNA
- <213> Artificial Sequence
- <220>
- <223> Description of Artificial Sequence:PFZ187-AP16
- <400> 34
- agccatgcga gcatgtacac

20

- <210> 35
- <211> 20
- <212> DNA
- <213> Artificial Sequence
- <220>
- <223> Description of Artificial Sequence:PFZ187-AP17
- <400> 35

WO 03/054755	PCT/IB02/05539
ctgtcatgat caaacctgtg	20
<210> 36	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence:PFZ187-AP18	
<400> 36	0.0
accgtctgca ttcacgagtg	20
<210> 37	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence:PFZ188-AP1	
<400> 37	
gccttccaat gatgctccac	20
<210> 38	
<211> 20 <212> DNA	
<213> Artificial Sequence	
(21) Altitud bequese	
<220>	
<223> Description of Artificial Sequence:PFZ188-AP2	
<400> 38	2.2
ggacgtagac ctgcattctg	20
010. 30	
<210> 39 <211> 20	
<211> 20 <212> DNA	
<213> Artificial Sequence	
The state of the s	

<223 > Description of Artificial Sequence:PFZ188-AP3

WO 03/054755	PCT/IB02/05539

cgcaatacgg gcatgaacac 20

<	2	1	0	>	4	O

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PFZ188-AP4

<400> 40

ttatggttat gatggacctc 20

<210> 41

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PFZ188-AP5

<400> 41

tggtactcct ttgagttctg 20

<210> 42

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PFZ188-AP6

<400> 42

cacacttgcg cggtaaccac 20

<210> 43

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

. <223> Description of Artificial Sequence:D0086

atgaaggtaa agtacttaat gc	22
<210> 44 <211> 25 <212> DNA <213> Artificial Sequence	
<220> <223> Description of Artificial Sequence:D0087	
<400> 44 agatgaatta cttggagcga acgat	25
<210> 45 <211> 27 <212> DNA <213> Artificial Sequence	
<220> <223> Description of Artificial Sequence: KWK-Pg-03	
<400> 45 ttacttggag cgaacgatta caacacg	27
<210> 46 <211> 20 <212> DNA <213> Artificial Sequence	
<220> <223> Description of Artificial Sequence:PFZ209-AP1	
<400> 46 ttggtgcagc tcacttcgac	20
<210> 47 <211> 20 <212> DNA <213> Artificial Sequence	
<220> <223> Description of Artificial Sequence:PFZ209-AP2	

PCT/IB02/05539

WO 03/054755

WO 03/054755	PCT/IB02/05539
accacatcaa acataaagtc	20
<210> 48	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: PFZ209-AP3	
-	
<400> 48	
acattcgggg catgatacag	20
0.10 4.0	
<210> 49	
<211> 20 <212> DNA	
<213> Artificial Sequence	
1210) Alexander	
<220>	
<223> Description of Artificial Sequence:PFZ209-AP4	
<400> 49	0.0
atgccattga gccaatggac	20
<210> 50	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence:PFZ210-AP1	
<400> 50	
ttgacttcat gttcgatgtg	20
	2.0
<210> 51	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence:PFZ210-AP2	

tgccaatgaa ttttatgctg	20
<210> 52 <211> 20 <212> DNA <213> Artificial Sequence	
<220> <223> Description of Artificial Sequence:PFZ210-AP3	
<400> 52 cgcttggaga gttcttcgac	20
<210> 53 <211> 20 <212> DNA <213> Artificial Sequence	
<220> <223> Description of Artificial Sequence:PFZ210-AP4	
<400> 53 tatcaacgat ctgaatggtc	20
<210> 54 <211> 20 <212> DNA <213> Artificial Sequence	
<220> <223> Description of Artificial Sequence:PFZ211-AP1	
<400> 54 aactacttca agccctacag	20
<210> 55 <211> 20 <212> DNA <213> Artificial Sequence	
<220> <223> Description of Artificial Sequence:PFZ211-AP2	

PCT/IB02/05539

WO 03/054755

WO 03/054755	PCT/IB02/05539

cgtaacccaa acctacccac 20

<210> 56	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence:PFZ211-AP3	
<400> 56	
acgggacgct tgctcaactc	20
<210> 57	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: PFZ211-AP4	
Cara Monoraboron or imparagram and annual and annual and	
.400 57	
<400> 57	20
attggggctt ggtaaatgac	20

<210> 58
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:PFZ211-AP5

<400> 58
atacgctcta cacgaggctc 20

<210> 59
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:PFZ212-AP1

<223> Description of Artificial Sequence: PF2212-AF1

15

ccgccatggc tggagctcac	20
<210> 60	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence:PFZ212-AP2	
<400> 60	
tttgaaacca tatcccacac	20
<210> 61	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence:PFZ212-AP3	
<400> 61	
agtaacttca ggacattctg	20
<210> 62	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence:PFZ212-AP4	
<400> 62	
acgtccagtt tcttgcccag	20
<210> 63	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: PFZ213-AP1	

PCT/IB02/05539

WO 03/054755

WO 03/054755	PCT/IB02/05539
ttgacttcat gttcgatgtg	20
<210> 64 <211> 20	
<212> DNA <213> Artificial Sequence	
<220> <223> Description of Artificial Sequence:PFZ213-AP2	
<400> 64 tttgtgttgg taaccaacac	20
<210> 65	
<212> DNA <213> Artificial Sequence	
<220> <223> Description of Artificial Sequence:PFZ213-AP3	
<400> 65 acaggacgct tagagagctc	20
<210> 66 <211> 20	
<212> DNA <213> Artificial Sequence	
<220> <223> Description of Artificial Sequence:PFZ213-AP4	

20

<210> 67 <211> 20

<400> 66

<212> DNA

<213> Artificial Sequence

acgcgcttat caacgatctg

<220>

<223> Description of Artificial Sequence:PFZ213-AP5

WO 03/054755	PCT/IB02/05539
cttcccaagg aacgtgtgtg	20
<210> 68	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: PFZ214-AP1	
<400> 68	
actttatgtt tgatgttgtg	20
<210> 69	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence:PFZ214-AP2	
<400> 69	
ccaacaccga accaaggcac	20
<210> 70	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence:PFZ214-AP3	
<400> 70	
teteaactea gtatteteag	20
<210> 71	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence:PFZ214-AP4	

WO 03/054755	PCT/IB02/05539
taaccttaat tttggtcgtg	20
<210> 72	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence:PFZ215-	-AP1
<400> 72	
cacacctaca acactgecac	20
<210> 73	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence:PFZ215-	-AP2
<400> 73	
tcaaacatga aatcatagtg	20
<210> 74	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence:PFZ215-	-AP3
<400> 74	
ctcggggcag aaagcaggac	20
<210> 75	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: PFZ215-	-AP4

gacttgaact ctcagatcag	20
<210> 76	
<211> 27	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: KWK-Pg-06	
<400> 76	0.77
atgcaggaaa atactgtacc ggcaacg	27
<210> 77	
<211> 29	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: KWK-Pgu-14	
<400> 77	
gtgtgtcata tgcaggaaaa tactgtacc	29
<210> 78	
<211> 31 <212> DNA	
<213> Artificial Sequence	
1215) Altificial bequence	
<220>	
<223> Description of Artificial Sequence: KWK-Pgu-15	
<400> 78	
gtgtgttcta gattattact tggagcgaac g	31
<210> 79	
<211> 22	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: KWK-Ps-02	

PCT/IB02/05539

WO 03/054755

acacctgaga ctcagacatt gc	22
<210> 80 <211> 21 <212> DNA <213> Artificial Sequence	
<220> <223> Description of Artificial Sequence: KWK-Ps-02	
<400> 80 catgcgcgag cctcaaaaag c	21
<210> 81 <211> 37 <212> DNA <213> Artificial Sequence	
<220> <223> Description of Artificial Sequence: KWK-Ps-04b	
<400> 81 cctgccactc aacagaaatc atatcagaag gaactcc	37
<210> 82 <211> 34 <212> DNA <213> Artificial Sequence	
<220> <223> Description of Artificial Sequence:KWK-Ps-05b	
<400> 82 ctgctcataa gacggctttt gaccgttctg cagg	34
<210> 83 <211> 39 <212> DNA <213> Artificial Sequence	
<220> <223> Description of Artificial Sequence: KWK-Ps-06b	
<400> 83	

PCT/IB02/05539

WO 03/054755

WO 03/054755	PCT/IB02/05539

39

cttttgaccg ttctgcagga cattggttct tgactctcc

```
<210> 84
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:D122
<400> 84
tggctaaryt gacygtaatg gtyta
                                                                   25
<210> 85
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:D123
<400> 85
agttyacyaa tacaggrtaa taggt
                                                                   25
<210> 86
<211> 572
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: P. gulae B43
      16S rRNA polynucleotide sequence
<400> 86
cacgcagtaa acgatgatta ctaggagttt gcgatatacc gtcaagcttc cacagcgaaa 60
gcgttaagta atccacctgg ggagtacgcc ggcaacggtg aaactcaaag gaattgacgg 120
gggcccgcac aagcggagga acatgtggtt taattcgatg atacgcgagg aaccttaccc 180
gggattgaaa tgtagacgac ggatggtgaa agccgtcttc ccttcggggc gtctatgtag 240
gtgctgcatg gttgtcgtca gctcgtgccg tgaggtgtcg gcttaagtgc cataacgagc 300
gcaacccaca teggtagttg ctaacaggtt tagetgagga etetacegag actgeegteg 360
taaggcgcga ggaaggtgtg gatgacgtca aatcagcacg gcccttacat ccggggcgac 420
acacgtgtta caatgggagg gacaaagggc agctaccggg cgaccgggtg cgaatctcga 480
aaccetteee cagtteggat eggagtetge aactegacte egtgaagetg gattegetag 540
taatcgcgca tcagccatgg cgcggtgaat ac
                                                                   572
```

```
<210> 87
<211> 571
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: P. cansulci B46
      16S rRNA polynucleotide sequence
<400> 87
cacgccgtaa acgatgatta ctcggagtat gcgatatgag tgtatgcttc ttagcgaaag 60
cyttaagtaa tccacctggg gagtacgtcg gcaacgatga aactcaaagg aattgacggg 120
ggcccgcaca agcggaggaa catgtggttt aattcgatga tacgcgagga accttacccg 180
ggattgaaat atagatgaca ggcagcgaga gttgttatcc cttcggggca tctatgtagg 240
tgctgcatgg ttgtcgtcag ctcgtgccgt gaggtgtcgg cttaagtgcc ctaacgagcg 300
caacccacat tattagttac taacaggtta agctgaggac tctaataaga ctgccggcgt 360
aagccgtgag gaaggtgtgg atgacgtcaa atcagcacgg cccttacatc cggggcgaca 420
cacgtgttac aatggtaggg acaaagggca gctaccgggc gaccggatgc gaatctccaa 480
accetatece agtteggate ggagtetgea actegaetet gtgaagetgg attegetagt 540
aatcgcgcat cagccatggc gcggtgaata c
                                                                   571
<210> 88
<211> 573
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:P.
      circumdentaria B52 16S rRNA polynucleotide
      sequence
<400> 88
cacgctgtaa acgatgaata ctagattttt gcgatataca gtaagagtct aagcgaaagc 60
gataagtatt ccagctgggg agtacgccgg caacggtgaa actcaaagga attgacgggg 120
gcccgcacaa gcggaggaac atgtggttta attcgatgat acgcgaggaa ccttacctgg 180
gattgaaatt taggagaacg atttatgaaa gtagattttc ccttcggggc tcctaagtag 240
gtgctgcatg gttgtcgtca gctcgtgccg tgaggtgtcg gcttaagtgc cataacgagc 300
gcaaccegeg ttgatagtta ctaacagata aagetgagga ctctategag acageegteg 360
taagacgcga ggaaggggcg gatgacgtca aatcagcacg gcccttacat ccagggcgac 420
acacgtgtta caatggcaag gacaaaggga agccacatag cgatatggag cagatcctca 480
aaccttgtcc cagttcggat cggagtctgc aactcgactc cgtgaagctg gattcgctag 540
taatcgcgca tcagccatgg cgcggtgaat acc
                                                                   573
<210> 89
```

<211> 573

```
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: P. gulae B69
      16S rRNA polynucleotide sequence
<400> 89
cacgcagtaa acgatgatta ctaggagttt gcgatatacc gataagcttc cacagcgaaa 60
gcgttaagta atccacctgg ggagtacgcc ggcaacggtg aaactcaaag gaattgacgg 120
gggcccgcac aagcggagga acatgtggtt taattcgatg atacgcgagg aaccttaccc 180
gggattgaaa tgtagatgac agatggtgaa agccgtcttc ccttcggggc gtctatgtag 240
gtgctgcatg gttgtcgtca gctcgtgccg tgaggtgtcg gcttaagtgc cataacgagc 300
gcaacccata teggtagttg ctaacaggte aagetgagga etetacegag actgeegteg 360
taaggegaga ggaaggtgtg gatgaegtea aateageaeg geeettacat eeggggegae 420
acacgtgtta caatgggagg gacaaagggc agctaccggg cgaccggatg cgaatctcga 480
aaccettece cagtteggat eggagtetge aactegaete egtgaagetg gattegetag 540
taatcgcgca tcagccatgg cgcggtgaat acc
                                                                   573
<210> 90
<211> 572
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:P.
      circumdentaria B97 16S rRNA polynucleotide
      sequence
cacgctgtaa acgatgaata ctagattttt gcgatataca gtaagagtct aagcgaaagc 60
gataagtatt ccacctgggg agtacgccgg caacggtgaa actcaaagga attgacgggg 120
gcccgcacaa gcggaggaac atgtggttta attcgatqat acqcqaqqaa ccttacctqq 180
gattgaaatt taggagaacg atttatgaaa gtagattttc ccttcggggc tcctaagtag 240
gtgctgcatg gttgtcgtca gctcgtgccg tgaggtgtcg gcttaagtgc cataacgagc 300
gcaacccgcg tcgatagtta ctaacaggta atgctgagga ctctatcgag acagccgtcg 360
taagacgaga ggaaggggcg gatgacgtca aatcagcacg gcccttacat ccagggcgac 420
acacgtgtta caatggcaag gacaaaggga agccacatag cgatatggag cagatcctca 480
aaccttgtcc cagttcggat cggagtctgc aactcgactc cgtgaagctg gattcgctag 540
taatcgcgca tcagccatgg cgcggtgaat ac
                                                                  572
<210> 91
<211> 571
<212> DNA
```

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:P.
cangingivalis B98 16S rRNA polynucleotide sequence
<400> 91

cagtaaacga tgattactcg gagtatgcga tatatggtat gctcccaagg gaaaccgata 60 agtaatccac ctggggagta cgccggcaac ggtgaaactc aaaggaattg acgggggccc 120 gcacaagcgg aggaacatgt ggtttaattc gatgatacgc gaggaacctt acccgggatt 180 gaaatgtaca tgacggttgg gcgagagcct gacttccctt cgggggcatgt atgtaggtgc 240 tgcatggttg tcgtcagctc gtgccgtgag gtgtcggctt aagtgccata acgagcgcaa 300 cccacatcgt cagttactaa caggtagagc tgaggactct gacgagactg ccgtcgtaag 360 gcgcgaggaa ggtgtggatg acgtcaaatc agcacggccc ttacatccgg ggcgacacac 420 gtgttacaat ggtagggac aagggcagct cgactcgtg aaggtggaa tctccaaacc 480 ctatctcagt tcggatcgg gtgaatacgt t

<210> 92
<211> 384
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:P. salivosa
B104 16S rRNA polynucleotide sequence

cagtaaacga tgataactgg gcgtatgcga tatacagtat gctcctgagc gaaagcgtta 60 agttatccac ctggggagta cgccggcaac ggtgaaactc aaaggaattg acgggggccc 120 gcacaagcgg aggaacatgt ggtttaattc gatgatacgc gaggaacctt acccgggatt 180 gaaatttagc ggactatgta tgaaagtaca tatcctgtca caaggccgct aagtaggtgc 240 tgcatggttg tcgtcagctc gtgccgtgag gtgtcggctt aagtgccata acgagcgcaa 300 cccacgttgt cagttactat cgggtaaagc cgaggactct gacaagactg ccgtcgtaag 360 gcgcgaggaa ggtgtggatg acgt

<210> 93 <211> 571 <212> DNA <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:P. denticanis B106 16S rRNA polynucleotide sequence

<400> 93
cacgccgtaa acgatgctca ccggctctat gcgataagac agtatggggc taatagaaat 60
aattaagtga gccacctggg gagtacgtcg gcaacgatga aactcaaagg aattgacggg 120

```
ggcccgcaca agcggaggaa catgtggttt aattcgatga tacgcgagga accttacccg 180
ggtttaaatg tatgttgcat tatgtagaaa tacgtatttt cttcggaact gcatacaagg 240
tgctgcatgg ttgtcgtcag ctcgtgccgt gaggtgtcgg gttaagtccc ataacgagcg 300
caaccettat gattagttgc taacggttca agccgagcac tctattcaca ctgccaccgt 360
aaggtgegag gaaggaggg atgatgteaa ateageaegg ceettatate eggggetaea 420
cacgtgttac aatggtcggt acagcgggtt gcatttacgt gagtaacagc taatcccaaa 480
aatcggtctc agttcggatt ggagtctgca actcgactcc atgaagttgg attcgctagt 540
aatcgcacat cagccatggt gcggtgaata c
                                                                   571
<210> 94
<211> 571
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: P. endodontalis
      B114 16S rRNA polynucleotide sequence
<400> 94
caccgcagta aacgatgaat actagatctt tgcgatatac ggtaagggtc taagcgaaag 60
cgataagtat tccacctggg gagtacgtcg gcaacgatga aactcaaagg aattgacggg 120
ggcccgcaca agcggaggaa catgtggttt aattcgatga tacgcgagga accttacccg 180
ggattgaaat ttagcgggcg ggctatgaga gtagcctttc ctacgggact gctaagtagg 240
tgctgcatgg ttgtcgtcag ctcgtgccgt gaggtgttgg cttaagtgcc ataacgagcg 300
caacccacgt tgatagttac taacagttaa agctgaggac tctatcgaga cagccggcgt 360
aagccgtgag gaaggtgtgg atgacgtcaa atcagcacgg cccttacatc cggggcgaca 420
cacgtgttac aatggtgagg acagcgggaa gcggcctggt gacaggtagc agatccccaa 480
acctcatccc agttcggatt ggagtctgca actcgactct atgaagctgg attcgctagt 540
aatcgcgcat cagccatggc gcggtgaata c
<210> 95
<211> 1024
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: P. gulae B43
      fimA polynucleotide sequence
<400> 95
tctaaatcga aaaagatcct aataaaacaa tattcacttt taaaacaaaa acgaqatgaa 60
aaagactaag tttttcttgt tgggacttgc tgcccttgct atgacagctt gtaacaaaga 120
caacgaagca gaacccgttg tagaaggtaa cgctaccatt agcgtagtat tgaagaccag 180
caatccgaat cgtgctttcg gggttgcaga tgacgaagca aaagtggcta aactgactgt 240
aatggtctac aagggtgagc agcaggaagc catcaaatca gccgaaaatg caattaaggt 300
tgagaacatc aaatgtggtg caggctcacg tacgctggtc gtaatggcca atacgggtgg 360
```

```
aatqqaattq qctqqcaaga ctcttqcaqa ggtaaaagca ttgacaactg aactaactgc 420
agaaaaccaa gaggctacag gtttgatcat gacagcagag cctgttgacg taacacttgt 480
cgccggcaat aactattatg gttatgatgg aactcaggga ggcaatcaga tttcgcaagg 540
tactcctctt gaaatcaaac gtgttcatgc ccgtattgcg ttcaccaaga ttgaagtgaa 600
gatgagcgag tcttatgtga acaaatacaa ctttaccccc gaaaacatct atgcacttgt 660
ggctaagaag aagtctaatc tattcggtac ttcattggca aatagtgatg atgcttattt 720
gaccggttct ttgacgactt tcaacggtgc ttatacccct gcaaactata ctcatgtcgt 780
ctggttggga agaggctaca cagcgccttc caatgatgct ccacaaggtt tctatgtttt 840
ggagagtgca tacgctcaga atgcaggtct acgtcctacc attctatgtg taaagggtaa 900
gctgacaaag catgatggta ctcctttgag ttctgaggaa atgacagctg cattcaatgc 960
cggctggatt gttgcaaaca atgatcctac gacctattat cctqtattag tgaactttga 1020
gagc
                                                                   1024
<210> 96
<211> 733
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:P.
      circumdentaria B52 fimA polynucleotide sequence
<400> 96
taatggagaa cagcaggaag ccatcgaatc agccgaaaat gcgactaaga ttgagaatat 60
caaatgtggt gcaggccaac gtacgctggt cgtaatggcc aatacgggtg gaatggaatt 120
ggctggcaag actcttgcag aggtaaaagc attgacaact gtactgactg aagaaaacca 180
agaggccaca ggtttgatca tgacagcaga gccaaaagca atcgttttga aggcaggcaa 240
gaactatatt ggatacgatg gagccggaga gggcaaccac attgagaatg ctcctcttga 300
aatcaaacgt gtacatgctc gcatggcttt caccgaaatt aaagtacaga tgagcgcagc 360
ctacgataac atttacacat ttacccctga aaagatttat ggtctcattg caaagaagca 420
atctaatttg ttcggggcaa cactcgtgaa tgcagacgct aattatctga caggttcttt 480
gaccacattt aacggtgctt acacacctac caactatgcc aatgttcctt ggttgagccg 540
tgattacgtt gcacctaccg ctggtgctcc tcagggcttc tacqtattaq aaaatgacta 600
ctcagctaac agtggaacta ttcatccgac aatcctgtgt gtttatggca aacttcagaa 660
aaacggagcc gacctgacgg gaaccgattt agcagcaqct caqqccqcca attqqqtqqa 720
tgcagaaggc aag
                                                                  733
<210> 97
<211> 1024
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: P. gulae B69
      fimA polynucleotide sequence
```

```
<400> 97
ggcgcagcat aacctcgacg aactgcgaca ctatatgcag gacaatctct aaatcgaata 60
aagattotaa taaaacaata ttoactttta aaacaaaaac aagatgaaaa agactaagtt 120
tttcttgttg ggacttgctg cccttgctat gacagcttgt aacaaagaca acgaagcaga 180
accepttgta gaaggtaacg ctaccattag cgtagtattg aagaccagca atccgaatcg 240
tgttttcggg gttgcagatg acgaagcaaa agtggctaag ttgaccgtaa tggtttataa 300
tggagaacag caggaagcca tcgaatcagc cgaaaatgcg actaagattg agaatatcaa 360
atgtggtgca ggccaacgta cgctggtcgt aatggccaat acgggtggaa tggaattggc 420
tggcaagact cttgcagagg taaaagcatt gacaactgta ctgactgaag aaaaccaagg 480
ggccacaggt ttgatcatga cagcagagcc aaaagcaatc gttttgaagg caggcaagaa 540
ctatattqqa tacqatqqag ccggagaggg caaccacatt gagaatgctc ctcttgaaat 600
caaacqtqta catqctcqca tggctttcac cgaaattaaa gtacagatga gcgcagccta 660
cgataacatt tacacattta cccctgaaaa gatttatggt ctcattgcaa agaagcaatc 720
taatttgttc ggggcaacac tcgtgaatgc agacgctaat tatctgacag gttctttgac 780
cacatttaac ggtgcttaca cacctaccaa ctatgccaat gttccttggt tgagccgtga 840
ttacgttgca cctaccgctg gtgctcctca gggcttctac gtattagaaa atgactactc 900
agctaacagt ggaactattc atccgacaat cctgtgtgtt tatggcaaac ttcagaaaaa 960
cggagccgac ctgacgggaa ccgatttagc agcagctcag gccgccaatt gggtggatgc 1020
                                                                  1024
agaa
<210> 98
<211> 733
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:P.
      circumdentaria B97 fimA polynucleotide sequence
<400> 98
taatggagaa cagcaggaag ccatcgaatc agccgaaaat gcgactaaga ttgagaatat 60
caaatgtggt gcaggccaac gtacgetggt cgtaatggcc aatacgggtg gaatggaatt 120
ggctggcaag actcttgcag aggtaaaagc attgacaact gtactgactg aagaaaacca 180
agaggccaca ggtttgatca tgacagcaga gccaaaagca atcgttttga aggcaggcaa 240
gaactatatt ggatacgatg gagccggaga gggcaaccac attgagaatg ctcctcttga 300
aatcaaacgt gtacatgctc gcatggcttt caccgaaatt aaagtacaga tgagcgcagc 360
ctacgataac atttacacat ttacccctga aaagatttat ggtctcattg caaagaagca 420
atctaatttg ttcggggcaa cactcgtgaa tgcagacgct aattatctga caggttcttt 480
gaccacattt aacggtgett acacacctac caactatgcc aatgtteett ggttgageeg 540
tgattacgtt gcacctaccg ctggtgctcc tcagggcttc tacgtattag aaaatgacta 600
ctcagctaac agtggaacta ttcatccgac aatcctgtgt gtttatggca aacttcagaa 660
aaacggagcc qacctqacqq qaaccgattt agcaqcaqct caqqccqcca attggqtqqa 720
tgcagaaggc aag
                                                                  733
```

<210> 99 <211> 1024

```
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: P.
      cangingivalis B98 fimA polynucleotide sequence
<400> 99
ggcctcgaga acaaagacaa cgaagcagaa cccgttgtag aaggtaacgc taccattagc 60
qtaqtattqa aqaccaqcaa tccgaatcgt gctttcgggg ttgcagatga cgaagcaaaa 120
gtggctaaac tgactgtaat ggtctacaag ggtgagcagc aggaagccat caaatcagcc 180
gaaaatgcaa ttaaggttga gaacatcaaa tgtggtgcag gctcacgtac gctggtcgta 240
atggccaata cgggtggaat ggaattggct ggcaagactc ttgcagaggt aaaagcattg 300
acaactgaac taactgcaga aaaccaagag gctacaggtt tgatcatgac agcagagcct 360
qttqacqtaa cacttgtcgc cggcaataac tattatggtt atgatggaac tcagggaggc 420
aatcagattt cgcaaggtac tcctcttgaa atcaaacgtg ttcatgcccg tattgcgttc 480
accaagattg aagtgaagat gagcgagtct tatgtgaaca aatacaactt tacccccgaa 540
aacatctatg cacttgtggc taagaagaag tctaatctat tcggtacttc attggcaaat 600
agtgatgatg cttatttgac cggttctttg acgactttca acggtgctta tacccctgca 660
aactatactc atgtcgtctg gttgggaaga ggctacacag cgccttccaa tgatgctcca 720
caaggtttct atgttttgga gagtgcatac gctcagaatg caggtctacg tcctaccatt 780
ctatgtgtaa agggtaagct gacaaagcat gatggtactc ctttgagttc tgaggaaatg 840
acagctgcat tcaatgccgg ctggattgtt gcaaacaatg atcctacgac ctattatcct 900
gtattagtga actttgagag caataattac acctacacag gtgatgctgt tgagaaaggg 960
aaaatcgttc gtaaccacaa gtttgacatc aatctgacga tcaccggtcc tggtacgaat 1020
                                                                   1024
aatc
<210> 100
<211> 783
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: P. salivosa
      B104 fimA polynucleotide sequence
<400> 100
tggctaartt gactgtaatg gtttataatg gagaacagca ggaagccatc raatcagccg 60
aaaatgcgac taagrttgar rayatcaaat gtrgtgcagg ccaacgtacg ctggtcgtaa 120
tggccaatac gggtgsaatg gaaytggytg gcaagactct tgcagaggta aaagcattga 180
caactgwact gactgmagaa aaccaagagg cyrcaggktt gatcatgaca gcagagccaa 240
aarcaatcgt tttgaaggca ggcaagaact ayattggata crrtggarcc ggagagggya 300
aycacattga gaatgmtcct cttraratca arcgtgtwca tgctcgcatg gctttcaccg 360
aaattaaagt rcaratgagc gcagcctacg ataacattta cacattyryc cctgaaaaga 420
tttatggtct cattgcaaag aagcaatcta atttgttcgg ggcaacactc gtraatgcag 480
acqctaatta tctgacaggt tctttgacca catttaacgg tgcttacaca cctrccaact 540
atgccaatgt keettggytg ageegtratt aegttgeace treegeygrt geteetcagg 600
```

```
gyttctacgt attagaaaat gactactcag ctaacrgtgg aactattcat ccgacaatcc 660
tgtgtgttta tggcaaactt cagaaaaacg gagccgacyt grcgggarcc gatttagcar 720
cwgctcaggc cgccaattgg gtggatgcag aaggcaagac ctattaccct gtattrgtra 780
                                                                   783
act
<210> 101
<211> 733
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: P. denticanis
      B106 fimA polynucleotide sequence
<400> 101
taatggagaa cagcaggaag ccatcgaatc agccgaaaat gcgactaaga ttgagaatat 60
caaatgtggt gcaggccaac gtacgctggt cgtaatggcc aatacgggtg gaatggaatt 120
ggctggcaag actcttgcag aggtaaaagc attgacaact gtactgactg aagaaaacca 180
agaggecaca ggtttgatea tgacagcaga gccaaaagca ategttttga aggcaggcaa 240
qaactatatt qqatacqatq qagccqqaqa gqqcaaccac attgagaatg ctcctcttga 300
aatcaaacgt gtacatgctc gcatggcttt caccgaaatt aaagtacaga tgagcgcagc 360
ctacgataac atttacacat ttacccctga aaagatttat ggtctcattg caaagaagca 420
atctaatttg ttcggggcaa cactcgtgaa tgcagacgct aattatctga caggttcttt 480
gaccacattt aacggtgctt acacacctac caactatgcc aatgtteett ggttgagccg 540
tgattacgtt gcacctaccg ctggtgctcc tcagggcttc tacgtattag aaaatgacta 600
ctcagctaac agtggaacta ttcatccgac aatcctgtgt gtttatggca aacttcagaa 660
aaacggagcc gacctgacgg gaaccgattt agcagcagct caggccgcca attgggtgga 720.
tgcagaaggc aag
                                                                   733
<210> 102
<211> 742
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: P. endodontalis
      B114 fimA polynucleotide sequence
<400> 102
caagggtgag cagcaggaag ccatcaaatc agccgaaaat gcaattaagg ttgagaacat 60
caaatqtqqt qcaqqctcac gtacgctgqt cqtaatqqcc aatacgqqtq qaatggaatt 120
ggctggcaag actcttgcag aggtaaaagc attgacaact gaactaactg cagaaaacca 180
agaggetaca ggtttgatca tgacagcaga gcctgttgac gtaacacttg tcgccggcaa 240
taactattat ggttatgatg gaactcaggg aggcaatcag atttcgcaag gtactcctct 300
tqaaatcaaa cgtgttcatg cccgtattgc gttcaccaaq attqaaqtqa aqatgagcga 360
```

grettatgtg aacaaataca actttacccc egaaaacate tatgcaettg tggetaagaa 420

```
gaagtctaat ctattcggta cttcattggc aaatagtgat gatgcttatt tgaccggttc 480
tttgacgact ttcaacggtg cttatacccc tgcaaactat actcatgtcg tctggttggg 540
aagaggctac acagcgcctt ccaatgatgc tccacaaggt ttctatgttt tggagagtgc 600
atacgeteag aatgeaggte taegteetae cattetatgt gtaaagggta agetgacaaa 660
gcatgatggt actcctttga gttctgagga aatgacagct gcattcaatg ccggctggat 720
tgttgcaaac aatgatccta cg
                                                                   742
<210> 103
<211> 281
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: P. gulae B43
      FimA polypeptide sequence
<400> 103
mkktkgaaam tacnkdnavv gnatsvvkts nnragvadda kvaktvmvyk gaksanakvn 60
kcgagsrtvv mantggmagk tavkatttan atgmtavdvt vagnnyygyd gtggnsgtkr 120
vharatkvkm ssyvnkyntn yavakkksng tsansddayt gsttngayta nythvvwgrg 180
ytasndagyv sayanagrtc vkgktkhdgt ssmtaanagw vanndttyyv vnsnnytytg 240
davkgkvrnh kdnttggtnn ntsannvncv vaawkgvvnv w
<210> 104
<211> 170
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:P.
      circumdentaria B52 FimA polypeptide sequence
<400> 104
ngasanatkn kegagrtvvm antggmagkt avkattvtna tgmtakavka gknygydgag 60
gnhnakrvha rmatkvmsaa ydnyttkyga kksngatvna danytgsttn gayttnyanv 120
wsrdyvatag agyvndysan sgthtcvygk kngadtgtda aaaanwvdag
<210> 105
<211> 275
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: P. gulae B69
```

FimA AA

```
<400> 105
 mkktkqaaam tacnkdnavv gnatsvvkts nnrvgvadda kvaktvmvyn gasanatknk 60
 cgagrtvvma ntggmagkta vkattvtnga tgmtakavka gknygydgag gnhnakrvha 120
 rmatkvmsaa ydnyttkyga kksngatvna danytgsttn gayttnyanv wsrdyvatag 180
 agyvndysan sgthtcvygk kngadtgtda aaaanwvdag ktyyvvnnsn nytydngytk 240
 nkrnhkydkt tggtnnntsa hnvctvawvv gnatw
                                                                    275
 <210> 106
 <211> 170
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence:P.
       circumdentaria B97 FimA polypeptide sequence
 <400> 106
 ngasanatkn kcgagrtvvm antggmagkt avkattvtna tgmtakavka gknygydgag 60
 gnhnakrvha rmatkvmsaa ydnyttkyga kksngatvna danytgsttn gayttnyanv 120
 wsrdyvatag agyvndysan sgthtcvygk kngadtgtda aaaanwvdag
                                                                    170
 <210> 107
 <211> 257
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence:P.
       cangingivalis B98 FimA AA
 <400> 107
 vvgnatsvvk tsnnragvad dakvaktvmv ykgaksanak vnkcgagsrt vvmantggma 60
. gktavkattt anatgmtavd vtvagnnyyg ydgtggnsgt krvharatkv kmssyvnkyn 120
 tnyavakkks ngtsansdda ytgsttngay tanythvvwg rgytasndag yvsayanagr 180
 tcvkgktkhd gtssmtaana gwvanndtty yvvnsnnyty tgdavkgkvr nhkdnttggt 240
                                                                    257
 nnntsannvn cvvaawk
 <210> 108
 <211> 161
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: P. salivosa
```

B104 FimA polypeptide sequence

```
<400> 108
atvmvyngas anatkkcagr tvvmantgmg ktavkatttn agmtakvkag kngyggghnr 60
vharmatkvm saaydnytky gakksngatv nadanytgst tngaytnyan vwsryvaaag 120
yvndysangt htcvygkkng adgdaaaanw vdagktyyvv n
                                                                   161
<210> 109
<211> 170
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: P. denticanis
      B106 FimA polypeptide sequence
<400> 109
ngasanatkn kcgagrtvvm antggmagkt avkattvtna tgmtakavka gknygydgag 60
gnhnakrvha rmatkvmsaa ydnyttkyga kksngatvna danytgsttn gayttnyanv 120
wsrdyvatag agyvndysan sgthtcvygk kngadtgtda aaaanwvdag
                                                                   170
<210> 110
<211> 177
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: P. endodontalis
     B114 FimA polypeptide sequence
<400> 110
kgaksanakv nkcgagsrtv vmantggmag ktavkattta natgmtavdv tvagnnyygy 60
dgtggnsgtk rvharatkvk mssyvnkynt nyavakkksn gtsansdday tgsttngayt 120
anythvvwgr gytasndagy vsayanagrt cvkgktkhdg tssmtaanag wvanndt
                                                                   177
<210> 111
<211> 1024
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: P. gulae B43
      oprF polynucleotide sequence
```

```
acattegttg gagetattge aetgaatgea agtgeaeagg aaaataetgt aeeggeaaeg 60
ggtcagttac ccgccaaaaa tgttgctttc gctcgcaaca aagcaggcag caattggttc 120
gtaacactgc agggcggtgt tgcagcgcag ttcctcaatg acaacaacaa caaagatttt 180
gtagaccgct tgggtgctgc cggctctatt tcagttggaa aatatcacaa tccattcttt 240
gcaacccgtt tgcaaattaa cggagctcag gcacacacgt tccttggaaa aaatgcggaa 300
caagaaatta agaccaattt tggcgcagct cactttgact tcatgttcga tgtggttaat 360
tactttgcgc catatcgcga aaatcgtttc ttccatttaa ttccatgggt aggtgttggt 420
taccagcata aattcattgg cagcaaatgg agtaaagaca atgtcgagtc tctgactgcc 480
aatctgggtg ttatgatggc tttcagatta ggaaaacgtg tagactttgt gatcgaagca 540
caagcagcac actccaatct caacttaagc cgtgctttca atgccaagcc gactcctatt 600
ttccaggatc aggaaggacg ttattacaat ggattccaag gaatggcgac agcaggtctt 660
aactteeget tgggtgetgt aggetteaat gecategage eeatggaeta egegettate 720
aacgatctga atggtcagat taatcgcctg cgcagagaag tcgaagaact ctccaagcgt 780
cctgtatcat gtcccgaatg ccccgacgtt acacccgtta ccaagacaga aaacaagcta 840
accgagaagg ctgtactctt ccgtttcgac agctatgttg tagacaaaga ccagcttatc 900
aatctgtatg acgtagctca gtttgtaaaa gaaaccaacg agccgattac tgttgtaggc 960
tatgctgatc ctacgggtga cactcagtac aacgaaagat tgtctgagcg tcgcgcaaaa 1020
acca
                                                                  1024
```

<210> 112

<211> 1024

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: P. cansulci B46 oprF polynucleotide sequence

<400> 112

acattggccg gggtttacgc cctttcagcc tctgctcagc aggaqaatat gccacqaatq 60 gggcagactc ccgccaagaa taccgcttac gctcgctctg aagccggtga caattggttt 120 gtgactttgc aaggaggtgc tgctatgcag ttttgggaaag gtaacgagga tgccgacttc 180 ttcgaccgcc aaactgttgc tcccactttt gccgtaggta aatggcacaa tcctttcttc 240 gggaccagat tgcaaatggg cttgggggta tctcacgact tctcgaacaa cgaagcgaaa 300 tccaagttgg agatgaacca cgctcgctat gctaacgcac actttgactt tatgtttgat 360 gtgattaact acttcaagcc ctacagtgag gaccgcgtat tccaccttat tccgtgggta 420 ggtttgggtt acgatcacaa gtttgagaaa aacagcaact tcaaggtgga tgctcttaca 480 gccaacgccg gtttgatgtt tgctttccgt gtgatggagc gtatggacat tgtgttggaa 540 agccaggtaa tgtattctga cttcaacctc aacacagctc tgcccgagcc tcgctacaca 600 gcttgctccg gcatgctcac tgccggtttg aacttccgta taggaaatat cggatggagc 660 gagatectae caatggattg gggettggta aatgacetga aeggacaaat caaegecatg 720 cgtgctaaga acgcagagtt gagcaagcgt cccgtttctt gccccgaatg cccggaagtt 780 gagcctcgtg tagagcgtat caatatgctt tcggacaagt ctgttctttt ccgtgccggc 840 aagacaactg tagacagcga tcaaatggta acgatcttcg acgtagctca gtttgcaaag 900 aagaatggca cacagatcac cgttacaggc tatgcagaca agaagggcaa agaaagcgat 960 cgcacctctg aacttcgtgc aaaagccgta gccaagattc tcaccgacaa gtacggtgta 1020 cctt 1024

```
<210> 113
 <211> 1024
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: P.
       circumdentaria B52 oprF polynucleotide sequence
 <400> 113
 totataatgg gagotacago actotocgog agtgotoaac aatotacgao acotgagaot 60
 caaactttgc cagctcgcaa gacggctttt gaccgttccg cgggtcactg gttcttgact 120
 ctacagggtg gtgtaaatgc acagtttttg gaagaaaacg agtctcaaga catcgtaaat 180
cgtctccgtg tgatgccaac tctttcttta ggaaagtggc acaatcccta ttttgcaacc 240
cgtttgcaag tttttggggg gccaacccct acttactaca aggaggtttc tggggaggtt 300
aagaccctaa ataccgccat ggctggagct cactttgatt ttatgtttga tgtagtaaac 360
ttctatgcaa agtataatcc taaacgagta ttccatttga ttccttggtt cggtgtggga 420
tatggtttca aatactataa cgattttgct gatttagctg atatgattca gtttaatgaa 480
cccttccgtc actcagcaac tgcgaatgct ggtttgatga tgagttttcg cttggcaaaa 540
cgtttggatt tggttctgga agggcaggct atatattcta acttgaatat tgtaaagcaa 600
gagatagatt ataaagcccc cattatgccc tattcaaata tctacaacgg attgacaggt 660
gtegttaetg caggteteaa etttaatete ggtegtgttg ettgggagte egtaacteet 720
arggatatgg atcttattaa tgacctaaac ggacaaatta accgtttgcg ttctgagaat 780
acagagttga gaaaacgtcc agtttcttgc ccagaatgtc ctgaagttac tgcagagacg 840
gaagtagtta ctgaaaacgt tttaggtgat aaggcgattg ttttcaagtt taatagcgca 900
actattgaca aagatcaaca cattgttttg caggatatcg ctgactttgt taaagatggc 960
aacaaagcta ttgttgtaat aggcttcgca gatacaacag gtgatattaa ttacaatatg 1020
catt
                                                                   1024
<210> 114
<211> 1024
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: P. gulae B69
      oprF polynucleotide sequence
<400> 114
acattcgttg gagctattgc actgaatgca agtgcacagg aaaatactgt accggcaacg 60
ggtcagttac ccgccaaaaa tgttgctttt gcccgcaata aagcaggcgg caattggttt 120
gtaacactgc aaggtggtgt tgcagcacag ttccttaatg acaacaacaa caaagatcta 180
gtagaccgct taggagctac cggatctatc tccgttggaa aatatcacaa tccattcttt 240
gcgactcgtt tgcaaattaa cggaggtcaa gcacacacgt tccttgggaa gaatgcggaa 300
caagaaatta acaccaattt tggagcagct cactttgact tcatgttcga tgtggttaac 360
```

PCT/IB02/05539

```
WO 03/054755
tactttgcgc catatcgcga aaaccgtttc ttccatttaa ttccatgggt aggtgttggt 420
taccaacaca aattcatcgg tagcgaatgg agtaaagaca acgtcgagtc gctgaccgca 480
aacatgggtg ttatgatggc tttcagatta gggaagcgcg tggactttgt gatcgaagca 540
caagetgete actecaatet taatttaagt egegeattea atgecaagaa aactectatt 600
ttccacgatc aagaaggtcg ctattacaat ggattccaag gaatggctac agcgggtctt 660
aacttccgct taggtgctgt tggcttcaat gccatcgagc caatggacta cgcgcttatc 720
aacgatctga atggtcagat taaccgtttg cgcagagaag ttgaagagct ctctaagcgt 780
cctgtatcat gcccgaatg tcccgatgta acacccgtta ctaaqacaqa aaacaagcta 840
accgagaagg ctgtactctt ccgcttcgac agctatgttg tagacaaaga ccagctgatc 900
aatctgtatg acgttgctca gttcgtaaaa gaaactaacg aaccgattac cgttgtaggt 960
tatgccgatc ctacgggcag cactcagtac aacgaaagat tgtctgagcg tcgcgcaaaa 1020
acca
                                                                  1024
<210> 115
<211> 1024
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:P.
      circumdentaria B97 oprF polynucleotide sequence
```

<400> 115

totgttatgg gagotacago actoacagtt agtgctcago aacotactac acctqaqact 60 cagacattgc ctgctcataa gacggctttt gaccgttctg caggacattg gttcttgact 120 ctccaaggtg gagttagtgc tcaattttta gaagaaaatg aaagtcaaga aatcttgaat 180 cgtcttcatg ttatgcctac aatctcttta qqcaaqtqqc acaatcctta ttttqcaact 240 cgtttgcaag tgttcggagg tcctactcct actttttata agaatgctgc tggtaaggtg 300 atgaaggaaa atgcggctat ggctggggct cactttgact ttatgtttga tgttgtgaac 360 tactttggta agtataatcc aaagagagtc tttcatcttg tgccttggtt cggtgttgga 420 tatggcttta aataccataa tgatttcgcc gaaatgagtg atatcattaa gtttaatgag 480 cettategee atteageaac agegaatgea gggttgatga tgagttteeg ettageaaaa 540 cgtcttgatt tagtgcttga aggacaggct atatattcta atttgaatat tgttaagcaa 600 gaaattgatt ataaagctcc ttctactcct tattctccaa attataatgg gcttttggga 660 gttgttacag caggtcttaa ctttaatctt ggtcgtgttg cttgggagac tgttactccc 720 atggatatgg atttgattaa tgatettaat ggteaaatea ategtttgeg ttetgagaat 780 actgagttga gaaaacgtcc tgtttcttgt cctgaatgcc cagaagtttc taaaqaaaca 840 actgtagtta cagaaaatgt attgggagac aaagctattg ttttcaaatt taatagtgca 900 actatcagca aagatcaaca tattgttttg caagacattg cggactttgt taagaatgga 960 aataaggggg ttgccgtgat aggtttcgca gatgtaacag gagatqccaa ttacaatatg 1020 caac 1024

<210> 116

<211> 948

<212> DNA

<213> Artificial Sequence

<220> <223> Description of Artificial Sequence:P. cangingivalis B98 oprF polynucleotide sequence <400> 116 ggtggagtta gtgctcaatt tttagaagaa aatgaaagtc aagaaatctt gaatcgtctt 60 catgttatqc ctacaatctc tttaqqcaaq tqqcacaatc cttattttqc aactcqtttg 120 caagtgttcg gaggtcctac tcctactttt tataagaatg ctgctggtaa ggtgatgaag 180 gaaaatgcgg ctatggctgg ggctcacttt gactttatgt ttgatgttgt gaactacttt 240 ggtaagtata atccaaagag agtctttcat cttgtgcctt ggttcggtgt tggatatggc 300 tttaaatacc ataatgattt cgccgaaatg agtgatatca ttaagtttaa tgagccttat 360 cgccattcag caacagcgaa tgcagggttg atgatgagtt tccgcttagc aaaacgtctt 420 gatttagtgc ttgaaggaca ggctatatat tctaatttga atattgttaa gcaagaaatt 480 gattataaag ctccttctac tccttattct ccaaattata atgggctttt gggagttgtt 540 acagcaggtc ttaactttaa tettggtegt gttgettggg agaetgttae teecatggat 600 atggatttga ttaatgatct taatggtcaa atcaatcgtt tgcgttctga gaatactgag 660 ttgagaaaac gtcctgtttc ttgtcctgaa tgcccagaag tttctaaaga aacaactgta 720 gttacagaaa atgtattggg agacaaagct attgttttca aatttaatag tgcaactatc 780 agcaaagatc aacatattgt tttgcaagac attgcggact ttgttaagaa tggaaataag 840 ggggttgccg tgataggttt cgcagatgta acaggagatg ccaattacaa tatgcaactt 900 tctgaacgtc gtgctaaggc tgttgcggaa gctcttgtga atcaattc 948 <210> 117 <211> 969 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: P. salivosa B104 oprF polynucleotide sequence <400> 117 cattggttct tgactctcca aggtggagtt agtgctcaat ttttagaaga aaatgaaagt 60 caagaaatct tgaatcgtct tcatgttatg cctacaatct ctttaggcaa gtggcacaat 120 cettattttg caactegttt geaagtgtte ggaggteeta etectaettt ttataagaat 180 gctgctggta aggtgatgaa ggaaaatgcg gctatggctg gggctcactt tgactttatg 240 tttgatgttg tgaactactt tggtaagtat aatccaaaga gagtctttca tcttgtgcct 300 tggttcggtg ttggatatgg ctttaaatac cataatgatt tcgccgaaat gagtgatatc 360 attaagttta atgagcctta tcgccattca gcaacagcga atgcagggtt gatgatgaqt 420 ttccgcttag caaaacgtct tgatttagtg cttgaaggac aggctatata ttctaatttg 480 aatattgtta agcaagaaat tgattataaa gctccttcta ctccttattc tccaaattat 540 aatgggcttt tgggagttgt tacagcaggt cttaacttta atcttggtcg tgttgcctqq 600 gagactatta ctcccatgga tatggatttg attaatgatc ttaatggtca aatcaatcqt 660

ttgcgttctg agaatactga gttgagaaaa cgtcctgttt cttgtcctga atgcccagaa 720 gtttctaaag aaacaactgt agttacagaa aatgtattgg gagacaaagc tattgttttc 780 aaatttaata gtgcaactat cagcaaagat caacatattg ttttgcaaga cattgcggac 840

tttgttaaga atggaaataa gggggttgcc gtgataggtt tcgcagatgt aacaggagat 900 gccaattaca atatgcaact ttctgaacgt cgtgctaagg ctgttgcgga agctcttgtg 960 aatcaattc 969

<210> 118
<211> 1024
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:P. denticanis
Blo6 oprF polynucleotide sequence

<400> 118

<210> 119

gctcataaga cggcttttga ccgttctgca ggacattggt tcttgactct ccaaggtgga 60 gttagtgctc aatttttaga agaaaatgaa agtcaagaaa tcttgaatcg tcttcatgtt 120 atgcctacaa tctctttagg caagtggcac aatccttatt ttgcaactcg tttgcaagtg 180 ttcggaggtc ctactcctac tttttataag aatgctgctg gtaaggtgat gaaggaaaat 240 gcggctatgg ctggggctca ctttgacttt atgtttgatg ttgtgaacta ctttggtaag 300 tataatccaa agagagtctt tcatcttgtg ccttggttcg gtgttggata tggctttaaa 360 taccataatg atttcgccga aatgagtgat atcattaagt ttaatgagcc ttatcgccat 420 tcagcaacag cgaatgcagg gttgatgatg agtttccgct tagcaaaacg tcttgattta 480 qtqcttqaaq qacaqqctat atattctaat ttgaatattg ttaagcaaga aattgattat 540 aaaqctcctt ctactcctta ttctccaaat tataatgggc ttttgggagt tgttacagca 600 ggtcttaact ttaatcttgg tcgtgttgct tgggagactg ttactcccat ggatatggat 660 ttqattaatg atcttaatgg tcaaatcaat cgtttgcgtt ctgagaatac tgagttgaga 720 aaacgtcctg tttcttgtcc tgaatgccca gaagtttcta aagaaacaac tgtagttaca 780 qaaaatgtat tgggagacaa agctattgtt ttcaaattta atagtgcaac tatcagcaaa 840 gatcaacata ttgttttgca agacattgcg gactttgtta agaatggaaa taagggggtt 900 gccgtgatag gtttcgcaga tgtaacagga gatgccaatt acaatatgca actttctgaa 960 cgtcgtgcta aggctgttgc ggaagctctt gtgaatcaat tcggagttcc ttctgatatg 1020 1024 attt

<211> 1024
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:P. endodontalis
B114 oprF polynucleotide sequence

<400> 119
tcagcactgg gggctttggc acttacagct agtgctcaac aaactacgaa accagcgaat 60
agtatgcccg cattcaagac tgcatttgaa cgcagcggcg gtcattggtt tctgacaatt 120
cagggtggcc tgagtgctca acttttgggt gaaaatgaaa agatggactt tggcaagcgt 180

ctgctacatg ctgccaaggc cagtgacaac acccaaacag aggctagcta cctacgcatc 240 atgcccacgc tctctgtagg taaatggcat aatccctact ttgctactcg tgtacagctc 300 ttcggtggtc tcactcctc ctacaatact gagggtggcg ttaatgtaca cacctacaac 360 accgccacga tcggtgccca ctatgatttc atgtttgatg tagtaaacta tttcgccaag 420 tacaacccca aacgtttctt cacggtaatt ccttgggtgg gtcttggtta caacttcaag 480 tatcatgatg tatttggatt caaggagccc tatcgtcact ctgtcacagg taacgcaggc 540 atggagtttg ctttccgcct cggtaagcgt gtagaccttg tactcgaagc tcaggtagtg 600 tacaacaacc tgaacctgat caagcaggaa gtcgactacg atgtagtcac tactccctat 660 gtacctgctg atacatacgc tggtcttatg accatgtta ctgctggtct taacttcaat 720 ctgggcaagg ttgagtgga aactgttgag ccgatggact accagctcat aaacgacttg 780 aactctcaga tcagccgtct acgtagcga aacgcagagc tttccaagcg tcctgctttc 840 tgccccgagt tgattgcta agaggaagta gaagatgttg ttgttgacca gtatgtcctc 900 accgacaagg ctatcctct cgactttgac aagagcaca tccgcaagga ccaacaagct 960 cagcttggta tgattgcta attcgtgaa aattcgtgaa aagagcaaca tccgcaagga ccaacaagct 960 cagcttggta tgattgcta attcgtgaag aactgtgaacaata cgcctatcgt ggtagtaggc 1020 tatg

<210> 120

<211> 375

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: P. gulae B43
OprF polypeptide sequence

<400> 120

Thr Phe Val Gly Ala Ile Ala Leu Asn Ala Ser Ala Gln Glu Asn Thr
1 5 10 15

Val Pro Ala Thr Gly Gln Leu Pro Ala Lys Asn Val Ala Phe Ala Arg 20 25 30

Asn Lys Ala Gly Ser Asn Trp Phe Val Thr Leu Gln Gly Gly Val Ala 35 40 45

Ala Gln Phe Leu Asn Asp Asn Asn Asn Lys Asp Phe Val Asp Arg Leu 50 55 60

Gly Ala Ala Gly Ser Ile Ser Val Gly Lys Tyr His Asn Pro Phe Phe 65 70 75 80

Ala Thr Arg Leu Gln Ile Asn Gly Ala Gln Ala His Thr Phe Leu Gly 85 90 95

Lys Asn Ala Glu Gln Glu Ile Lys Thr Asn Phe Gly Ala Ala His Phe 100 105 110

Asp Phe Met Phe Asp Val Val Asn Tyr Phe Ala Pro Tyr Arg Glu Asn 115 120 125

- Arg Phe Phe His Leu Ile Pro Trp Val Gly Val Gly Tyr Gln His Lys
 130 135 140
- Phe Ile Gly Ser Lys Trp Ser Lys Asp Asn Val Glu Ser Leu Thr Ala
 145 150 155 160
- Asn Leu Gly Val Met Met Ala Phe Arg Leu Gly Lys Arg Val Asp Phe 165 170 175
- Val Ile Glu Ala Gln Ala Ala His Ser Asn Leu Asn Leu Ser Arg Ala 180 185 190
- Phe Asn Ala Lys Pro Thr Pro Ile Phe Gln Asp Gln Glu Gly Arg Tyr 195 200 205
- Tyr Asn Gly Phe Gln Gly Met Ala Thr Ala Gly Leu Asn Phe Arg Leu 210 220
- Gly Ala Val Gly Phe Asn Ala Ile Glu Pro Met Asp Tyr Ala Leu Ile 225 230 235 240
- Asn Asp Leu Asn Gly Gln Ile Asn Arg Leu Arg Arg Glu Val Glu Glu 245 250 255
- Leu Ser Lys Arg Pro Val Ser Cys Pro Glu Cys Pro Asp Val Thr Pro
 260 265 270
- Val Thr Lys Thr Glu Asn Lys Leu Thr Glu Lys Ala Val Leu Phe Arg 275 280 285
- Phe Asp Ser Tyr Val Val Asp Lys Asp Gln Leu Ile Asn Leu Tyr Asp 290 295 300
- Val Ala Gln Phe Val Lys Glu Thr Asn Glu Pro Ile Thr Val Val Gly 305 310 315 320
- Tyr Ala Asp Pro Thr Gly Asp Thr Gln Tyr Asn Glu Arg Leu Ser Glu 325 330 335
- Arg Arg Ala Lys Ala Val Val Asp Val Leu Thr Gly Lys Tyr Gly Val 340 345 350
- Pro Ser Glu Leu Ile Ser Val Glu Trp Lys Gly Asp Thr Thr Gln Pro 355 360 365

Phe Asn Lys Lys Ala Trp Asn 370 375

<210> 121

<211> 366

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: P. cansulci B46 OprF polypeptide sequence

<400> 121

Thr Leu Ala Gly Val Tyr Ala Leu Ser Ala Ser Ala Gln Gln Glu Asn
1 5 10 15

Met Pro Arg Met Gly Gln Thr Pro Ala Lys Asn Thr Ala Tyr Ala Arg
20 25 30

Ser Glu Ala Gly Asp Asn Trp Phe Val Thr Leu Gln Gly Gly Ala Ala 35 40 45

Met Gln Phe Gly Lys Gly Asn Glu Asp Ala Asp Phe Phe Asp Arg Gln 50 55 60

Thr Val Ala Pro Thr Phe Ala Val Gly Lys Trp His Asn Pro Phe Phe 65 70 75 80

Gly Thr Arg Leu Gln Met Gly Leu Gly Val Ser His Asp Phe Ser Asn 85 90 95

Asn Glu Ala Lys Ser Lys Leu Glu Met Asn His Ala Arg Tyr Ala Asn 100 105 110

Ala His Phe Asp Phe Met Phe Asp Val Ile Asn Tyr Phe Lys Pro Tyr
115 120 125

Ser Glu Asp Arg Val Phe His Leu Ile Pro Trp Val Gly Leu Gly Tyr 130 135 140

Asp His Lys Phe Glu Lys Asn Ser Asn Phe Lys Val Asp Ala Leu Thr 145 150 155 160

Ala Asn Ala Gly Leu Met Phe Ala Phe Arg Val Met Glu Arg Met Asp 165 170 175

Ile Val Leu Glu Ser Gln Val Met Tyr Ser Asp Phe Asn Leu Asn Thr

180 185 190

Ala Leu Pro Glu Pro Arg Tyr Thr Ala Cys Ser Gly Met Leu Thr Ala 195 200 205

Gly Leu Asn Phe Arg Ile Gly Asn Ile Gly Trp Ser Glu Ile Leu Pro 210 215 220

Met Asp Trp Gly Leu Val Asn Asp Leu Asn Gly Gln Ile Asn Ala Met 225 230 235 240

Arg Ala Lys Asn Ala Glu Leu Ser Lys Arg Pro Val Ser Cys Pro Glu 245 250 255

Cys Pro Glu Val Glu Pro Arg Val Glu Arg Ile Asn Met Leu Ser Asp 260 265 270

Lys Ser Val Leu Phe Arg Ala Gly Lys Thr Thr Val Asp Ser Asp Gln 275 280 285

Met Val Thr Ile Phe Asp Val Ala Gln Phe Ala Lys Lys Asn Gly Thr 290 295 300

Gln Ile Thr Val Thr Gly Tyr Ala Asp Lys Lys Gly Lys Glu Ser Asp 305 310 315 320

Arg Thr Ser Glu Leu Arg Ala Lys Ala Val Ala Lys Ile Leu Thr Asp 325 330 335

Lys Tyr Gly Val Pro Ser Asp Arg Ile Ser Ile Glu Trp Lys Gly Val 340 345 350

Ser Glu Gln Val Tyr Asp Asn Arg Asp Trp Asn Arg Val Val 355 360 365

<210> 122

<211> 382

<212> PRT

<213> Artificial Sequence

. <220>

<223> Description of Artificial Sequence:P. circumdentaria B52 OprF polypeptide sequence

<400> 122

Ser Ile Met Gly Ala Thr Ala Leu Ser Ala Ser Ala Gln Gln Ser Thr

1 5 10 15

Thr Pro Glu Thr Gln Thr Leu Pro Ala Arg Lys Thr Ala Phe Asp Arg Ser Ala Gly His Trp Phe Leu Thr Leu Gln Gly Gly Val Asn Ala Gln Phe Leu Glu Glu Asn Glu Ser Gln Asp Ile Val Asn Arg Leu Arg Val Met Pro Thr Leu Ser Leu Gly Lys Trp His Asn Pro Tyr Phe Ala Thr Arg Leu Gln Val Phe Gly Gly Pro Thr Pro Thr Tyr Tyr Lys Glu Val Ser Gly Glu Val Lys Thr Leu Asn Thr Ala Met Ala Gly Ala His Phe Asp Phe Met Phe Asp Val Val Asn Phe Tyr Ala Lys Tyr Asn Pro Lys Arg Val Phe His Leu Ile Pro Trp Phe Gly Val Gly Tyr Gly Phe Lys Tyr Tyr Asn Asp Phe Ala Asp Leu Ala Asp Met Ile Gln Phe Asn Glu Pro Phe Arg His Ser Ala Thr Ala Asn Ala Gly Leu Met Met Ser Phe Arg Leu Ala Lys Arg Leu Asp Leu Val Leu Glu Gly Gln Ala Ile Tyr Ser Asn Leu Asn Ile Val Lys Gln Glu Ile Asp Tyr Lys Ala Pro Ile Met Pro Tyr Ser Asn Ile Tyr Asn Gly Leu Thr Gly Val Val Thr Ala Gly Leu Asn Phe Asn Leu Gly Arg Val Ala Trp Glu Ser Val Thr Pro Met Asp Met Asp Leu Ile Asn Asp Leu Asn Gly Gln Ile Asn Arg Leu Arg Ser Glu Asn Thr Glu Leu Arg Lys Arg Pro Val Ser Cys Pro Glu

Cys Pro Glu Val Thr Ala Glu Thr Glu Val Val Thr Glu Asn Val Leu 275 280 285

Gly Asp Lys Ala Ile Val Phe Lys Phe Asn Ser Ala Thr Ile Asp Lys 290 295 300

Asp Gln His Ile Val Leu Gln Asp Ile Ala Asp Phe Val Lys Asp Gly 305 310 315 320

Asn Lys Ala Ile Val Val Ile Gly Phe Ala Asp Thr Thr Gly Asp Ile 325 330 335

Asn Tyr Asn Met His Leu Ser Glu Arg Arg Ala Lys Ala Val Ala Glu 340 345 350

Ala Leu Val Asn Lys Phe Gly Val Ser Ser Asp Met Ile Ser Val Glu 355 360 365

Trp Gln Gly Glu Thr Glu Gln Phe Asn Pro Arg Ala Trp Asn 370 375 380

<210> 123

<211> 375

<212> PRT

<213> Artificial Sequence

<220>

<400> 123

Thr Phe Val Gly Ala Ile Ala Leu Asn Ala Ser Ala Gln Glu Asn Thr

1 10 15

Val Pro Ala Thr Gly Gln Leu Pro Ala Lys Asn Val Ala Phe Ala Arg
20 25 30

Asn Lys Ala Gly Gly Asn Trp Phe Val Thr Leu Gln Gly Gly Val Ala
35 40 45

Ala Gln Phe Leu Asn Asp Asn Asn Asn Lys Asp Leu Val Asp Arg Leu 50 55 60

Gly Ala Thr Gly Ser Ile Ser Val Gly Lys Tyr His Asn Pro Phe Phe 65 70 75 80

Ala Thr Arg Leu Gln Ile Asn Gly Gly Gln Ala His Thr Phe Leu Gly 85 90 95

- Lys Asn Ala Glu Gln Glu Ile Asn Thr Asn Phe Gly Ala Ala His Phe
 100 105 110
- Asp Phe Met Phe Asp Val Val Asn Tyr Phe Ala Pro Tyr Arg Glu Asn 115 120 125
- Arg Phe Phe His Leu Ile Pro Trp Val Gly Val Gly Tyr Gln His Lys
 130 135 140
- Asn Met Gly Val Met Met Ala Phe Arg Leu Gly Lys Arg Val Asp Phe 165 170 175
- Val Ile Glu Ala Gln Ala Ala His Ser Asn Leu Asn Leu Ser Arg Ala 180 185 190
- Phe Asn Ala Lys Lys Thr Pro Ile Phe His Asp Gln Glu Gly Arg Tyr
 195 200 205
- Tyr Asn Gly Phe Gln Gly Met Ala Thr Ala Gly Leu Asn Phe Arg Leu 210 215 220
- Gly Ala Val Gly Phe Asn Ala Ile Glu Pro Met Asp Tyr Ala Leu Ile 225 230 235 240
- Asn Asp Leu Asn Gly Gln Ile Asn Arg Leu Arg Arg Glu Val Glu Glu 245 250 255
- Leu Ser Lys Arg Pro Val Ser Cys Pro Glu Cys Pro Asp Val Thr Pro 260 265 270
- Val Thr Lys Thr Glu Asn Lys Leu Thr Glu Lys Ala Val Leu Phe Arg 275 280 285
- Phe Asp Ser Tyr Val Val Asp Lys Asp Gln Leu Ile Asn Leu Tyr Asp 290 295 300
- Val Ala Gln Phe Val Lys Glu Thr Asn Glu Pro Ile Thr Val Val Gly 305 310 315 320
- Tyr Ala Asp Pro Thr Gly Ser Thr Gln Tyr Asn Glu Arg Leu Ser Glu 325 330 335

Arg Arg Ala Lys Ala Val Val Asp Val Leu Thr Gly Lys Tyr Gly Val 340 345 350

Pro Ser Glu Leu Ile Ser Val Glu Trp Lys Gly Asp Ser Thr Gln Pro 355 360 365

Phe Asn Lys Lys Ala Trp Asn 370 375

<210> 124

<211> 382

<212> PRT

<213> Artificial Sequence

<220>

<400> 124

Ser Val Met Gly Ala Thr Ala Leu Thr Val Ser Ala Gln Gln Pro Thr

1 5 10 15

Thr Pro Glu Thr Gln Thr Leu Pro Ala His Lys Thr Ala Phe Asp Arg
20 25 30

Ser Ala Gly His Trp Phe Leu Thr Leu Gln Gly Gly Val Ser Ala Gln
35 40 45

Phe Leu Glu Glu Asn Glu Ser Gln Glu Ile Leu Asn Arg Leu His Val
50 55 60

Met Pro Thr Ile Ser Leu Gly Lys Trp His Asn Pro Tyr Phe Ala Thr 65 70 75 80

Arg Leu Gln Val Phe Gly Gly Pro Thr Pro Thr Phe Tyr Lys Asn Ala 85 90 95

Ala Gly Lys Val Met Lys Glu Asn Ala Ala Met Ala Gly Ala His Phe 100 105 110

Asp Phe Met Phe Asp Val Val Asn Tyr Phe Gly Lys Tyr Asn Pro Lys 115 120 125

Arg Val Phe His Leu Val Pro Trp Phe Gly Val Gly Tyr Gly Phe Lys
130 135 140

Tyr His Asn Asp Phe Ala Glu Met Ser Asp Ile Ile Lys Phe Asn Glu

WO 03/054755	PCT/IB02/05539
--------------	----------------

•	100	70017	-												10.
145					150					155					160
Pro	Tyr	Arg	His	Ser 165	Ala	Thr	Ala	Asn	Ala 170	Gly	Leu	Met	Met	Ser 175	Phe
Arg	Leu	Ala	Lys 180	Arg	Leu	Asp	Leu	Val 185	Leu	Glu	Gly	Gln	Ala 190	Ile	Tyr
Ser	Asn	Leu 195	Asn	Ile	Val	Lys	Gln 200	Glu	Ile	Asp	Tyr	Lys 205	Ala	Pro	Ser
Thr	Pro 210	Tyr	Ser	Pro	Asn	Tyr 215	Asn	Gly	Leu	Leu	Gly 220	Val	Val	Thr	Ala
Gly 225	Leu	Asn	Phe	Asn	Leu 230	Gly	Arg	Val	Ala	Trp 235	Glu	Thr	Val	Thr	Pro 240
Met	Asp	Met	Asp	Leu 245	Ile	Asn	Asp	Leu	Asn 250	Gly	Gln	Ile	Asn	Arg 255	Leu
Arg	Ser	Glu	Asn 260	Thr	Glu	Leu	Arg	Lys 265	Arg	Pro	Val	Ser	Cys 270	Pro	Glu
Cys	Pro	Glu 275	Val	Ser	Lys	Glu	Thr 280	Thr	Val	Val	Thr	Glu 285	Asn	Val	Leu
Gly	Asp 290	Lys	Alà	Ile	Val	Phe 295	Lys	Phe	Asn	Ser	Ala 300	Thr	Ile	Ser	Lys
Asp 305	Gln	His	Ile	Val	Leu 310	Gln	Asp	Ile	Ala	Asp 315	Phe	Val	Lys	Asn	Gly 320
Asn	Lys	Gly	Val	Ala 325	Val	Ile	Gly	Phe	Ala 330	Asp	Val	Thr	Gly	Asp 335	Ala
Asn	Tyr	Asn	Met 340	Gln	Leu	Ser	Glu	Arg 345	Arg	Ala	Lys	Ala	Val 350	Ala	Glu
Ala	Leu	Val 355	Asn	Gln	Phe	Gly	Val 360	Pro	Ser	Asp	Met	Ile 365	Ser	Val	Glu
Trp	Gln 370	Gly	Glu	Thr	Glu	Leu 375	Phe	Glu	Ala	Arg	Ala 380	Trp	Asn		

<210> 125

<211> 316

<212> PRT

<213> Artificial Sequence

<220>

<400> 125

Gly Gly Val Ser Ala Gln Phe Leu Glu Glu Asn Glu Ser Gln Glu Ile 1 5 10 15

Leu Asn Arg Leu His Val Met Pro Thr Ile Ser Leu Gly Lys Trp His
20 25 30

Asn Pro Tyr Phe Ala Thr Arg Leu Gln Val Phe Gly Gly Pro Thr Pro 35 40 45

Thr Phe Tyr Lys Asn Ala Ala Gly Lys Val Met Lys Glu Asn Ala Ala 50 55 60

Met Ala Gly Ala His Phe Asp Phe Met Phe Asp Val Val Asn Tyr Phe 65 70 75 80

Gly Lys Tyr Asn Pro Lys Arg Val Phe His Leu Val Pro Trp Phe Gly
85 90 95

Val Gly Tyr Gly Phe Lys Tyr His Asn Asp Phe Ala Glu Met Ser Asp 100 105 110

Ile Ile Lys Phe Asn Glu Pro Tyr Arg His Ser Ala Thr Ala Asn Ala 115 120 125

Gly Leu Met Met Ser Phe Arg Leu Ala Lys Arg Leu Asp Leu Val Leu 130 135 140

Glu Gly Gln Ala Ile Tyr Ser Asn Leu Asn Ile Val Lys Gln Glu Ile 145 150 155 160

Asp Tyr Lys Ala Pro Ser Thr Pro Tyr Ser Pro Asn Tyr Asn Gly Leu 165 170 175

Leu Gly Val Val Thr Ala Gly Leu Asn Phe Asn Leu Gly Arg Val Ala 180 185 . 190

Trp Glu Thr Val Thr Pro Met Asp Met Asp Leu Ile Asn Asp Leu Asn 195 200 205

Gly Gln Ile Asn Arg Leu Arg Ser Glu Asn Thr Glu Leu Arg Lys Arg 210 215 220

Pro Val Ser Cys Pro Glu Cys Pro Glu Val Ser Lys Glu Thr Thr Val 225 230 235 240

Val Thr Glu Asn Val Leu Gly Asp Lys Ala Ile Val Phe Lys Phe Asn 245 250 255

Ser Ala Thr Ile Ser Lys Asp Gln His Ile Val Leu Gln Asp Ile Ala 260 265 270

Asp Phe Val Lys Asn Gly Asn Lys Gly Val Ala Val Ile Gly Phe Ala 275 280 285

Asp Val Thr Gly Asp Ala Asn Tyr Asn Met Gln Leu Ser Glu Arg Arg 290 295 300

Ala Lys Ala Val Ala Glu Ala Leu Val Asn Gln Phe 305 310 315

<210> 126

<211> 323

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: P. salivosa B104 OprF polypeptide sequence

<400> 126

His Trp Phe Leu Thr Leu Gln Gly Gly Val Ser Ala Gln Phe Leu Glu
1 5 10 15

Glu Asn Glu Ser Gln Glu Ile Leu Asn Arg Leu His Val Met Pro Thr
20 25 30

Ile Ser Leu Gly Lys Trp His Asn Pro Tyr Phe Ala Thr Arg Leu Gln
35 40 45

Val Phe Gly Gly Pro Thr Pro Thr Phe Tyr Lys Asn Ala Ala Gly Lys
50 55 60

Val Met Lys Glu Asn Ala Ala Met Ala Gly Ala His Phe Asp Phe Met 65 70 75 80

Phe Asp Val Val Asn Tyr Phe Gly Lys Tyr Asn Pro Lys Arg Val Phe
85 90 95

His Leu Val Pro Trp Phe Gly Val Gly Tyr Gly Phe Lys Tyr His Asn 100 105 110

Asp Phe Ala Glu Met Ser Asp Ile Ile Lys Phe Asn Glu Pro Tyr Arg 115 120 125

His Ser Ala Thr Ala Asn Ala Gly Leu Met Met Ser Phe Arg Leu Ala 130 135 140

Lys Arg Leu Asp Leu Val Leu Glu Gly Gln Ala Ile Tyr Ser Asn Leu 145 150 155 160

Asn Ile Val Lys Gln Glu Ile Asp Tyr Lys Ala Pro Ser Thr Pro Tyr 165 170 175

Ser Pro Asn Tyr Asn Gly Leu Leu Gly Val Val Thr Ala Gly Leu Asn 180 185 190

Phe Asn Leu Gly Arg Val Ala Trp Glu Thr Ile Thr Pro Met Asp Met 195 200 205

Asp Leu Ile Asn Asp Leu Asn Gly Gln Ile Asn Arg Leu Arg Ser Glu 210 215 220

Asn Thr Glu Leu Arg Lys Arg Pro Val Ser Cys Pro Glu Cys Pro Glu 225 230 235 240

Val Ser Lys Glu Thr Thr Val Val Thr Glu Asn Val Leu Gly Asp Lys
245
250
255

Ala Ile Val Phe Lys Phe Asn Ser Ala Thr Ile Ser Lys Asp Gln His
260 265 270

Ile Val Leu Gln Asp Ile Ala Asp Phe Val Lys Asn Gly Asn Lys Gly 275 280 285

Val Ala Val Ile Gly Phe Ala Asp Val Thr Gly Asp Ala Asn Tyr Asn 290 295 300

Met Gln Leu Ser Glu Arg Arg Ala Lys Ala Val Ala Glu Ala Leu Val 305 310 315 320

Asn Gln Phe

<210> 127

<211> 349

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: P. denticanis B106 OprF polypeptide sequence

<400> 127

Ala His Lys Thr Ala Phe Asp Arg Ser Ala Gly His Trp Phe Leu Thr 1 5 10 15

Leu Gln Gly Gly Val Ser Ala Gln Phe Leu Glu Glu Asn Glu Ser Gln
20 25 30

Glu Ile Leu Asn Arg Leu His Val Met Pro Thr Ile Ser Leu Gly Lys
35 40 45

Trp His Asn Pro Tyr Phe Ala Thr Arg Leu Gln Val Phe Gly Gly Pro 50 55 60

Thr Pro Thr Phe Tyr Lys Asn Ala Ala Gly Lys Val Met Lys Glu Asn 65 70 75 80

Ala Ala Met Ala Gly Ala His Phe Asp Phe Met Phe Asp Val Val Asn 85 90 95

Tyr Phe Gly Lys Tyr Asn Pro Lys Arg Val Phe His Leu Val Pro Trp
100 105 110

Phe Gly Val Gly Tyr Gly Phe Lys Tyr His Asn Asp Phe Ala Glu Met 115 120 125

Ser Asp Ile Ile Lys Phe Asn Glu Pro Tyr Arg His Ser Ala Thr Ala 130 135 140

Val Leu Glu Gly Gln Ala Ile Tyr Ser Asn Leu Asn Ile Val Lys Gln 165 170 175

Glu Ile Asp Tyr Lys Ala Pro Ser Thr Pro Tyr Ser Pro Asn Tyr Asn 180 185 190

Gly Leu Leu Gly Val Val Thr Ala Gly Leu Asn Phe Asn Leu Gly Arg 195 200 205

Val Ala Trp Glu Thr Val Thr Pro Met Asp Met Asp Leu Ile Asn Asp

210 215 220

Leu Asn Gly Gln Ile Asn Arg Leu Arg Ser Glu Asn Thr Glu Leu Arg 225 230 235 240

Lys Arg Pro Val Ser Cys Pro Glu Cys Pro Glu Val Ser Lys Glu Thr 245 250 255

Thr Val Val Thr Glu Asn Val Leu Gly Asp Lys Ala Ile Val Phe Lys
260 265 270

Phe Asn Ser Ala Thr Ile Ser Lys Asp Gln His Ile Val Leu Gln Asp 275 280 285

Ile Ala Asp Phe Val Lys Asn Gly Asn Lys Gly Val Ala Val Ile Gly 290 295 300

Phe Ala Asp Val Thr Gly Asp Ala Asn Tyr Asn Met Gln Leu Ser Glu 305 310 315 320

Arg Arg Ala Lys Ala Val Ala Glu Ala Leu Val Asn Gln Phe Gly Val
325
330
335

Pro Ser Asp Met Ile Ser Val Glu Trp Gln Gly Glu Thr
340 345

<210> 128

<211> 395

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:P. endodontalis B114 OprF polypeptide sequence

<400> 128

Ser Ala Leu Gly Ala Leu Ala Leu Thr Ala Ser Ala Gln Gln Thr Thr

1 5 10 15

Lys Pro Ala Asn Ser Met Pro Ala Phe Lys Thr Ala Phe Glu Arg Ser 20 25 30

Gly Gly His Trp Phe Leu Thr Ile Gln Gly Gly Leu Ser Ala Gln Leu
35 40 45

Leu Gly Glu Asn Glu Lys Met Asp Phe Gly Lys Arg Leu Leu His Ala 50 55 60

Ala Lys Ala Ser Asp Asn Thr Gln Thr Glu Ala Ser Tyr Leu Arg Ile Met Pro Thr Leu Ser Val Gly Lys Trp His Asn Pro Tyr Phe Ala Thr Arg Val Gln Leu Phe Gly Gly Leu Thr Pro Leu Tyr Asn Thr Glu Gly Gly Val Asn Val His Thr Tyr Asn Thr Ala Thr Ile Gly Ala His Tyr Asp Phe Met Phe Asp Val Val Asn Tyr Phe Ala Lys Tyr Asn Pro Lys Arg Phe Phe His Val Ile Pro Trp Val Gly Leu Gly Tyr Asn Phe Lys Tyr His Asp Val Phe Gly Phe Lys Glu Pro Tyr Arg His Ser Val Thr Gly Asn Ala Gly Met Glu Phe Ala Phe Arg Leu Gly Lys Arg Val Asp Leu Val Leu Glu Ala Gln Val Val Tyr Asn Asn Leu Asn Leu Ile Lys Gln Glu Val Asp Tyr Asp Val Val Thr Thr Pro Tyr Val Pro Ala Asp Thr Tyr Ala Gly Leu Met Thr Met Phe Thr Ala Gly Leu Asn Phe Asn Leu Gly Lys Val Glu Trp Glu Thr Val Glu Pro Met Asp Tyr Gln Leu Ile Asn Asp Leu Asn Ser Gln Ile Ser Arg Leu Arg Ser Glu Asn Ala Glu Leu Ser Lys Arg Pro Ala Phe Cys Pro Glu Cys Pro Glu Val Glu Glu Val Glu Asp Val Val Val Asp Gln Tyr Val Leu Thr Asp Lys Ala Ile Leu Phe Asp Phe Asp Lys Ser Asn Ile Arg Lys Asp Gln Gln Ala

Gln Leu Gly Met Ile Ala Glu Phe Val Lys Lys Tyr Asn Thr Pro Ile Val Val Val Gly Tyr Ala Asp Pro Thr Gly Lys Ser Lys Tyr Asn Met 340 345 350 Glu Leu Ser Lys Arg Arg Ala Gln Ala Val Val Asn Glu Leu Thr Asn 360 Arg His Gly Val Pro Ala Asp Leu Ile Thr Met Glu Trp Glu Gly Ala 375 380 Thr Asn Lys Phe Thr Pro Pro Thr Ala Trp Asn 390 <210> 129 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: P. gulae B43 FimA polypeptide fragment sequence #1 <400> 129 Ala Cys Asn Lys Asp Asn Glu Ala Glu Pro Val Val 5 <210> 130 <211> 21 <212> PRT <213> Artificial Seguence <223> Description of Artificial Sequence: P. gulae B43 FimA polypeptide fragment sequence #2 <400> 130 Tyr Pro Val Leu Val Asn Phe Glu Ser Asn Asn Tyr Thr Tyr Thr Gly 10 Asp Ala Val Glu Lys 20

```
<210> 131
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:P. gulae B43
      FimA polypeptide fragment sequence #3
<400> 131
Thr Gly Pro Gly Thr Asn Asn Pro Glu Asn Pro Ile Thr Glu Ser Ala
                                     10
<210> 132
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: P. gulae B43
      OprF polypeptide fragment sequence #1
<400> 132
Asn Asp Asn Asn Lys Asp Phe Val Asp Arg Leu Gly Ala
                                     10
                  5
<210> 133
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: P. gulae B43
      OprF polypeptide fragment sequence #2
<400> 133
Asp Leu Asn Gly Gln Ile Asn Arg Leu Arg Arg Glu Val Glu Glu Leu
Ser Lys Arg Pro Val Ser Cys Pro Glu Cys Pro Asp Val
             20
                                 25
```

<210> 134
<211> 21

<212> PRT

<213> Artificial Sequence <220> <223> Description of Artificial Sequence: P. gulae B43 OprF polypeptide fragment sequence #3 <400> 134 Ala Asp Pro Thr Gly Asp Thr Gln Tyr Asn Glu Arg Leu Ser Glu Arg 10 15 Arg Ala Lys Ala Val 20 <210> 135 <211> 47 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence:pBAD-HisA Amino-terminal polypeptide sequence <400> 135 Met Gly Gly Ser His His His His His Gly Met Ala Ser Met Thr Gly Gln Met Gly Arg Asp Leu Tyr Asp Asp Asp Asp Lys Asp Arg 20 25 Trp Gly Ser Glu Leu Glu Ile Cys Ser Gln Tyr His Met Gly Ile 35 40 <210> 136 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence:pBAD-TOPO Amino-terminal polypeptide sequence <400> 136 Met Gly Ser Gly Ser Gly Asp Asp Asp Lys Leu Ala Leu Met 10

<210> 137

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: l vector Amino-terminal polypeptide sequence

<400> 137

Met Gly Thr Thr Thr Thr Thr Thr Ser Leu His Met
1 5 10